EP0839798B1 - Intermediates for preparating non-peptide retroviral protease inhibitors - Google Patents
Intermediates for preparating non-peptide retroviral protease inhibitors Download PDFInfo
- Publication number
- EP0839798B1 EP0839798B1 EP97119700A EP97119700A EP0839798B1 EP 0839798 B1 EP0839798 B1 EP 0839798B1 EP 97119700 A EP97119700 A EP 97119700A EP 97119700 A EP97119700 A EP 97119700A EP 0839798 B1 EP0839798 B1 EP 0839798B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino
- dihydroxy
- diphenylhexane
- mmol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001177 retroviral effect Effects 0.000 title abstract description 12
- 239000000543 intermediate Substances 0.000 title description 9
- 108090000765 processed proteins & peptides Proteins 0.000 title description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 367
- 125000002252 acyl group Chemical group 0.000 claims abstract description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 4
- -1 t-butylacetyl Chemical group 0.000 claims description 22
- ROSQXCOWODZPRU-XSLAGTTESA-N (2s,3s,4s,5s)-2,5-diamino-1,6-diphenylhexane-3,4-diol Chemical compound C([C@H](N)[C@H](O)[C@@H](O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 ROSQXCOWODZPRU-XSLAGTTESA-N 0.000 claims description 14
- ROSQXCOWODZPRU-XLAORIBOSA-N (2s,3r,4s,5s)-2,5-diamino-1,6-diphenylhexane-3,4-diol Chemical compound C([C@H](N)[C@H](O)[C@H](O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 ROSQXCOWODZPRU-XLAORIBOSA-N 0.000 claims description 13
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 9
- XEFORNHNQOHGSE-CJRSTVEYSA-N tert-butyl n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 XEFORNHNQOHGSE-CJRSTVEYSA-N 0.000 claims description 7
- ROSQXCOWODZPRU-WNRNVDISSA-N (2s,3r,4r,5s)-2,5-diamino-1,6-diphenylhexane-3,4-diol Chemical compound C([C@H](N)[C@@H](O)[C@H](O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 ROSQXCOWODZPRU-WNRNVDISSA-N 0.000 claims description 5
- XEFORNHNQOHGSE-NEWJYFPISA-N tert-butyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 XEFORNHNQOHGSE-NEWJYFPISA-N 0.000 claims description 5
- XEFORNHNQOHGSE-ZJZGAYNASA-N tert-butyl n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 XEFORNHNQOHGSE-ZJZGAYNASA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- BABCLRPKNPMXJL-MGEKTERKSA-N (2s)-2-amino-n-[(2s,3r,4r,5s)-5-[[(2s)-2-amino-3-methylbutanoyl]amino]-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-3-methylbutanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)C)C1=CC=CC=C1 BABCLRPKNPMXJL-MGEKTERKSA-N 0.000 claims description 3
- BABCLRPKNPMXJL-CVIYXSBDSA-N (2s)-2-amino-n-[(2s,3r,4s,5s)-5-[[(2s)-2-amino-3-methylbutanoyl]amino]-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-3-methylbutanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)C)C1=CC=CC=C1 BABCLRPKNPMXJL-CVIYXSBDSA-N 0.000 claims description 3
- BABCLRPKNPMXJL-FRSCJGFNSA-N (2s)-2-amino-n-[(2s,3s,4s,5s)-5-[[(2s)-2-amino-3-methylbutanoyl]amino]-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-3-methylbutanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)C(C)C)C1=CC=CC=C1 BABCLRPKNPMXJL-FRSCJGFNSA-N 0.000 claims description 3
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- TZRRVSCDIPHXHN-RRUVMKMCSA-N benzyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 TZRRVSCDIPHXHN-RRUVMKMCSA-N 0.000 claims description 3
- TZRRVSCDIPHXHN-BYAJYZPISA-N benzyl n-[(2s)-1-[[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 TZRRVSCDIPHXHN-BYAJYZPISA-N 0.000 claims description 3
- TZRRVSCDIPHXHN-UNHORJANSA-N benzyl n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 TZRRVSCDIPHXHN-UNHORJANSA-N 0.000 claims description 3
- XEFORNHNQOHGSE-UHFFFAOYSA-N tert-butyl n-[3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(NC(=O)OC(C)(C)C)C(O)C(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 XEFORNHNQOHGSE-UHFFFAOYSA-N 0.000 claims description 3
- RYOLSDKDPIMILE-UHFFFAOYSA-N 2-amino-5-(benzylamino)-1,6-diphenylhexane-3,4-diol;dihydrochloride Chemical compound Cl.Cl.C=1C=CC=CC=1CC(NCC=1C=CC=CC=1)C(O)C(O)C(N)CC1=CC=CC=C1 RYOLSDKDPIMILE-UHFFFAOYSA-N 0.000 claims description 2
- DQPJTHPVMVTZGY-UHFFFAOYSA-N benzyl n-benzyl-n-[3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(N(CC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)C(O)C(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 DQPJTHPVMVTZGY-UHFFFAOYSA-N 0.000 claims description 2
- FCWJMHLXSAALMS-UHFFFAOYSA-N tert-butyl n-(5-amino-3,4-dihydroxy-1,6-diphenylhexan-2-yl)carbamate Chemical compound C=1C=CC=CC=1CC(N)C(O)C(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 FCWJMHLXSAALMS-UHFFFAOYSA-N 0.000 claims description 2
- VFOIVAJNUJGQCL-UHFFFAOYSA-N tert-butyl n-[5-(benzylamino)-3,4-dihydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(NCC=1C=CC=CC=1)C(O)C(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 VFOIVAJNUJGQCL-UHFFFAOYSA-N 0.000 claims description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 16
- 108091005804 Peptidases Proteins 0.000 abstract description 15
- 239000004365 Protease Substances 0.000 abstract description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract description 10
- 150000002148 esters Chemical class 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 125000000217 alkyl group Chemical group 0.000 abstract description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 303
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 208
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 174
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 135
- 239000000243 solution Substances 0.000 description 130
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 117
- 238000000034 method Methods 0.000 description 97
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 74
- 239000007787 solid Substances 0.000 description 61
- 238000001819 mass spectrum Methods 0.000 description 60
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- 239000000203 mixture Substances 0.000 description 51
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 44
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 43
- 238000010898 silica gel chromatography Methods 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 238000010168 coupling process Methods 0.000 description 31
- 238000005859 coupling reaction Methods 0.000 description 31
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 230000008878 coupling Effects 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- 239000003921 oil Substances 0.000 description 25
- 229910052938 sodium sulfate Inorganic materials 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 24
- 239000007832 Na2SO4 Substances 0.000 description 23
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 150000001718 carbodiimides Chemical class 0.000 description 20
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 20
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 238000003818 flash chromatography Methods 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 13
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 10
- 239000012299 nitrogen atmosphere Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- PTMBWNZJOQBTBK-UHFFFAOYSA-N pyridin-4-ylmethanol Chemical compound OCC1=CC=NC=C1 PTMBWNZJOQBTBK-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- NJDZCCJYUBNBMK-KSSFIOAISA-N (4-nitrophenyl) (2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoate Chemical compound N([C@@H]([C@@H](C)CC)C(=O)OC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 NJDZCCJYUBNBMK-KSSFIOAISA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- QWUQVUDPBXFOKF-MERQFXBCSA-N benzyl (2s)-2-amino-3-methylbutanoate;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 QWUQVUDPBXFOKF-MERQFXBCSA-N 0.000 description 4
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- KUGLDBMQKZTXPW-JEDNCBNOSA-N methyl (2s)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C(C)C KUGLDBMQKZTXPW-JEDNCBNOSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 3
- VUVORVXMOLQFMO-UHFFFAOYSA-N 3-pyridin-3-ylprop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CN=C1 VUVORVXMOLQFMO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 108010010369 HIV Protease Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- RILPIWOPNGRASR-AKGZTFGVSA-N (2s)-2-hydroxy-3-methylpentanoic acid Chemical compound CCC(C)[C@H](O)C(O)=O RILPIWOPNGRASR-AKGZTFGVSA-N 0.000 description 2
- GLFONBITBIYJPS-KRWDZBQOSA-N (4-nitrophenyl) (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoate Chemical compound N([C@@H](C(C)C)C(=O)OC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)OCC1=CC=CC=C1 GLFONBITBIYJPS-KRWDZBQOSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- ARGCQEVBJHPOGB-UHFFFAOYSA-N 2,5-dihydrofuran Chemical compound C1OCC=C1 ARGCQEVBJHPOGB-UHFFFAOYSA-N 0.000 description 2
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- LKDFTXDJKHGCAC-UHFFFAOYSA-N 3-pyridin-2-ylprop-2-enoic acid Chemical compound OC(=O)C=CC1=CC=CC=N1 LKDFTXDJKHGCAC-UHFFFAOYSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- SVWCVXFHTHCJJB-UHFFFAOYSA-N 4-methylpentanoyl chloride Chemical compound CC(C)CCC(Cl)=O SVWCVXFHTHCJJB-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- YBUPWRYTXGAWJX-UHFFFAOYSA-N 4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)C1COC(=O)N1 YBUPWRYTXGAWJX-UHFFFAOYSA-N 0.000 description 2
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108700022715 Viral Proteases Proteins 0.000 description 2
- 229910007565 Zn—Cu Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- FCWJMHLXSAALMS-BURNTYAHSA-N tert-butyl n-[(2s,3s,4r,5s)-5-amino-3,4-dihydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@H](O)[C@H](O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FCWJMHLXSAALMS-BURNTYAHSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 230000007442 viral DNA synthesis Effects 0.000 description 2
- MFAOBGXYLNLLJE-HNNXBMFYSA-N (2,5-dioxopyrrolidin-1-yl) (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoate Chemical compound N([C@@H](C(C)C)C(=O)ON1C(CCC1=O)=O)C(=O)OCC1=CC=CC=C1 MFAOBGXYLNLLJE-HNNXBMFYSA-N 0.000 description 1
- CNFSCZRHPSWMGL-MLWJPKLSSA-N (2S)-2-(methoxymethoxy)-3-methylpentanoic acid Chemical compound COCO[C@H](C(=O)O)C(CC)C CNFSCZRHPSWMGL-MLWJPKLSSA-N 0.000 description 1
- AGHDGSLAODJMKF-ZZDDQDSOSA-N (2S)-N-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S)-3-methyl-2-(3-pyridin-2-ylprop-2-enoylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-(3-pyridin-2-ylprop-2-enoylamino)butanamide Chemical compound N1=C(C=CC=C1)C=CC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)[C@H]([C@@H]([C@H](CC1=CC=CC=C1)NC([C@@H](NC(C=CC1=NC=CC=C1)=O)C(C)C)=O)O)O AGHDGSLAODJMKF-ZZDDQDSOSA-N 0.000 description 1
- XOYXESIZZFUVRD-YGGZJJQXSA-N (2S,3S,4R,5S,6R)-6-[(2R,3R,4R,5S,6S)-6-[(2R,3S,4S,5S,6S)-5-acetamido-6-[(2R,3R,4R,5S,6S)-4-acetyloxy-6-[(2R,3R,4R,5S,6S)-4-acetyloxy-6-[(2R,3R,4R,5S,6R)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-acetyloxy-3-[(2S,3S,4R,5R,6R)-4-acetyloxy-5-[(2S,3S,4R,5R,6R)-4-acetyloxy-3-hydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxyoxane-2-carboxylic acid Polymers CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](CO)[C@@H](OC)[C@H](OC(C)=O)[C@@H]8O)[C@H](OC(C)=O)[C@@H]7O)[C@H](OC(C)=O)[C@@H]6O)C(O)=O)[C@H](OC(C)=O)[C@@H]5O)[C@@H](O)[C@@H]4NC(C)=O)[C@H](OC(C)=O)[C@@H]3O)[C@H](OC(C)=O)[C@@H]2O)[C@H](OC(C)=O)[C@@H]1O XOYXESIZZFUVRD-YGGZJJQXSA-N 0.000 description 1
- QLSQGASUBXAXST-XZSFGIKTSA-N (2s)-2-(dimethylamino)-n-[(2s,3r,4r,5s)-5-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-3-methylbutanamide Chemical compound C([C@H](NC(=O)[C@@H](N(C)C)C(C)C)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C(C)C)N(C)C)C1=CC=CC=C1 QLSQGASUBXAXST-XZSFGIKTSA-N 0.000 description 1
- HILANAOEGRRUEB-ZDUSSCGKSA-N (2s)-2-(n-phenylmethoxycarbonylanilino)propanoic acid Chemical compound C=1C=CC=CC=1N([C@@H](C)C(O)=O)C(=O)OCC1=CC=CC=C1 HILANAOEGRRUEB-ZDUSSCGKSA-N 0.000 description 1
- VOGHFRBYAHVPGC-NSHDSACASA-N (2s)-2-[2-[methyl(pyridin-2-ylmethyl)amino]-2-oxoethyl]pentanoic acid Chemical compound CCC[C@H](C(O)=O)CC(=O)N(C)CC1=CC=CC=N1 VOGHFRBYAHVPGC-NSHDSACASA-N 0.000 description 1
- IPVUJBGTGWGPGV-GJZGRUSLSA-N (2s)-2-[[(2s)-2-[(6-methoxy-6-oxohexanoyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoic acid Chemical compound COC(=O)CCCCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IPVUJBGTGWGPGV-GJZGRUSLSA-N 0.000 description 1
- HIWWEXGYBYGNDX-JTQLQIEISA-N (2s)-3-methyl-2-(pyridin-2-ylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=N1 HIWWEXGYBYGNDX-JTQLQIEISA-N 0.000 description 1
- QBWUAJGXNZOAQO-VIFPVBQESA-N (2s)-3-methyl-2-(pyridine-3-carbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)C1=CC=CN=C1 QBWUAJGXNZOAQO-VIFPVBQESA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- BEWLIRNLCHMRPW-NSHDSACASA-N (2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NS(=O)(=O)N(C)CC1=CC=CC=N1 BEWLIRNLCHMRPW-NSHDSACASA-N 0.000 description 1
- NUBAMOILJLNHMH-ZZDDQDSOSA-N (2s)-n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(3-pyridin-2-ylpropanoylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-(3-pyridin-2-ylpropanoylamino)butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CCC=1N=CC=CC=1)C(C)C)C(=O)CCC1=CC=CC=N1 NUBAMOILJLNHMH-ZZDDQDSOSA-N 0.000 description 1
- SMFGUWLVDOUAEO-ZZDDQDSOSA-N (2s)-n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(3-pyridin-3-ylpropanoylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-(3-pyridin-3-ylpropanoylamino)butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CCC=1C=NC=CC=1)C(C)C)C(=O)CCC1=CC=CN=C1 SMFGUWLVDOUAEO-ZZDDQDSOSA-N 0.000 description 1
- QPVWMQXBTCSLCB-RRUVMKMCSA-N (2s)-n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)N(C)CC=1N=CC=CC=1)C(C)C)C(=O)N(C)CC1=CC=CC=N1 QPVWMQXBTCSLCB-RRUVMKMCSA-N 0.000 description 1
- BFOOFWVAELCGMN-RRUVMKMCSA-N (2s)-n-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NS(=O)(=O)N(C)CC=1N=CC=CC=1)C(C)C)S(=O)(=O)N(C)CC1=CC=CC=N1 BFOOFWVAELCGMN-RRUVMKMCSA-N 0.000 description 1
- QPVWMQXBTCSLCB-BYAJYZPISA-N (2s)-n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)N(C)CC=1N=CC=CC=1)C(C)C)C(=O)N(C)CC1=CC=CC=N1 QPVWMQXBTCSLCB-BYAJYZPISA-N 0.000 description 1
- BFOOFWVAELCGMN-BYAJYZPISA-N (2s)-n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NS(=O)(=O)N(C)CC=1N=CC=CC=1)C(C)C)S(=O)(=O)N(C)CC1=CC=CC=N1 BFOOFWVAELCGMN-BYAJYZPISA-N 0.000 description 1
- QPVWMQXBTCSLCB-UNHORJANSA-N (2s)-n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)N(C)CC=1N=CC=CC=1)C(C)C)C(=O)N(C)CC1=CC=CC=N1 QPVWMQXBTCSLCB-UNHORJANSA-N 0.000 description 1
- BFOOFWVAELCGMN-UNHORJANSA-N (2s)-n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NS(=O)(=O)N(C)CC=1N=CC=CC=1)C(C)C)S(=O)(=O)N(C)CC1=CC=CC=N1 BFOOFWVAELCGMN-UNHORJANSA-N 0.000 description 1
- CFMRKUYJARYXBX-CYBMUJFWSA-N (3r)-5-methyl-3-phenylmethoxycarbonylhexanoic acid Chemical compound CC(C)C[C@H](CC(O)=O)C(=O)OCC1=CC=CC=C1 CFMRKUYJARYXBX-CYBMUJFWSA-N 0.000 description 1
- ALAAFIPFACETRF-LBPRGKRZSA-N (3s)-3-phenylmethoxycarbonylhexanoic acid Chemical compound CCC[C@@H](CC(O)=O)C(=O)OCC1=CC=CC=C1 ALAAFIPFACETRF-LBPRGKRZSA-N 0.000 description 1
- XJLFHNYOOJRSSV-INIZCTEOSA-N (4-nitrophenyl) (2s)-3-methyl-2-(pyridin-2-ylmethoxycarbonylamino)butanoate Chemical compound N([C@@H](C(C)C)C(=O)OC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)OCC1=CC=CC=N1 XJLFHNYOOJRSSV-INIZCTEOSA-N 0.000 description 1
- UFIXYARPPLZFJA-INIZCTEOSA-N (4-nitrophenyl) (2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoate Chemical compound N([C@@H](C(C)C)C(=O)OC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)OCC1=CC=CN=C1 UFIXYARPPLZFJA-INIZCTEOSA-N 0.000 description 1
- NQUHIZBGRAMJSC-INIZCTEOSA-N (4-nitrophenyl) (2s)-3-methyl-2-(pyridin-4-ylmethoxycarbonylamino)butanoate Chemical compound N([C@@H](C(C)C)C(=O)OC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)OCC1=CC=NC=C1 NQUHIZBGRAMJSC-INIZCTEOSA-N 0.000 description 1
- GYNUTYVMBZNYFR-KRWDZBQOSA-N (4-nitrophenyl) (2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanoate Chemical compound N([C@@H](C(C)C)C(=O)OC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)N(C)CC1=CC=CC=N1 GYNUTYVMBZNYFR-KRWDZBQOSA-N 0.000 description 1
- VGMWZVMXAAKMKC-SNVBAGLBSA-N (4s)-3-(4-methylpentanoyl)-4-propan-2-yl-1,3-oxazolidin-2-one Chemical compound CC(C)CCC(=O)N1[C@@H](C(C)C)COC1=O VGMWZVMXAAKMKC-SNVBAGLBSA-N 0.000 description 1
- JHGXEUXQJIKZMY-ZDUSSCGKSA-N (4s)-4-benzyl-3-(3-methylbutanoyl)-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N(C(=O)CC(C)C)[C@H]1CC1=CC=CC=C1 JHGXEUXQJIKZMY-ZDUSSCGKSA-N 0.000 description 1
- RBLAZCABYHLJEI-YPKPFQOOSA-N (z)-4-[tert-butyl(dimethyl)silyl]oxy-6-phenylhex-2-enoic acid Chemical compound CC(C)(C)[Si](C)(C)OC(\C=C/C(O)=O)CCC1=CC=CC=C1 RBLAZCABYHLJEI-YPKPFQOOSA-N 0.000 description 1
- BLWAXLYCYVVZEK-NXVVXOECSA-N (z)-4-[tert-butyl(dimethyl)silyl]oxy-n-(3-methylbutyl)-6-phenylhex-2-enamide Chemical compound CC(C)CCNC(=O)\C=C/C(O[Si](C)(C)C(C)(C)C)CCC1=CC=CC=C1 BLWAXLYCYVVZEK-NXVVXOECSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- OCCMAQCPWUXRIX-NEWJYFPISA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-1,6-diphenyl-5-(propan-2-ylcarbamoylamino)hexan-2-yl]-3-propan-2-ylurea Chemical compound C([C@H](NC(=O)NC(C)C)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)NC(C)C)C1=CC=CC=C1 OCCMAQCPWUXRIX-NEWJYFPISA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IJHOLMCJRXVNJP-MRXNPFEDSA-N 1-o-benzyl 4-o-tert-butyl (2r)-2-(2-methylpropyl)butanedioate Chemical compound CC(C)(C)OC(=O)C[C@@H](CC(C)C)C(=O)OCC1=CC=CC=C1 IJHOLMCJRXVNJP-MRXNPFEDSA-N 0.000 description 1
- KRCMCNKEWCSWRO-HNNXBMFYSA-N 1-o-benzyl 4-o-tert-butyl (2s)-2-propylbutanedioate Chemical compound CC(C)(C)OC(=O)C[C@H](CCC)C(=O)OCC1=CC=CC=C1 KRCMCNKEWCSWRO-HNNXBMFYSA-N 0.000 description 1
- KUUYKRYSUCKLEN-NEWJYFPISA-N 1-tert-butyl-3-[(2s,3s,4r,5s)-5-(tert-butylcarbamoylamino)-3,4-dihydroxy-1,6-diphenylhexan-2-yl]urea Chemical compound C([C@H](NC(=O)NC(C)(C)C)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)NC(C)(C)C)C1=CC=CC=C1 KUUYKRYSUCKLEN-NEWJYFPISA-N 0.000 description 1
- LHJGJYXLEPZJPM-UHFFFAOYSA-N 2,4,5-trichlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C=C1Cl LHJGJYXLEPZJPM-UHFFFAOYSA-N 0.000 description 1
- RZJRRPMTAYJRII-UHFFFAOYSA-N 2-(1,1-dioxo-2h-thiazin-4-yl)-n-[5-[[2-(1,1-dioxo-2h-thiazin-4-yl)-3-methylbutanoyl]amino]-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-3-methylbutanamide Chemical compound C=1NS(=O)(=O)C=CC=1C(C(C)C)C(=O)NC(C(O)C(O)C(CC=1C=CC=CC=1)NC(=O)C(C(C)C)C=1C=CS(=O)(=O)NC=1)CC1=CC=CC=C1 RZJRRPMTAYJRII-UHFFFAOYSA-N 0.000 description 1
- TXZFBHYDQGYOIT-UHFFFAOYSA-N 2-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=CC=C1C(Cl)=O TXZFBHYDQGYOIT-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- IHQAJFDAWJOQSX-UHFFFAOYSA-N 2-(ethyliminomethylideneamino)-n,n-dimethylethanamine Chemical compound CCN=C=NCCN(C)C IHQAJFDAWJOQSX-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- PEGLRXRNFUMUFH-UHFFFAOYSA-N 2-(morpholin-4-ylmethyl)butanoic acid Chemical compound CCC(C(O)=O)CN1CCOCC1 PEGLRXRNFUMUFH-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- PGCPUWANWSAXSH-UHFFFAOYSA-N 2-[(1,1-dioxo-1,4-thiazin-4-yl)methyl]butanoic acid Chemical compound CCC(C(O)=O)CN1C=CS(=O)(=O)C=C1 PGCPUWANWSAXSH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- LGAVLRNNQPBTOJ-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxy-4-phenylbutanal Chemical compound CC(C)(C)[Si](C)(C)OC(C=O)CCC1=CC=CC=C1 LGAVLRNNQPBTOJ-UHFFFAOYSA-N 0.000 description 1
- ACDVMADOSCVVME-UHFFFAOYSA-N 2-amino-4-azido-1,5-diphenylpentan-3-ol hydrochloride Chemical compound Cl.C=1C=CC=CC=1CC(N=[N+]=[N-])C(O)C(N)CC1=CC=CC=C1 ACDVMADOSCVVME-UHFFFAOYSA-N 0.000 description 1
- RYNDYESLUKWOEE-UHFFFAOYSA-N 2-benzylprop-2-enoic acid Chemical compound OC(=O)C(=C)CC1=CC=CC=C1 RYNDYESLUKWOEE-UHFFFAOYSA-N 0.000 description 1
- FABHFSYEKFWSTP-UHFFFAOYSA-N 2-bromo-1-(4-methylpiperazin-1-yl)hexan-1-one Chemical compound CCCCC(Br)C(=O)N1CCN(C)CC1 FABHFSYEKFWSTP-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- HZTPKMIMXLTOSK-UHFFFAOYSA-N 2-bromohexanoic acid Chemical compound CCCCC(Br)C(O)=O HZTPKMIMXLTOSK-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- FXIOWUZTGVXZQL-RHIIWVEJSA-N 2-morpholin-4-ylethyl n-[(2s)-1-[[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(2-morpholin-4-ylethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCCN1CCOCC1)C(C)C)C(=O)OCCN1CCOCC1 FXIOWUZTGVXZQL-RHIIWVEJSA-N 0.000 description 1
- BPSNETAIJADFTO-UHFFFAOYSA-N 2-pyridinylacetic acid Chemical compound OC(=O)CC1=CC=CC=N1 BPSNETAIJADFTO-UHFFFAOYSA-N 0.000 description 1
- LCKXJCKRKBQVJZ-UHFFFAOYSA-N 2h-1,4-thiazine 1,1-dioxide Chemical compound O=S1(=O)CC=NC=C1 LCKXJCKRKBQVJZ-UHFFFAOYSA-N 0.000 description 1
- WDGXIUUWINKTGP-UHFFFAOYSA-N 3-(3-pyridinyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CN=C1 WDGXIUUWINKTGP-UHFFFAOYSA-N 0.000 description 1
- ZCMHRUIWQHBIBE-OUXOBZDESA-N 3-[[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamoyl]-4-methylpentanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C([C@H](NC(=O)C(CC(O)=O)C(C)C)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=NC=CC=1)C(C)C)C1=CC=CC=C1 ZCMHRUIWQHBIBE-OUXOBZDESA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- QGXQKGLWWDUOEY-UHFFFAOYSA-N 3-n-hydroxybicyclo[2.2.1]hept-5-ene-2,3-dicarboxamide Chemical compound C1C2C=CC1C(C(=O)N)C2C(=O)NO QGXQKGLWWDUOEY-UHFFFAOYSA-N 0.000 description 1
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- QMCJVFYCDSYHGW-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxy]-4-oxo-2-propan-2-ylbutanoic acid Chemical compound CC(C)C(C(O)=O)CC(=O)OC(C)(C)C QMCJVFYCDSYHGW-UHFFFAOYSA-N 0.000 description 1
- OJOFMLDBXPDXLQ-UHFFFAOYSA-N 4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)NC1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- VMUJXKHHANQVNB-UHFFFAOYSA-N 5-phenylpent-1-en-3-ol Chemical compound C=CC(O)CCC1=CC=CC=C1 VMUJXKHHANQVNB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- MVYUHJLTDNJQAY-IENPIDJESA-N CCN[C@H](C1)[O](C)C(C)(C)[O]2C1NC2 Chemical compound CCN[C@H](C1)[O](C)C(C)(C)[O]2C1NC2 MVYUHJLTDNJQAY-IENPIDJESA-N 0.000 description 1
- KBEINRBJFFSSGO-PFONDFGASA-N COC(=O)\C=C/C(O[Si](C)(C)C(C)(C)C)CCC1=CC=CC=C1 Chemical compound COC(=O)\C=C/C(O[Si](C)(C)C(C)(C)C)CCC1=CC=CC=C1 KBEINRBJFFSSGO-PFONDFGASA-N 0.000 description 1
- 0 C[C@](C(*)Cc1ccccc1)C([C@@](C(*)CC1(C)C=CC=CC1)O)O Chemical compound C[C@](C(*)Cc1ccccc1)C([C@@](C(*)CC1(C)C=CC=CC1)O)O 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000701459 Caulimovirus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical group OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- APGLTERDKORUHK-LURJTMIESA-N N,N-dimethyl-L-Valine Chemical compound CC(C)[C@H](N(C)C)C(O)=O APGLTERDKORUHK-LURJTMIESA-N 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910010062 TiCl3 Inorganic materials 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- HRWDJSSGCPPFMU-SFHVURJKSA-N benzyl (2s)-2-[2-[methyl(pyridin-2-ylmethyl)amino]-2-oxoethyl]pentanoate Chemical compound C([C@H](CCC)C(=O)OCC=1C=CC=CC=1)C(=O)N(C)CC1=CC=CC=N1 HRWDJSSGCPPFMU-SFHVURJKSA-N 0.000 description 1
- YIRBOOICRQFSOK-NSHDSACASA-N benzyl (2s)-2-amino-3-methylbutanoate Chemical compound CC(C)[C@H](N)C(=O)OCC1=CC=CC=C1 YIRBOOICRQFSOK-NSHDSACASA-N 0.000 description 1
- PLTMZBGTWZPXAU-INIZCTEOSA-N benzyl (2s)-3-methyl-2-(pyridine-3-carbonylamino)butanoate Chemical compound N([C@@H](C(C)C)C(=O)OCC=1C=CC=CC=1)C(=O)C1=CC=CN=C1 PLTMZBGTWZPXAU-INIZCTEOSA-N 0.000 description 1
- UMJASUPYSMZDFE-ROUUACIJSA-N benzyl (2s)-3-methyl-2-[[(2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)OCC1=CC=CC=C1 UMJASUPYSMZDFE-ROUUACIJSA-N 0.000 description 1
- ZQJYLCPDRUXQDL-UHFFFAOYSA-N benzyl 2-(morpholin-4-ylmethyl)butanoate Chemical compound C=1C=CC=CC=1COC(=O)C(CC)CN1CCOCC1 ZQJYLCPDRUXQDL-UHFFFAOYSA-N 0.000 description 1
- MDPKYAPCYDAGSN-UHFFFAOYSA-N benzyl 2-imidazol-1-ylacetate Chemical compound C=1C=CC=CC=1COC(=O)CN1C=CN=C1 MDPKYAPCYDAGSN-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HYJWIXPOGJYYHG-MGDPKONKSA-N benzyl n-[(2s)-1-[(4-amino-3-hydroxy-1,5-diphenylpentan-2-yl)amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(N)CC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 HYJWIXPOGJYYHG-MGDPKONKSA-N 0.000 description 1
- YQSCTUXZGUMVMW-RRUVMKMCSA-N benzyl n-[(2s)-1-[[(2s,3r,4r,5s)-5-amino-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N([C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@@H](N)CC=1C=CC=CC=1)C(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 YQSCTUXZGUMVMW-RRUVMKMCSA-N 0.000 description 1
- YQSCTUXZGUMVMW-UNHORJANSA-N benzyl n-[(2s)-1-[[(2s,3s,4s,5s)-5-amino-3,4-dihydroxy-1,6-diphenylhexan-2-yl]-[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N([C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@@H](N)CC=1C=CC=CC=1)C(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 YQSCTUXZGUMVMW-UNHORJANSA-N 0.000 description 1
- IPFSIGSYFHYZFH-GFWDPPTMSA-N benzyl n-[(2s)-1-[[(6s,7r,8r,9s)-9-amino-7,8-dihydroxytetradecan-6-yl]-[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N([C@@H](CCCCC)[C@@H](O)[C@H](O)[C@@H](N)CCCCC)C(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)C(C)C)C(=O)OCC1=CC=CC=C1 IPFSIGSYFHYZFH-GFWDPPTMSA-N 0.000 description 1
- HWBCNAPQJAIMEV-KEELMNHESA-N benzyl n-[(2s)-1-[[3,4-dihydroxy-1,6-diphenyl-5-[[(2s)-2-(phenylmethoxycarbonylamino)propanoyl]amino]hexan-2-yl]amino]-1-oxopropan-2-yl]carbamate Chemical compound N([C@@H](C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(O)C(CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)OCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 HWBCNAPQJAIMEV-KEELMNHESA-N 0.000 description 1
- PVEHXCKFHCCQBY-VIXXNIOISA-N benzyl n-[(2s)-1-[[3,4-dihydroxy-1,6-diphenyl-5-[[(2s)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoyl]amino]hexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)C(O)C(O)C(NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 PVEHXCKFHCCQBY-VIXXNIOISA-N 0.000 description 1
- ZHMGAUIRMSGIIL-YHKYZAEUSA-N benzyl n-[(2s)-1-[[3,4-dihydroxy-5-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(O)C(CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)OCC=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 ZHMGAUIRMSGIIL-YHKYZAEUSA-N 0.000 description 1
- GEANBHANAKKWSL-SZKDOGBVSA-N benzyl n-[(2s)-1-[[3-hydroxy-4-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,5-diphenylpentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 GEANBHANAKKWSL-SZKDOGBVSA-N 0.000 description 1
- UFBYFCVYYOVKPG-VWVPSQRVSA-N benzyl n-[(2s,3s)-1-[[3,4-dihydroxy-5-[[(2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H]([C@@H](C)CC)C(=O)NC(CC=1C=CC=CC=1)C(O)C(O)C(CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CC=CC=1)[C@@H](C)CC)C(=O)OCC1=CC=CC=C1 UFBYFCVYYOVKPG-VWVPSQRVSA-N 0.000 description 1
- RNYRWIMSVNYCGZ-QHCPKHFHSA-N benzyl n-benzyl-n-[(2s)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](C=O)N(CC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 RNYRWIMSVNYCGZ-QHCPKHFHSA-N 0.000 description 1
- VSOJZRSNBXPUMZ-OCOZRVBESA-N benzyl n-benzyl-n-[(e)-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhex-3-en-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(N(CC=1C=CC=CC=1)C(=O)OCC=1C=CC=CC=1)/C=C/C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 VSOJZRSNBXPUMZ-OCOZRVBESA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- BEHRPENWTDCRBQ-UHFFFAOYSA-N dimethyl 2,5-dibenzyl-3,4-dihydroxyhexanedioate Chemical compound C=1C=CC=CC=1CC(C(=O)OC)C(O)C(O)C(C(=O)OC)CC1=CC=CC=C1 BEHRPENWTDCRBQ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- BEQVQKJCLJBTKZ-UHFFFAOYSA-N diphenylphosphinic acid Chemical compound C=1C=CC=CC=1P(=O)(O)C1=CC=CC=C1 BEQVQKJCLJBTKZ-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- KLWMOCBNXFKZOS-VOTSOKGWSA-N ethyl (e)-3-pyridin-2-ylprop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=CC=N1 KLWMOCBNXFKZOS-VOTSOKGWSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000007478 fluorogenic assay Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- QAFBDRSXXHEXGB-UHFFFAOYSA-N imidazol-1-ylacetic acid Chemical compound OC(=O)CN1C=CN=C1 QAFBDRSXXHEXGB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GUWHRJQTTVADPB-UHFFFAOYSA-N lithium azide Chemical compound [Li+].[N-]=[N+]=[N-] GUWHRJQTTVADPB-UHFFFAOYSA-N 0.000 description 1
- OPYADDBXXPDORW-PPHPATTJSA-M lithium;(2s)-3-methyl-2-(2-morpholin-4-ylethoxycarbonylamino)butanoate Chemical compound [Li+].CC(C)[C@@H](C([O-])=O)NC(=O)OCCN1CCOCC1 OPYADDBXXPDORW-PPHPATTJSA-M 0.000 description 1
- NZIUUZMHGBPHDS-PPHPATTJSA-M lithium;(2s)-3-methyl-2-(pyridin-2-ylmethoxycarbonylamino)butanoate Chemical compound [Li+].CC(C)[C@@H](C([O-])=O)NC(=O)OCC1=CC=CC=N1 NZIUUZMHGBPHDS-PPHPATTJSA-M 0.000 description 1
- RXWYXIFRQNQPSC-PPHPATTJSA-M lithium;(2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoate Chemical compound [Li+].CC(C)[C@@H](C([O-])=O)NC(=O)OCC1=CC=CN=C1 RXWYXIFRQNQPSC-PPHPATTJSA-M 0.000 description 1
- BTJRCGMBGJNNTE-PPHPATTJSA-M lithium;(2s)-3-methyl-2-(pyridin-4-ylmethoxycarbonylamino)butanoate Chemical compound [Li+].CC(C)[C@@H](C([O-])=O)NC(=O)OCC1=CC=NC=C1 BTJRCGMBGJNNTE-PPHPATTJSA-M 0.000 description 1
- DBYQHFPBWKKZAT-UHFFFAOYSA-N lithium;benzene Chemical compound [Li+].C1=CC=[C-]C=C1 DBYQHFPBWKKZAT-UHFFFAOYSA-N 0.000 description 1
- YNXURHRFIMQACJ-UHFFFAOYSA-N lithium;methanidylbenzene Chemical compound [Li+].[CH2-]C1=CC=CC=C1 YNXURHRFIMQACJ-UHFFFAOYSA-N 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- ILWUUZUKEOGOBC-YFKPBYRVSA-N methyl (2s)-2-(chlorosulfonylamino)-3-methylbutanoate Chemical compound COC(=O)[C@H](C(C)C)NS(Cl)(=O)=O ILWUUZUKEOGOBC-YFKPBYRVSA-N 0.000 description 1
- HCWOSOQJESWXRN-NSHDSACASA-N methyl (2s)-3-methyl-2-(2-morpholin-4-ylethoxycarbonylamino)butanoate Chemical compound COC(=O)[C@H](C(C)C)NC(=O)OCCN1CCOCC1 HCWOSOQJESWXRN-NSHDSACASA-N 0.000 description 1
- IKXIDZXFFVOHAT-NSHDSACASA-N methyl (2s)-3-methyl-2-(pyridin-2-ylmethoxycarbonylamino)butanoate Chemical compound COC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=N1 IKXIDZXFFVOHAT-NSHDSACASA-N 0.000 description 1
- ZOLKQNSKOGQZDP-NSHDSACASA-N methyl (2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoate Chemical compound COC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CN=C1 ZOLKQNSKOGQZDP-NSHDSACASA-N 0.000 description 1
- IKHUZTARBGRCDT-NSHDSACASA-N methyl (2s)-3-methyl-2-(pyridin-4-ylmethoxycarbonylamino)butanoate Chemical compound COC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=NC=C1 IKHUZTARBGRCDT-NSHDSACASA-N 0.000 description 1
- PLMZQCKSBYZWKI-AWEZNQCLSA-N methyl (2s)-3-methyl-2-[(2-oxo-2-phenylmethoxyethyl)amino]butanoate Chemical compound COC(=O)[C@H](C(C)C)NCC(=O)OCC1=CC=CC=C1 PLMZQCKSBYZWKI-AWEZNQCLSA-N 0.000 description 1
- NLKOHXLWUHJRPC-LBPRGKRZSA-N methyl (2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanoate Chemical compound COC(=O)[C@H](C(C)C)NC(=O)N(C)CC1=CC=CC=N1 NLKOHXLWUHJRPC-LBPRGKRZSA-N 0.000 description 1
- PQCBXJNNPHYHJB-LBPRGKRZSA-N methyl (2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)sulfamoyl]amino]butanoate Chemical compound COC(=O)[C@H](C(C)C)NS(=O)(=O)N(C)CC1=CC=CC=N1 PQCBXJNNPHYHJB-LBPRGKRZSA-N 0.000 description 1
- PVSJXEDBEXYLML-UHFFFAOYSA-N methyl 2-[bis(2,2,2-trifluoroethoxy)phosphoryl]acetate Chemical compound COC(=O)CP(=O)(OCC(F)(F)F)OCC(F)(F)F PVSJXEDBEXYLML-UHFFFAOYSA-N 0.000 description 1
- HXOWHYIABSAJHW-UHFFFAOYSA-N methyl 2-benzyl-3-[[5-[(2-benzyl-3-methoxy-3-oxopropyl)amino]-3,4-dihydroxy-1,6-diphenylhexan-2-yl]amino]propanoate Chemical compound C=1C=CC=CC=1CC(C(=O)OC)CNC(C(O)C(O)C(CC=1C=CC=CC=1)NCC(CC=1C=CC=CC=1)C(=O)OC)CC1=CC=CC=C1 HXOWHYIABSAJHW-UHFFFAOYSA-N 0.000 description 1
- XGUYXJUKIGCLLA-UHFFFAOYSA-N methyl 2-benzyl-3-[methoxy(methyl)amino]propanoate Chemical compound CON(C)CC(C(=O)OC)CC1=CC=CC=C1 XGUYXJUKIGCLLA-UHFFFAOYSA-N 0.000 description 1
- VWEWQCUHWMQTNX-UHFFFAOYSA-N methyl 2-benzyl-3-pyrazol-1-ylpropanoate Chemical compound C1=CC=NN1CC(C(=O)OC)CC1=CC=CC=C1 VWEWQCUHWMQTNX-UHFFFAOYSA-N 0.000 description 1
- DQQJYBYIABSMFM-UHFFFAOYSA-N methyl 2-benzylprop-2-enoate Chemical compound COC(=O)C(=C)CC1=CC=CC=C1 DQQJYBYIABSMFM-UHFFFAOYSA-N 0.000 description 1
- ZCBNCWPVQIJPDI-VXKWHMMOSA-N methyl 6-[[(2s)-3-methyl-1-[[(2s)-3-methyl-1-oxo-1-phenylmethoxybutan-2-yl]amino]-1-oxobutan-2-yl]amino]-6-oxohexanoate Chemical compound COC(=O)CCCCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)OCC1=CC=CC=C1 ZCBNCWPVQIJPDI-VXKWHMMOSA-N 0.000 description 1
- UOBSVARXACCLLH-UHFFFAOYSA-N monomethyl adipate Chemical compound COC(=O)CCCCC(O)=O UOBSVARXACCLLH-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- ADAMEOZKZQRNKP-UHFFFAOYSA-N n'-propylmethanediimine Chemical compound CCCN=C=N ADAMEOZKZQRNKP-UHFFFAOYSA-N 0.000 description 1
- JMEJHSVHJMSHQZ-ZZDDQDSOSA-N n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-2-(1h-indole-2-carbonylamino)-3-methylbutanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(C)C)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(C)C)C1=CC=CC=C1 JMEJHSVHJMSHQZ-ZZDDQDSOSA-N 0.000 description 1
- SJPLIKXOXFEZIX-GFWDPPTMSA-N n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridine-2-carbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pyridine-2-carboxamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1N=CC=CC=1)C(C)C)C(=O)C1=CC=CC=N1 SJPLIKXOXFEZIX-GFWDPPTMSA-N 0.000 description 1
- SFUOTSSFTYEDIX-FEHIJEOVSA-N n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(quinoline-2-carbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]quinoline-2-carboxamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)C1=CC=CC=C1 SFUOTSSFTYEDIX-FEHIJEOVSA-N 0.000 description 1
- JMEJHSVHJMSHQZ-PYROVWSWSA-N n-[(2s)-1-[[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-2-(1h-indole-2-carbonylamino)-3-methylbutanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(C)C)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(C)C)C1=CC=CC=C1 JMEJHSVHJMSHQZ-PYROVWSWSA-N 0.000 description 1
- SFUOTSSFTYEDIX-GCXOEQSJSA-N n-[(2s)-1-[[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(quinoline-2-carbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]quinoline-2-carboxamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)C1=CC=CC=C1 SFUOTSSFTYEDIX-GCXOEQSJSA-N 0.000 description 1
- JMEJHSVHJMSHQZ-AKTFRGFQSA-N n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-2-(1h-indole-2-carbonylamino)-3-methylbutanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-1h-indole-2-carboxamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(C)C)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(C)C)C1=CC=CC=C1 JMEJHSVHJMSHQZ-AKTFRGFQSA-N 0.000 description 1
- SFUOTSSFTYEDIX-WGXSSYHUSA-N n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(quinoline-2-carbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]quinoline-2-carboxamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)C1=CC=CC=C1 SFUOTSSFTYEDIX-WGXSSYHUSA-N 0.000 description 1
- GJXMQMGWTFLTRH-WTURYBQISA-N n-[(2s)-1-[[3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridine-3-carbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pyridine-3-carboxamide Chemical compound N([C@@H](C(C)C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(O)C(CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1C=NC=CC=1)C(C)C)C(=O)C1=CC=CN=C1 GJXMQMGWTFLTRH-WTURYBQISA-N 0.000 description 1
- TZAZCOODBFUOLP-WEGZLFGBSA-N n-[(2s)-1-[[3-hydroxy-4-[[(2s)-3-methyl-2-(pyridine-3-carbonylamino)butanoyl]amino]-1,5-diphenylpentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]pyridine-3-carboxamide Chemical compound N([C@@H](C(C)C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)C=1C=NC=CC=1)C(C)C)C(=O)C1=CC=CN=C1 TZAZCOODBFUOLP-WEGZLFGBSA-N 0.000 description 1
- INSNRWNFWAZGCL-UHFFFAOYSA-N n-[3,4-dihydroxy-1,6-diphenyl-5-(pyridine-3-carbonylamino)hexan-2-yl]pyridine-3-carboxamide Chemical compound C=1C=CC=CC=1CC(NC(=O)C=1C=NC=CC=1)C(O)C(O)C(NC(=O)C=1C=NC=CC=1)CC1=CC=CC=C1 INSNRWNFWAZGCL-UHFFFAOYSA-N 0.000 description 1
- FVKPQDOIZGJVAS-UHFFFAOYSA-N n-[3,4-dihydroxy-1,6-diphenyl-5-(pyridine-4-carbonylamino)hexan-2-yl]pyridine-4-carboxamide Chemical compound C=1C=CC=CC=1CC(NC(=O)C=1C=CN=CC=1)C(O)C(O)C(NC(=O)C=1C=CN=CC=1)CC1=CC=CC=C1 FVKPQDOIZGJVAS-UHFFFAOYSA-N 0.000 description 1
- ZGESZOFXCSQVIG-UHFFFAOYSA-N n-[3,4-dihydroxy-5-[(3-methyl-2-morpholin-4-ylbutanoyl)amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-morpholin-4-ylbutanamide Chemical compound C=1C=CC=CC=1CC(C(O)C(O)C(CC=1C=CC=CC=1)NC(=O)C(C(C)C)N1CCOCC1)NC(=O)C(C(C)C)N1CCOCC1 ZGESZOFXCSQVIG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- DRTZAIDVOGUYSP-UHFFFAOYSA-N pyridin-1-ium;chloride;hydrochloride Chemical compound Cl.Cl.C1=CC=NC=C1 DRTZAIDVOGUYSP-UHFFFAOYSA-N 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- HKIRXDARVDUJOP-AEKIIXOMSA-N pyridin-2-ylmethyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-2-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1N=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=N1 HKIRXDARVDUJOP-AEKIIXOMSA-N 0.000 description 1
- DPPMKRONCJJBLZ-OFEGBEERSA-N pyridin-2-ylmethyl n-[(2s)-1-[[(2s,3r,4s,5s)-3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=N1 DPPMKRONCJJBLZ-OFEGBEERSA-N 0.000 description 1
- HKIRXDARVDUJOP-RHIIWVEJSA-N pyridin-2-ylmethyl n-[(2s)-1-[[(2s,3r,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-2-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1N=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=N1 HKIRXDARVDUJOP-RHIIWVEJSA-N 0.000 description 1
- HKIRXDARVDUJOP-JPRYDEJLSA-N pyridin-2-ylmethyl n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-2-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1N=CC=CC=1)C(C)C)C(=O)OCC1=CC=CC=N1 HKIRXDARVDUJOP-JPRYDEJLSA-N 0.000 description 1
- ACUNRNHXDMKZIB-AEKIIXOMSA-N pyridin-3-ylmethyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=NC=CC=1)C(C)C)C(=O)OCC1=CC=CN=C1 ACUNRNHXDMKZIB-AEKIIXOMSA-N 0.000 description 1
- HSEARMJICJRBHE-OFEGBEERSA-N pyridin-3-ylmethyl n-[(2s)-1-[[(2s,3r,4s,5s)-3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CN=C1 HSEARMJICJRBHE-OFEGBEERSA-N 0.000 description 1
- IKTOVCCDERRTQU-OBBCHVIHSA-N pyridin-3-ylmethyl n-[(2s)-1-[[(2s,3r,4s,5s)-5-amino-3,4-dihydroxy-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@@H](N)CC=1C=CC=CC=1)C(=O)OCC1=CC=CN=C1 IKTOVCCDERRTQU-OBBCHVIHSA-N 0.000 description 1
- ACUNRNHXDMKZIB-RHIIWVEJSA-N pyridin-3-ylmethyl n-[(2s)-1-[[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=NC=CC=1)C(C)C)C(=O)OCC1=CC=CN=C1 ACUNRNHXDMKZIB-RHIIWVEJSA-N 0.000 description 1
- ACUNRNHXDMKZIB-JPRYDEJLSA-N pyridin-3-ylmethyl n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=NC=CC=1)C(C)C)C(=O)OCC1=CC=CN=C1 ACUNRNHXDMKZIB-JPRYDEJLSA-N 0.000 description 1
- TZYOFBHYLHBTFK-AEKIIXOMSA-N pyridin-4-ylmethyl n-[(2s)-1-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-4-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CN=CC=1)C(C)C)C(=O)OCC1=CC=NC=C1 TZYOFBHYLHBTFK-AEKIIXOMSA-N 0.000 description 1
- TZYOFBHYLHBTFK-JPRYDEJLSA-N pyridin-4-ylmethyl n-[(2s)-1-[[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-4-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CN=CC=1)C(C)C)C(=O)OCC1=CC=NC=C1 TZYOFBHYLHBTFK-JPRYDEJLSA-N 0.000 description 1
- DSDWCXRXVMLBOA-YZBFVKAISA-N pyridin-4-ylmethyl n-[(2s)-1-[[3-hydroxy-4-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,5-diphenylpentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=CN=CC=1)C(C)C)C(=O)OCC1=CC=CC=C1 DSDWCXRXVMLBOA-YZBFVKAISA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000006456 reductive dimerization reaction Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- MBDNRNMVTZADMQ-UHFFFAOYSA-N sulfolene Chemical compound O=S1(=O)CC=CC1 MBDNRNMVTZADMQ-UHFFFAOYSA-N 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HAKYKBFEICTZID-KBJUPQRZSA-N tert-butyl 2-[[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-1,6-diphenylhexan-2-yl]amino]acetate Chemical compound C([C@H](NCC(=O)OC(C)(C)C)[C@@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NCC(=O)OC(C)(C)C)C1=CC=CC=C1 HAKYKBFEICTZID-KBJUPQRZSA-N 0.000 description 1
- ZIPMLRZZRLPRNA-LADVFBNQSA-N tert-butyl 3-[[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(pyridin-3-ylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamoyl]-4-methylpentanoate Chemical compound C([C@H](NC(=O)C(CC(=O)OC(C)(C)C)C(C)C)[C@H](O)[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)OCC=1C=NC=CC=1)C(C)C)C1=CC=CC=C1 ZIPMLRZZRLPRNA-LADVFBNQSA-N 0.000 description 1
- UIPXTUUPKZTHLH-UHFFFAOYSA-N tert-butyl n-(1,5-diphenylpent-3-en-2-yl)carbamate Chemical compound C=1C=CC=CC=1CC=CC(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 UIPXTUUPKZTHLH-UHFFFAOYSA-N 0.000 description 1
- DBVORMANDZVFIG-UHFFFAOYSA-N tert-butyl n-(4-amino-3-hydroxy-1,5-diphenylpentan-2-yl)carbamate Chemical compound C=1C=CC=CC=1CC(N)C(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 DBVORMANDZVFIG-UHFFFAOYSA-N 0.000 description 1
- MRXNTJUDKVTSBQ-UHFFFAOYSA-N tert-butyl n-(4-azido-3-hydroxy-1,5-diphenylpentan-2-yl)carbamate Chemical compound C=1C=CC=CC=1CC(N=[N+]=[N-])C(O)C(NC(=O)OC(C)(C)C)CC1=CC=CC=C1 MRXNTJUDKVTSBQ-UHFFFAOYSA-N 0.000 description 1
- RKVWMMAKYQABGS-UHFFFAOYSA-N tert-butyl n-(pyridin-2-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC=N1 RKVWMMAKYQABGS-UHFFFAOYSA-N 0.000 description 1
- LDKDMDVMMCXTMO-LBPRGKRZSA-N tert-butyl n-[(2s)-1-hydroxy-3-phenylpropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](CO)CC1=CC=CC=C1 LDKDMDVMMCXTMO-LBPRGKRZSA-N 0.000 description 1
- ZJTYRNPLVNMVPQ-LBPRGKRZSA-N tert-butyl n-[(2s)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C=O)CC1=CC=CC=C1 ZJTYRNPLVNMVPQ-LBPRGKRZSA-N 0.000 description 1
- WFWUPYLIEZRRSI-CJRSTVEYSA-N tert-butyl n-[(2s,3r,4r,5s)-1,6-dicyclohexyl-3,4-dihydroxy-5-[(2-methylpropan-2-yl)oxycarbonylamino]hexan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)[C@@H](O)[C@H](O)[C@H](CC1CCCCC1)NC(=O)OC(C)(C)C)C1CCCCC1 WFWUPYLIEZRRSI-CJRSTVEYSA-N 0.000 description 1
- BYZJECOSQNSUHJ-NRQMHRBESA-N tert-butyl n-[(2s,3s,4r,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)[C@@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 BYZJECOSQNSUHJ-NRQMHRBESA-N 0.000 description 1
- HZDGWTQOIZFBBB-PCQZLOAOSA-N tert-butyl n-[3-hydroxy-4-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-1,5-diphenylpentan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)NC(CC=1C=CC=CC=1)C(O)C(CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C(=O)OCC1=CC=CC=C1 HZDGWTQOIZFBBB-PCQZLOAOSA-N 0.000 description 1
- XOMSOPZJGFQUAC-UHFFFAOYSA-N tert-butyl n-methyl-n-(pyridin-2-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(C)CC1=CC=CC=N1 XOMSOPZJGFQUAC-UHFFFAOYSA-N 0.000 description 1
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- LJHRGXQEYKTFSW-UHFFFAOYSA-N tert-butyl-dimethyl-(5-phenylpent-1-en-3-yloxy)silane Chemical compound CC(C)(C)[Si](C)(C)OC(C=C)CCC1=CC=CC=C1 LJHRGXQEYKTFSW-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/18—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with hydroxy groups and at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/10—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of unsubstituted hydrocarbon radicals or of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/18—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/08—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
- C07C247/10—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/40—Halogenated unsaturated alcohols
- C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/164—Unsaturated ethers containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/17—Unsaturated ethers containing halogen
- C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
- C07C43/1742—Unsaturated ethers containing halogen containing six-membered aromatic rings with halogen atoms bound to the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
- C07C43/2055—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/567—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with sulfur as the only hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
- C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
- C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/62—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by hydrogenation of carbon-to-carbon double or triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
- C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/65—Halogen-containing esters of unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/48—Compounds containing oxirane rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3241—Esters of arylalkanephosphinic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5333—Arylalkane phosphine oxides or thioxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to novel synthetic intermediates for making compounds for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease, and for treating a retroviral infection and in particular an HIV infection.
- HIV human immunodeficiency virus
- Retroviruses are those viruses which utilize a ribonucleic acid (RNA) intermediate and a RNA-dependent deoxyribonucleic acid (DNA) polymerase, reverse transcriptase, during their life cycle. Retroviruses include, but are not limited to, the RNA viruses of the Retroviridae family, and also the DNA viruses of the Hepadnavirus and Caulimovirus families. Retroviruses cause a variety of disease states in man, animals and plants.
- RNA ribonucleic acid
- DNA RNA-dependent deoxyribonucleic acid
- retroviruses from a pathological standpoint include human immunodeficiency viruses (HIV-1 and HIV-2), which cause acquired immune deficiency syndrome (AIDS) in man, hepatitis B virus, which causes hepatitis and hepatic carcinomas in man, human T-cell lymphotrophic viruses I, II, IV and V, which cause human acute cell leukemia, and bovine and feline leukemia viruses which cause leukemia in domestic animals.
- HIV-1 and HIV-2 human immunodeficiency viruses
- HIV-2 acquired immune deficiency syndrome
- hepatitis B virus which causes hepatitis and hepatic carcinomas in man
- human T-cell lymphotrophic viruses I, II, IV and V which cause human acute cell leukemia
- bovine and feline leukemia viruses which cause leukemia in domestic animals.
- Proteases are enzymes which cleave proteins at specific peptide bonds. Many biological functions are controlled or mediated by proteases and their complementary protease inhibitors. For example, the protease renin cleaves the peptide angiotensinogen to produce the peptide angiotensin I. Angiotensin I is further cleaved by the protease angiotensin converting enzyme (ACE) to form the hypotensive peptide angiotensin II. Inhibitors of renin and ACE are known to reduce high blood pressure in vivo . An inhibitor of a retroviral protease should provide a therapeutic agent for diseases caused by the retrovirus.
- retroviruses encode a protease that is responsible for the proteolytic processing of one or more polyprotein precursors such as the pol and gag gene products. See Wellink, Arch. Virol. 98 1 (1988). Retroviral proteases most commonly process the gag precursor into core proteins, and also process the pol precursor into reverse transciptase and retroviral protease. In addition, retroviral proteases are sequence specific. See Pearl, Nature 328 482 (1987).
- Inhibitors of HIV protease are disclosed by Moore, Biochem. Biophys. Res. Commun., 159 420 (1989); Billich, J. Biol. Chem., 263 1790S (1988); Richards, FEBS Lett., 247 113 (1989); Miller, Science 246 1149 (1989); Meek, Nature 343 90 (1990); McQuade, Science 247 454 (1990); Sigal, et al., EP-A-337714, published October 18, 1989; Kempf, et al., WO89/10752, published November 16, 1989; Molling, et al., EP-A-354522, published February 14, 1990; Sigal, et al., 357332, published March 7, 1990; Handa, et al., EP-A-346847, published December 20, 1989; Desolms, et al, EP-A-356223, published February 28, 1990; Schirlin, et al., EP-A-362002, published April 4, 1990
- U.S. Patent No. 4,652,552 discloses methyl ketone derivatives of tetrapeptides as inhibitors of viral proteases.
- U.S. Patent No. 4,644,055 discloses halomethylketone derivatives of peptides as inhibitors of viral proteases.
- the chiral centers of the compounds of the invention may be racemic or asymmetric. Racemic mixtures, mixtures of diastereomers, as well as single diastereomers of the compounds of the invention are included in the present invention.
- the terms "S” and "R” configuration are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13 - 30.
- Al Al
- Al Al
- Ile Al
- Leu Leu
- Lys Benz
- Pro Pro
- amino acid abbreviations used herein follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature for amino acids and peptides (Eur. J. Biochem. 1984, 158 , 9-31).
- N-protecting group or “N-protected” as used herein refers to those groups intended to protect nitrogen atoms against undesirable reactions during synthetic procedures or to prevent the attack of exopeptidases on the final compounds or to increase the solubility of the final compounds and includes but is not limited to acyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or benzoyl groups or an L- or D-aminoacyl residue, which may itself be N-protected similarly.
- loweralkyl refers to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.
- Compounds of the invention may be selected from 2-(N-benzylamino)-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane; 2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane; 5-amino-2-(N-benzylamino)-3,4-dihydroxy-1,6-diphenylhexane dihydrochloride; 2-amino-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane; 2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,
- such compounds may be selected from (2S,3R,4R,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; and (2S,3R,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane.
- Still further compounds of the invention are selected from (2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; (2S,3R,4S,5S)-2,5-di-(N-(valin
- intermediates of the invention are selected from 2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; 2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and 2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide.
- alkylamino refers to a loweralkyl appended to an NH radical.
- cycloalkyl refers to an aliphatic ring having 3 to 7 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl and the like. Cycloalkyl groups can be unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, haloalkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, mercapto, nitro, carboxaldehyde, carboxy, carboalkoxy and carboxamide.
- alkoxy and thioalkoxy refer to R 18 O- and R 18 S-, respectively, wherein R 18 is a loweralkyl group or benzyl.
- polyalkoxy refers to -OR 45 wherein R 45 is a straight or branched chain containing 1-5, C n' -O-C n" linkages wherein n' and n" are independently selected from 1 to 3, including but not limited to methoxyethoxymethoxy, methoxymethoxy and the like.
- halo or halogen as used herein refers to -Cl, -Br, -I or -F.
- haloalkyl refers to a loweralkyl radical in which one or more of the hydrogen atoms are replaced by halogen including, but not limited to, chloromethyl, trifluoromethyl, 1-chloro-2-fluoroethyl and the like.
- heterocyclic ring refers to any 3- or 4-membered ring containing a heteroatom selected from oxygen, nitrogen and sulfur; or a 5- or 6-membered ring containing one, two or three nitrogen atoms; one nitrogen and one sulfur atom; or one nitrogen and one oxygen atom.
- the 5-membered ring has 0-2 double bonds and the 6-membered ring has 0-3 double bonds.
- the nitrogen and sulfur heteroatoms can be optionally oxidized.
- the nitrogen heteroatoms can be optionally quaternized.
- heterocyclic also includes bicyclic groups in which any of the above heterocyclic rings is fused to a benzene ring or or a cyclohexane ring or another heterocyclic ring.
- Heterocyclics include: pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, iso
- Heterocyclics also include:
- nitrogen containing heterocycles can be N-protected.
- the A, X and B components may have asymmetric centers and occur as racemates, racemic mixtures, mixtures of diastereomers and as individual diastereomers, with all isomeric forms being included.
- Coupling reagents known in the art which can be used include, but are not limited to, dicyclohexylcarbodiimide (DCC), 3-ethyl-3'-(dimethylamino)propylcarbodiimide (EDC), bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (BOP-Cl), dipenylphosphoryl azide (DPPA) and the like.
- DCC dicyclohexylcarbodiimide
- EDC 3-ethyl-3'-(dimethylamino)propylcarbodiimide
- BOP-Cl bis(2-oxo-3-oxazolidinyl)-phosphinic chloride
- DPPA dipenylphosphoryl azide
- Acid halide and other activated ester derivatives of the carboxylic acid or sulfonic acid are useful for the coupling reactions with (II).
- Acid halide derivatives include the acid chloride.
- Activated ester derivatives include activated esters commonly used by those skilled in the art for activating carboxylic acid groups for coupling with an amine to form an amide bond or for coupling with an alcohol to form an ester bond including, but not limited to, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides such as isobutyloxycarbonylchloride and the like, N-hydroxysuccinimide derived esters, N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters, N-hydroxy-5-norbornene-2,3-dicarboxamide derived esters, 2,4,5-trichlorophenol derived esters and the like.
- These compounds are in turn treated with various nucleophiles, such as thiols, alcohols, amines, or organometallic reagents, which serve to open the aziridine ring.
- the acetonide can be removed by acid hydrolysis.
- G is a sulfonic acid residue, e.g. p-toluenesulfonyl
- this group may be removed reductively, for example, with sodium in liquid ammonia or with sodium napthalenide, to provide compounds of the formula XXXII wherein G is hydrogen.
- These compounds in turn, can be N-acylated with protected amino acids, e.g. Cbz-valine, to provide additional compounds of the formula XXXII.
- compounds of the invention of the formula XXXVI and XXXVII where R 3 is benzyl may be prepared by acylation of XXXIII with bromoacetyl bromide, followed by displacement of the bromide with various amine nucleophiles.
- R 800 and R 801 may be selected independently from hydrogen and alkyl, or may constitute a heterocyclic ring incorporating the nitrogen to which they are appended, e.g., rings such as morpholine, piperidine, and piperazine.
- Compounds of formula XL and XLI may be prepared by acylation of XXXIII with (chloromethyl)benzoyl chloride, followed by displacement of the benzylic chloride group with various amine nucleophiles.
- the compound of the formula LXIII may be oxidized with the Swem reagent in a solvent like THF, and without isolation, treated with an organometallic reagent, such as a Grignard reagent, to provide compounds of the formula LXVII where R 3 is benzyl. These compounds, may in turn, be converted to the carbamates LXVIII with an isocyanate, wherein R 804 is hydrogen or benzyl or substituted benzyl.
- carbamates may then be treated with a strong base such as potassium t-butoxide or sodium hydride in a suitable solvent such as THF, and the resulting cyclic carbamates treated with hydrogen over a palladium catalyst to provide compounds of the formula LXIX.
- a strong base such as potassium t-butoxide or sodium hydride in a suitable solvent such as THF
- a suspension of 120 mg (3.0 mmol) of sodium hydride (60% suspension in oil) in 20 ml of tetrahydrofuran was cooled to 0°C and treated with a solution of 937 mg (2.95 mmol) of bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate in 5 ml of tetrahydrofuran.
- the resulting solution was stirred for 10 min at 0°C, treated with a solution of 2.93 mmol of the resultant compound of Example 1C in 5 ml of tetrahydrofuran, and stirred at ambient temperature for 1 h.
- the bath was then removed, and the solution was immediately treated with 100 ml of saturated aqueous ammonium chloride followed by 300 ml of ether.
- 100 ml of 1 N NH 4 OH was added, and the mixture was stirred under air atmosphere for several hours while the aqueous layer turned dark blue.
- the mixture was then extracted with 500 ml of ether.
- the organic layer was washed with saturated brine and concentrated in vacuo without drying to give a yellow oil.
- the combined aqueous layers were extracted with 500 ml of additional ether, which was added to the above oil.
- the resulting solution was washed with saturated brine, dried over MgSO 4 , and concentrated to a yellow oil.
- the oil was taken up in 100 ml of dichloromethane, treated with 50 g of silica gel, and concentrated in vacuo until the residue was a freely flowing solid.
- the solid was placed on top of a 60 mm column containing 300 g of silica gel and eluted sequentially with 1200 ml of hexane (to bring out biphenyl formed as a side product) followed by 5000 ml of 5% ethyl acetate in hexane. Combination of the pure fractions gave 11.95 g (65%) of the desired compound.
- the two-phase mixture was stirred for 2 hours, and the layers were separated.
- the organic layer was washed sequentially with 200 ml portions of 2 M NaOH, water, and saturated brine.
- the combined aqueous layers were extracted with 200 ml of ether, which was washed sequentially with 50 ml of water and 50 mL of aqueous brine, combined with the original organic phase, dried over MgSO 4 , and concentrated in vacuo.
- the resulting oil was taken up in 100 ml of dichloromethane, treated with 50 g of silica gel, and concentrated in vacuo until the residue was a freely flowing solid.
- the combined organic layers were washed sequentially with 400 ml of water and 200 ml of saturated brine, dried over MgSO 4 , and concentrated in vacuo to a solid.
- the solid was taken up in 100 ml of dichloromethane, treated with 50 g of silica gel, and concentrated in vacuo until the residue was a freely flowing solid.
- the solid was placed on top of a 60 mm column containing 300 g of silica gel and eluted sequentially with 1000 ml of 10% ethyl acetate in hexane, 1000 ml of 15% ethyl acetate in hexane, and 2000 ml of 25% ethyl acetate in hexane.
- a solution of 40 mg (0.068 mmol) of the resultant compound of Example 4A in 1 ml of tetrahydrofuran was treated sequentially with 0.034 ml (0.0034 mmol) of osmium tetroxide (2.5% in t-butanol) and 20 mg (0.14 mmol) of 4-methylmorpholine-N-oxide. After 20 h, the solution was treated with 10% Na 2 S 2 O 3 , stirred for 15 min, diluted with ether, washed with two portions of 10% Na 2 S 2 O 3 , one portion of water, and one portion of saturated aqueous NaHCO 3 , dried over Na 2 SO 4 , and concentrated in vacuo.
- Example 5 The resultant compound of Example 5 (18.5 mg, 0.038 mmol) was treated with 1 ml of 4 M HCl in dioxane. After 1 h, the solution was concentrated in vacuo to give the desired compound.
- Example 2C The resultant compound of Example 2C (25 mg, 0.063 mmol) was treated with 1 ml of 4 M HCl in dioxane, stirred for 0.5 h at ambient temperature, and concentrated in vacuo to give the desired compound.
- Example 13A The resultant compound of Example 13A (0.50 g, 1.23 mmol) was deprotected according to the procedure of Example 9 and coupled to adipic acid monomethyl ester (0.21 g, 1.28 mmol) using the mixed anhydride procedure of Example 7A to give, after flash chromatography using 40% ethyl acetate in chloroform, 0.53 g (96%) of the desired compound.
- Example 13B A mixture of the resultant compound of Example 13B (0.53 g, 1.18 mmol) and 100 mg of 10% palladium on carbon in 30 ml of methanol was stirred under one atmosphere of hydrogen. After 5 h, the mixture was filtered through Celite and concentrated to give 0.40 g (93%) of the desired compound as a solid.
- Example 14 (reference example).
- Example 14A To a stirred solution of the resultant compound of Example 14A (8.72 mmol) in anhydrous tetrahydrofuran (30 ml) under a nitrogen atmosphere at -78°C was added a solution of sodium hexamethyldisilylamide (9.6 ml, 9.59 mmol) in tetrahydrofuran. After stirring for 30 min at -78°C, t-butyl bromoacetate (2.21 g, 11.34 mmol) was added in anhydrous tetrahydrofuran and the resulting solution stirred 1 h at -78°C. The reaction was quenched by adding 20 ml of saturated aqueous ammonium chloride and partitioned between water and ether.
- Example 14C The resultant compound of Example 14C (1.47 mmol) was dissolved in a 1:1 (v:v) solution (6 ml) of trifluoroacetic acid and dichloromethane and stirred at room temperature for 1 h. The volatiles were removed in vacuo to provide the desired compound. The unpurified material was of sufficient purity to employ in subsequent steps.
- Example 15B Using the procedure of Example 15B but replacing N-methyl,O-methylhydroxylamine hydrochloride and NaHCO 3 with pyrazole provided the desired product as an oil.
- 1 H NMR (CDCl 3 ) ⁇ 7.52 (d, 1H), 7.10-7.35 (m,6H), 6.10 (dd,1H), 4.38 (dd,1H), 4.24 (dd,1H), 3.57 (s,3H), 3.37 (m,1H), 2.98 (dd,1H), 2.82 (dd,1H). coupled to the resultant compound of Example 138 to give the desired compound.
- Example 12 The resultant compound of Example 12 was hydrogenolyzed according to the procedure of Example 13C to provide the desired compound (R f 0.1, 10% methanol in chloroform) as a white solid, m.p. 131-132°C.
- Example 20C Using the procedure of Example 20C with the resultant compound of Example 21A provided the desired compound.
- Example 20C Using the procedure of Example 20C with the resultant compound of Example 22A provided the desired compound.
- the resulting solution was stirred at -60°C for 45 min, and was subsequently treated via syringe with 11 ml (80 mmol) of dry triethylamine. After being stirred for an additional 15 min at -60°C, the solution was quenched by addition of 10% aqueous citric acid, then immediately poured into a rapidly stirred mixture of 200 ml of 1:1 hexane:ether and 100 ml of 10% aqueous citric acid. The reaction flask was rinsed with ether which was added to the above mixture. The mixture was poured into a separatory funnel and the layers were separated. The aqueous layer was washed sequentially with dilute aqueous sodium bicarbonate and saturated brine, dried over MgSO 4 , and concentrated in vacuo to provide the crude desired compound.
- a 500 ml three-neck flask was charged with 27 g of TiCl 3 (DME) 2 followed by 200 ml of anhydrous dimethoxyethane (DME).
- DME TiCl 3
- DME dimethoxyethane
- a separate flask was charged with 20 g of Zn-Cu couple and connected to one of the side necks of the three-neck flask with Gooch tubing.
- the flask was sealed with septa, removed from the glove bag, and outfitted under positive argon flow with an overhead mechanical stirrer. Under positive argon pressure, Zn-Cu was added in portions with vigorous stirring. After addition, the Gooch tubing was removed and replaced with a rubber septum.
- the powder was placed on the top of a silica gel column and eluted first with 70:30 hexane:ethyl acetate to bring off the more mobile product (R f 0.26, 70:30 hexane:ethyl acetate) which contained two diastereomers (2S,3S,4S,5S and 2S,3R,4S,5S) followed by 60:40 hexane:ethyl acetate to bring off the less mobile product (R f 0.10) which contained one major diastereomer (2S,3R,4R,5S).
- (2S,3R,4R,5S)-2,5-Di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane (2.7 g, 5.4 mmol) was treated with 200 ml of 6N aqueous hydrochloric acid and heated to 90°C until the solid had completely dissolved (30 min). The resulting solution was cooled, concentrated in vacuo, treated with saturated brine and 3N aqueous NaOH, extracted with chloroform, dried over Na 2 SO 4 , and concentrated in vacuo.
- Example 30 Using the procedure of Example 30 with the resultant compound of Example 28 provided the desired compound.
- Example 30 Using the procedure of Example 30 but replacing the resultant compound of Example 17 with the resultant compound of Example 26 provided the desired compound.
- Example 30 Using the procedure of Example 30 but replacing the resultant compound of Example 17 with the resultant compound of Example 26 and replacing nicotinyl chloride hydrochloride with isonicotinyl chloride hydrochloride provided the desired compound.
- Example 23B Using the procedure of Example 23B with the resultant compound of Example 34A provided the desired compound.
- Example 34B was coupled to the resultant compound of Example 28 using the coupling procedure of Example 8 provided, after silica gel chromatography using a gradient of 3-5% methanol in chloroform, the desired compound (R f 0.31, 10% methanol in chloroform).
- Example 35A was hydrogenolyzed according to the procedure of Example 23B except that water was added prior to filtration to solubilize the product. Removal of the solvent after filtration provided the desired compound.
- Example 35B The resultant compound of Example 35B was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure described in Example 8 to give a crude mixture in which the product was soluble. The mixture was diluted with ethyl acetate, filtered, and the solid was washed sequentially with water and ethyl acetate. The residue was air-dried to provide the desired compound in 40% yield.
- Example 19A Using the procedure of Example 19A but replacing the resultant compound of Example 15A with the resultant compound of Example 36A and replacing O-benzylhydroxylamine hydrochloride with the resultant compound of Example 26 provided the desired compound.
- Example 19A Using the procedure of Example 19A but replacing O-benzylhydroxylamine hydrochloride with the resultant compound of Example 26 provided the desired compound.
- Example 38A was hydrogenolyzed according to the procedure of Example 23B to provide the desired compound.
- Example 38B was coupled to the resultant compound of Example 26 using the coupling procedure described in Example 20D to provide the desired compound.
- Example 39A was hydrogenolyzed according to the procedure of Example 23B to provide the desired compound.
- Example 39B was coupled to the resultant compound of Example 26 using the coupling procedure described in Example 20D to provide the desired compound.
- Example 26 Using the procedure of Example 26 with the more mobile mixture of compounds of Example 25B provided a mixture of diamines which were separated by silica gel chromatography using 2% isopropylamine in chloroform containing sequential amounts of 1%, 2% and 5% methanol.
- Example 46 Using the procedure of Example 46 with (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided the desired compound (R f 0.32, 30% ethyl acetate in hexane), as a white solid, m.p. 208-212°C.
- Example 51 The resultant compound of Example 51 was coupled to Cbz-valine using the carbodiimide coupling procedure of Example 8 to provide the desired compound (R f 0.48, 5% methanol in chloroform) as a white solid, m.p. 178-182°C, in 88% yield.
- Mass spectrum: (M + H) + 634.
- Example 53A was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 8 to provide the desired compound (20%, R f 0.3, 10% methanol in chloroform) as a white solid, m.p. 200-204°C.
- Mass spectrum: (M + H) + 555.
- Example 57B The resultant compound of Example 57B (3.05 g, 13.7 mmol) was treated with 30 ml of 4N HCl in dioxane and heated at 40°C for 0.5 h. The solvent was removed in vacuo to provide the crude desired compound as a light brown solid.
- Example 29A and Example 54A Using the procedures of Example 29A and Example 54A but replacing the resultant compound of Example 22A with the resultant compound of Example 57D provided the desired compound.
- Picolinic acid was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure described in Example 8 to provide after silica gel chromatography using a gradient of 5-10% methanol in chloroform, the desired compound (R f 0.16, 10% methanol in chloroform) as a white solid, m.p. 167-171°C, in 61% yield.
- Mass spectrum: (M + H) + 709.
- Example 61A The resultant compound of Example 61A was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure described in Example 8 to provide after silica gel chromatography using a gradient of 5-10% methanol in chloroform, the desired compound (R f 0.1, 10% methanol in chloroform) as a white solid, m.p. 260-263°C, in 37% yield.
- Mass spectrum: (M + H) + 765.
- Example 29A and Example 54A Using the procedures of Example 29A and Example 54A but replacing the resultant compound of Example 22A with the resultant compound of Example 20B provided the desired compound.
- Example 29A and Example 54A Using the procedures of Example 29A and Example 54A but replacing the resultant compound of Example 22A with the resultant compound of Example 21A provided the desired compound.
- Example 69 The resultant compound of Example 69 (200 mg, 0.31 mmol) was treated with 20 ml of 4N HCl in dioxane. After being stirred at ambient temperature for 2 h, the solvent was removed in vacuo. The residue was partitioned between chloroform and aqueous NaHCO 3 , dried over Na 2 SO 4 , and concentrated. Silica gel chromatography using a gradient of 2% methanol/2% isopropylamine in chloroform provided 140 mg (84%) of the desired compound.
- Example 72C The resultant compound of Example 72C was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 8 to provide, after silica gel chromatography using 2% methanol in chloroform, the desired compound (45%, R f 0.5, 10% methanol in chloroform) as a white solid, m.p. 85-89°C.
- Mass spectrum: (M + H) + 867.
- Example 14A Using the procedure of Example 14A but replacing 4-(2-propyl)-oxazolidine-2-one with 4-benzyloxazolidine-2-one and replacing 4-methylpentanoyl chloride with isovaleryl chloride provided the desired compound.
- Example 14B Using the procedure of Example 14B with the resultant compound of Example 73A provided, after silica gel chromatography using 15% ethyl acetate in hexane followed by dichloromethane, the desired compound (R f 0.35, 20% ethyl acetate in hexane) in 88% yield.
- Example 14C Using the procedure of Example 14C with the resultant compound of Example 73B provided, after silica gel chromatography using 6% ethyl acetate in hexane, the desired compound (R f 0.43, 10% ethyl acetate in hexane) in 60% yield.
- Example 14D Using the procedure of Example 14D with the resultant compound of Example 73C provided the desired compound as a crude colorless oil.
- Example 73D was coupled to the resultant compound of Example 57C using the mixed anhydride coupling method described in Example 1F to provide, after silica gel chromatography using 60% ethyl acetate in chloroform, the desired compound (R f 0.19, 60% ethyl acetate in chloroform) in 73% yield.
- Example 73E The resultant compound of Example 73E was hydrogenolyzed according to the procedure described in Example 13C to provide the desired compound.
- Example 74A The resultant compound of Example 74A was hydrolyzed according to the procedure of Example 29A to provide the desired compound.
- Example 74B Using the procedures of Example 61A and Example 61B but replacing 3-(3-pyridinyl)acrylic acid with the resultant compound of Example 74B provided the desired compound.
- Example 24B was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 20D to provide, after silica gel chromatography using 5% methanol in chloroform, the desired compound (R f 0.21, 10% methanol in chloroform) as a white solid, m.p. 227-230°C (dec) in 47% yield.
- Mass spectrum: (M + H) + 813.
- Example 73B The resultant compound of Example 73B was hydroyzed according to the procedure of Example 1D except that excess 30% hydrogen peroxide was included in the reaction mixture to provide the crude desired compound.
- Example 82A was coupled to the resultant compound of Example 70 using the carbodiimide coupling procedure of Example 8 to provide, after silica gel chromatography using a gradient of 1-5% methanol in chloroform, the desired compound in 22% yield.
- Example 82B The resultant compound of Example 82B (45 mg) was treated with 1.5 ml of 2:1 dichloromethane/trifluoroacetic acid. After 4 h at ambient temperature, the solution was concentrated in vacuo to provide 28 mg (55%) of the desired compound as an off-white solid, m.p. 208-210°C.
- Example 84 (reference example)
- Example 84A The resultant compound of Example 84A in 3 mL of anhydrous diethyl ether was added to -75 mL of liquid ammonia and small pieces of sodium metal were added until a blue color persisted for 5 minutes. The reaction was quenched with ammonium chloride and the ammonia was evaporated. The residue was dissolved in diethyl ether and the ether solution was washed with dilute aqueous ammonium hydroxide and brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the intermediate 6,9-diamino compound. The diamine (159 mg, 0.53 mmol) was dissolved in 5 mL of THF and the THF solution was cooled in an ice bath.
- Example 85A The resultant compound of Example 85A was converted to the title compound in a manner analogous to that described in Examples 84B and 84C
- dialdehyde is purifed by chromatography on silica gel and then oxidized to dimethyl 2,3:4,5-diepoxyadipate according to the procedure of D.R. Williams, et al (Tetrahederon Letters, 1988, 5087-5090).
- the diepoxide is then treated with the cuprate reagent prepared from benzyl lithium and CuBr-Me 2 S or CuCN in an ethereal solvent such as tetrahydrofuran or diethyl ether, to affored dimethyl 3,4-dihydroxy-2,5-bis(phenylmethyl)adipate.
- the resulting diol is then protected as the bis(t-butyldiphenylsilyl) ether by treatment with t-butyldiphenylsilyl chloride in DMF in the presence of imidazole.
- Saponification of the diester with LiOH in aqueous THF, followed by acidification and coupling to valine benzyl ester in the manner described in Example 304, followed by deprotection with tetrabutylammmonium fluoride in THF affords the title compound.
- the resulting diol is treated with benzyl isocyanate, in the presence of either DMAP or diisopropylethylamine, in an inert solvent, such as benzene or THF.
- the resulting bis-carbamate is then treated with 2 equivalents of NaH or potassium t-butoxide in THF.
- the resulting diol is then treated with hydrogen over a Pd catalyst in a solvent such as MeOH to afford (2S, 3S, 4S, 5S)-3,4-dihydroxy-1,6-diphenyl-hexane-2,5-diamine. This is then converted into the title compound by treatment with Cbz-valine p-nitrophenyl ester in THF in the presence of triethylamine.
- Example 46 Using the procedure of Example 46 with the resultant compound of Example 89 provided the desired compound.
- Example 13C Using the procedure of Example 13C with the resultant compound of Example 49 provided the desired compound.
- Example 13C Using the procedure of Example 13C with the resultant compound of Example 48 provided the desired compound.
- Indole-2-carboxylic acid was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Indole-2-carboxylic acid was coupled to the resultant compound of Example 92 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Indole-2-carboxylic acid was coupled to the resultant compound of Example 94 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Example 44A Using the procedure of Example 44A but replacing L-valine methyl ester hydrochloride with the resultant compound of Example 26 and replacing benzyl bromoacetate with t-butylbromoacetate provided the desired compound.
- the inhibitory potency of the retroviral protease inhibiting Compounds disclosed herein can be determined by the following method.
- Such a compound is dissolved in DMSO and a small aliquot further diluted with DMSO to 100 times the final concentration desired for testing.
- the reaction is carried out in a 6 X 50 mm tube in a total volume of 300 microliters.
- the final concentrations of the components in the reaction buffer are: 125 mM sodium acetate, 1 M sodium chloride, 5 mM dithiothreitol, 0:5 mg/ml bovine serum albumin, 1.3 uM fluorogenic substrate, 2% (v/v) dimethylsulfoxide, pH 4.5.
- the reaction mixture is placed in the fluorometer cell holder and incubated at 30°C for several minutes.
- the reaction is initiated by the addition of a small aliquot of cold HIV protease.
- the fluorescence intensity (excitation 340 nM, emmision 490 nM) is recorded as a function of time.
- the reaction rate is determined for the first six to eight minutes. The observed rate is directly proportional to the moles of substrate cleaved per unit time. The percent inhibition is 100 X (1 - (rate in presence of inhibitor)/(rate in absence of inhibitor)).
- Retroviral protease inhibiting compounds disclosed herein inhibit HIV-1 protease at concentrations between 0.01 nM and 500,000 nM.
- Table 3 shows the inhibitory potencies of specific compounds against HIV-1 protease.
- Compound of Example Percent Inhibition Inhibitor Concentration (micromolar) 10 100 270 25B 40 0.01 27B 74 0.001 31 58 0.005 47 44 0.01 48 56 0.001 49 65 0.001 50 67 0.1 52 86 0.005 53 73 0.005 54 81 0.001 55 84 0.001 56 76 0.001 57 45 0.001 58 68 0.001 59 62 0.001 60 78 0.1 61 38 0.001 62 62 0.005 63 74 0.005 66 44 0.002 67 78 0.001 68 69 0.001 69 67 0.005 71 68 0.01 73 45 0.01 75 69 0.001 76 74 0.001 77 33 0.01 78 40
- the anti-HIV activity of compounds disclosed herein can be determined by the following method.
- a mixture of 0.1 ml (2 X 10 5 cells/ml) of H9 cells and 0.1 ml (100 infectious units) of HIV-1 3B was incubated on a shaker for 2 h at 37°C.
- the resulting culture was washed three times and resuspended into 2 ml of medium containing 10 ul of a compound of the invention in dimethylsulfoxide.
- the control culture was treated in an identical manner except no compound was added to the medium. Aliquots of culture supernatants were removed at 3 time points, usually 4, 7 and 10 days, and monitored for HIV-1 antigen EIA (HIVAG-1) (Paul, et al., J. Med. Virol., 22 357 (1987)).
- Cell viability was determined by trypan blue dye exclusion, and cells were refed with media containing compound (except for control wells which were refed with media only) at these time points.
- Per cent inhibition of HIV by the compound was determined by comparing HIV antigen levels in the supernatants of infected cells incubated with compound to supernatants from the control culture without compound.
- the IC 50 is the concentration of compound that gives 50% inhibition of HIV activity.
- the LD 50 is the concentration of compound at which 50% of the cells remain viable.
- Table 4 shows the inhibitory potencies of compounds disclosed herein against HIV-1 in H9 cells: Compound of Example IC 50 (micromolar) LD 50 (micromolar) 27 0.12 11 47 2.3-4.5 25 48 0.015-0.027 60 49 0.05-0.07 >100 52 0.54 30 54 0.10 >100 55 0.04-0.1 >100 57 0.42 >100 58 0.05-0.1 >100 59 0.09-0.18 >100 63 0.27 >100 75 0.4-1.6 >100 76 0.25 180 77 1.2-7.5 >100 78 0.3-0.9 45
Abstract
Description
- This invention was made with Government support under contract number AI27220-01 awarded by the National Institute of Allergy and Infectious Diseases. The Government has certain rights in this invention.
- The present invention relates to novel synthetic intermediates for making compounds for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease, and for treating a retroviral infection and in particular an HIV infection.
- Retroviruses are those viruses which utilize a ribonucleic acid (RNA) intermediate and a RNA-dependent deoxyribonucleic acid (DNA) polymerase, reverse transcriptase, during their life cycle. Retroviruses include, but are not limited to, the RNA viruses of the Retroviridae family, and also the DNA viruses of the Hepadnavirus and Caulimovirus families. Retroviruses cause a variety of disease states in man, animals and plants. Some of the more important retroviruses from a pathological standpoint include human immunodeficiency viruses (HIV-1 and HIV-2), which cause acquired immune deficiency syndrome (AIDS) in man, hepatitis B virus, which causes hepatitis and hepatic carcinomas in man, human T-cell lymphotrophic viruses I, II, IV and V, which cause human acute cell leukemia, and bovine and feline leukemia viruses which cause leukemia in domestic animals.
- Proteases are enzymes which cleave proteins at specific peptide bonds. Many biological functions are controlled or mediated by proteases and their complementary protease inhibitors. For example, the protease renin cleaves the peptide angiotensinogen to produce the peptide angiotensin I. Angiotensin I is further cleaved by the protease angiotensin converting enzyme (ACE) to form the hypotensive peptide angiotensin II. Inhibitors of renin and ACE are known to reduce high blood pressure in vivo. An inhibitor of a retroviral protease should provide a therapeutic agent for diseases caused by the retrovirus.
- The genomes of retroviruses encode a protease that is responsible for the proteolytic processing of one or more polyprotein precursors such as the pol and gag gene products. See Wellink, Arch. Virol. 98 1 (1988). Retroviral proteases most commonly process the gag precursor into core proteins, and also process the pol precursor into reverse transciptase and retroviral protease. In addition, retroviral proteases are sequence specific. See Pearl, Nature 328 482 (1987).
- The correct processing of the precursor polyproteins by the retroviral protease is necessary for the assembly of infectious virions. It has been shown that in vitro mutagenesis that produces protease-defective virus leads to the production of immature core forms which lack infectivity. See Crawford, J. Virol. 53 899 (1985); Katoh, et al., Virology 145 280 (1985). Therefore, retroviral protease inhibition provides an attractive target for antiviral therapy. See Mitsuya, Nature 325 775 (1987).
- Current treatments for viral diseases usually involve administration of compounds that inhibit viral DNA synthesis. Current treatments for AIDS (Dagani, Chem. Eng. News, November 23, 1987 pp. 41-49) involve administration of compounds such as 2',3'-dideoxycytidine, trisodium phosphonoformate, ammonium 21-tungsto-9-antimoniate, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide, 3'-azido-3'-deoxythymidine, and adriamycin that inhibit viral DNA synthesis; compounds such as AL-721 and polymannoacetate which may prevent HIV from penetrating the host cell; and compounds which treat the opportunistic infections caused by the immunosuppression resulting from HIV infection. None of the current AIDS treatments have proven to be totally effective in treating and/or reversing the disease. In addition, many of the compounds currently used to treat AIDS cause adverse side effects including low platelet count, renal toxicity and bone marrow cytopenia.
- Inhibitors of HIV protease are disclosed by Moore, Biochem. Biophys. Res. Commun., 159 420 (1989); Billich, J. Biol. Chem., 263 1790S (1988); Richards, FEBS Lett., 247 113 (1989); Miller, Science 246 1149 (1989); Meek, Nature 343 90 (1990); McQuade, Science 247 454 (1990); Sigal, et al., EP-A-337714, published October 18, 1989; Kempf, et al., WO89/10752, published November 16, 1989; Molling, et al., EP-A-354522, published February 14, 1990; Sigal, et al., 357332, published March 7, 1990; Handa, et al., EP-A-346847, published December 20, 1989; Desolms, et al, EP-A-356223, published February 28, 1990; Schirlin, et al., EP-A-362002, published April 4, 1990; Dreyer, et al., WO90/00399, published January 25, 1990; and Hanko, et al., EP-A-361341, published April 4, 1990.
- U.S. Patent No. 4,652,552 discloses methyl ketone derivatives of tetrapeptides as inhibitors of viral proteases. U.S. Patent No. 4,644,055 discloses halomethylketone derivatives of peptides as inhibitors of viral proteases.
- None of the references mentioned above disclose or suggest the invention claimed herein.
- The compounds (A-X-B) shown in Table 1 are disclosed in the following list of references. None of these references disclose or suggest the use of these compounds as inhibitors of retroviral protease or as antiviral agents.
- 1. S. Apparao, et al., Synthesis, 896 (1987).
- 2. A. Padwa, et al., J. Chem. Soc. Perkin Trans. I, 2639 (1988).
- 3. M. McKervey, et al., Tet. Let., 23 2509 (1982).
- 4. M. Fujiwara, et al., Chem. Abstr. 91:149446.
- 5. C. Piantadosi, et al., J. Med. Chem., 19 222 (1976).
- 6. M. Midland, et al., J. Org. Chem., 39 732 (1974).
- 7. R. Dybas, et al., U.S. Patent No. 4172094, published October 23, 1979.
- 8. A. Hosomi, et al., Chem. Pharm. Bull., 36 3736 (1988).
- 9. K. Taniguchi, et al., Chem. Abstr. 108:29541.
- 10. R. Freidlina, et al., Chem. Abstr. 57:16464.
- 11. T. Morikawa, Chem. Abstr. 54:19588.
- 12. M. Sorokin, et al., Chem. Abstr. 108:111518.
- 13. G. Ostroumova, Chem. Abstr. 72:56187.
- 14. T. Kamijo, et al., Chem. Pharm. Bull., 31 4189 (1983).
- 15. T. Takeda, et al., Bull. Chem. Soc. Jpn., 57 1863 (1984).
- 16. S. Kukalenko, et al., Chem. Abstr. 78:71621.
- 17. K. Ito, et al., Chem. Pharm. Bull., 27 1691 (1979).
- 18. H. Kleiner, Chem. Abstr. 73:45598.
- 19. G. Rawson, et al., Tetrahedron, 26 5653 (1970).
- 20. M. Il'ina, et al., Chém. Abstr. 70:37885.
- 21. E. Regel, et al., U.S. Patent No. 4,618619, issued October 21, 1986.
- 22. V. Plakhov, et al., Chem. Abstr. 73:30312.
- 23. K. Dathe, et al., Chem. Abstr. 84:73203.
- 24. W. Wegener, et al., Chem. Abstr. 77:101763.
- 25. E. Mukhametzyanova, et al., Chem. Abstr. 71:39096.
- 26. K. Petrov, et al., Chem. Abstr. 74:141977.
- 27. H. Gilman, et al., Chem. Abstr. 89:172760.
- 28. T. Hosokawa, et al., Bull. Chem. Soc. Jpn., 58 194 (1985).
- 29. G. Olah, et al., Synthesis, 221 (1980). (In the table "Ph" represents phenyl).
-
-
- The chiral centers of the compounds of the invention may be racemic or asymmetric. Racemic mixtures, mixtures of diastereomers, as well as single diastereomers of the compounds of the invention are included in the present invention. The terms "S" and "R" configuration are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13 - 30.
- The terms "Ala", "Asn", "Gly", "Ile", "Leu", "Lys", "Phe", "Pro", "Ser", and "Val" as used herein refer to alanine, asparagine, glycine, isoleucine, leucine, lysine, phenylalanine, proline, serine and valine, respectively. In general, the amino acid abbreviations used herein follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature for amino acids and peptides (Eur. J. Biochem. 1984, 158, 9-31).
- The term "N-protecting group" or "N-protected" as used herein refers to those groups intended to protect nitrogen atoms against undesirable reactions during synthetic procedures or to prevent the attack of exopeptidases on the final compounds or to increase the solubility of the final compounds and includes but is not limited to acyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz) or benzoyl groups or an L- or D-aminoacyl residue, which may itself be N-protected similarly.
- The term "loweralkyl" as used herein refers to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.
- Compounds of the invention, which are useful as intermediates, may be selected from 2-(N-benzylamino)-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane;
2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane;
5-amino-2-(N-benzylamino)-3,4-dihydroxy-1,6-diphenylhexane dihydrochloride;
2-amino-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane;
2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4R,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4R,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane or a hydrochloride salt thereof;
(2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane or a hydrochloride salt thereof;
(2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane or a hydrochloride salt thereof;
(2S,3S,4R,5S)-5-amino-2-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
and
(2S,3R,4S,5S)-2,5-di-(N-((isopropylaminocarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane. - According to preferred embodiments, such compounds may be selected from (2S,3R,4R,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; and
(2S,3R,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane. - Also preferred are those compounds selected from (2S,3R,4R,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane; and
(2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane;
or a hydrochloride salt thereof. - Still further compounds of the invention are selected from (2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;
(2S,3R,4R,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; and
(2S,3S,4R,5S)-2-(N-(t-butyloxy)carbonyl)amino)-5-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane. - Other intermediates of the invention are selected from 2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide;
2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and
2,5-di-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide. - The term "alkylamino" as used herein refers to a loweralkyl appended to an NH radical.
- The term "cycloalkyl" as used herein refers to an aliphatic ring having 3 to 7 carbon atoms including, but not limited to, cyclopropyl, cyclopentyl, cyclohexyl and the like. Cycloalkyl groups can be unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, haloalkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, mercapto, nitro, carboxaldehyde, carboxy, carboalkoxy and carboxamide.
- The terms "alkoxy" and "thioalkoxy" as used herein refer to R18O- and R18S-, respectively, wherein R18 is a loweralkyl group or benzyl.
- The term "polyalkoxy" as used herein refers to -OR45 wherein R45 is a straight or branched chain containing 1-5, Cn'-O-Cn" linkages wherein n' and n" are independently selected from 1 to 3, including but not limited to methoxyethoxymethoxy, methoxymethoxy and the like.
- The term "halo" or "halogen" as used herein refers to -Cl, -Br, -I or -F.
- The term "haloalkyl" as used herein refers to a loweralkyl radical in which one or more of the hydrogen atoms are replaced by halogen including, but not limited to, chloromethyl, trifluoromethyl, 1-chloro-2-fluoroethyl and the like.
- The term "heterocyclic ring" or "heterocyclic" as used herein refers to any 3- or 4-membered ring containing a heteroatom selected from oxygen, nitrogen and sulfur; or a 5- or 6-membered ring containing one, two or three nitrogen atoms; one nitrogen and one sulfur atom; or one nitrogen and one oxygen atom. The 5-membered ring has 0-2 double bonds and the 6-membered ring has 0-3 double bonds. The nitrogen and sulfur heteroatoms can be optionally oxidized. The nitrogen heteroatoms can be optionally quaternized.
The term "heterocyclic" also includes bicyclic groups in which any of the above heterocyclic rings is fused to a benzene ring or or a cyclohexane ring or another heterocyclic ring. Heterocyclics include: pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, piperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, furyl, thienyl and benzothienyl. -
- Heterocyclics can be unsubstituted or monosubstituted or disubstituted with substituents independently selected from hydroxy, halo, oxo (=O), alkylimino (R*N= wherein R* is a loweralkyl group), amino, alkylamino, dialkylamino, alkoxy, polyalkoxy, haloalkyl, cycloalkyl, -COOH, -SO3H and loweralkyl. In addition, nitrogen containing heterocycles can be N-protected.
- In the compounds disclosed herein, the A, X and B components may have asymmetric centers and occur as racemates, racemic mixtures, mixtures of diastereomers and as individual diastereomers, with all isomeric forms being included.
-
- The intermediates of the invention or compounds made from these intermediates can be prepared as shown in Schemes 1-5. The syntheses of segments (II) are described in the Examples. The process shown in Scheme 1 discloses the condensation of carboxylic or sulfonic acid G - OH to segments (II) in the presence of a coupling reagent to give (VI).
- Coupling reagents known in the art which can be used include, but are not limited to, dicyclohexylcarbodiimide (DCC), 3-ethyl-3'-(dimethylamino)propylcarbodiimide (EDC), bis(2-oxo-3-oxazolidinyl)-phosphinic chloride (BOP-Cl), dipenylphosphoryl azide (DPPA) and the like.
- In addition to the use of the carboxylic acids or sulfonic acids shown in the scheme, acid halide and other activated ester derivatives of the carboxylic acid or sulfonic acid are useful for the coupling reactions with (II). Acid halide derivatives include the acid chloride. Activated ester derivatives include activated esters commonly used by those skilled in the art for activating carboxylic acid groups for coupling with an amine to form an amide bond or for coupling with an alcohol to form an ester bond including, but not limited to, formic and acetic acid derived anhydrides, anhydrides derived from alkoxycarbonyl halides such as isobutyloxycarbonylchloride and the like, N-hydroxysuccinimide derived esters, N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters, N-hydroxy-5-norbornene-2,3-dicarboxamide derived esters, 2,4,5-trichlorophenol derived esters and the like.
- Compounds of the invention wherein X is -CH(OH)-CH(OH)- and R3 is phenyl can be prepared as shown in Scheme 2. The process shown in Scheme 2 discloses the oxidation of XXVI to protected aminoaldehyde XXVII. Reductive dimerization of XXVII provides the doubly protected diaminodiol XXVIII, which is deprotected to give diaminodiol XXIX. Coupling of XXIX according to Scheme 1 provides compounds of the invention.
- Compounds of the invention of the the type XXXII may be prepared as outlined in Scheme 3. Thus the known aziridine XXX (Y. L. Merrer, et al Heterocycles, 1987, 25, 541-548) is acylated (e.g. with G=Cbz-valine), sulfonated (e.g. with G=p-toluene sulfonic acid), or phosphorylated (e.g. with G=diphenylphosphinic acid), to provide compounds of the formula XXXI. These compounds are in turn treated with various nucleophiles, such as thiols, alcohols, amines, or organometallic reagents, which serve to open the aziridine ring. The acetonide can be removed by acid hydrolysis. When G is a sulfonic acid residue, e.g. p-toluenesulfonyl, this group may be removed reductively, for example, with sodium in liquid ammonia or with sodium napthalenide, to provide compounds of the formula XXXII wherein G is hydrogen. These compounds, in turn, can be N-acylated with protected amino acids, e.g. Cbz-valine, to provide additional compounds of the formula XXXII.
- As outlined in Scheme 4, compounds of the invention of the formula XXXVI and XXXVII where R3 is benzyl may be prepared by acylation of XXXIII with bromoacetyl bromide, followed by displacement of the bromide with various amine nucleophiles. R800 and R801 may be selected independently from hydrogen and alkyl, or may constitute a heterocyclic ring incorporating the nitrogen to which they are appended, e.g., rings such as morpholine, piperidine, and piperazine. Compounds of formula XL and XLI may be prepared by acylation of XXXIII with (chloromethyl)benzoyl chloride, followed by displacement of the benzylic chloride group with various amine nucleophiles.
- As outlined in Scheme 5, the compound of the formula LXIII may be oxidized with the Swem reagent in a solvent like THF, and without isolation, treated with an organometallic reagent, such as a Grignard reagent, to provide compounds of the formula LXVII where R3 is benzyl. These compounds, may in turn, be converted to the carbamates LXVIII with an isocyanate, wherein R804 is hydrogen or benzyl or substituted benzyl. These carbamates may then be treated with a strong base such as potassium t-butoxide or sodium hydride in a suitable solvent such as THF, and the resulting cyclic carbamates treated with hydrogen over a palladium catalyst to provide compounds of the formula LXIX.
- Vinylmagnesium Bromide (120 mmol, 1 M) in ether was added to 80 ml of dry tetrahydrofuran and cooled under inert atmosphere to 0°C. Hydrocinnamaldehyde (8.0 ml, 61 mmol) was added dropwise, and the solution was stirred for 10 min, quenched cautiously with saturated aqueous ammonium chloride, extracted with ether, washed with saturated brine, dried over MgSO4, and concentrated to give 9.82 g (98.6%) of the crude desired product.
- A solution of the resultant compound of Example 1A (9.82 g, 60.6 mmol) and 8.2 g (120 mmol) of imidazole in 30 ml of dimethylformamide was treated with cooling (cold water bath) with 10 g (66 mmol) of t-butyldimethylsilyl chloride and stirred at ambient temperature. After 1 h, the solution was diluted with 1:1 ether:hexane, washed with three portions of water, dried over MgSO4, and concentrated in vacuo. Flash chromatography using 3% ethyl acetate in hexane gave 13.2 g (79%) of the desired compound as a colorless oil. 1H NMR (CDCl3) δ 0.04 (s, 3 H), 0.07 (s, 3 H), 0.90 (s, 9 H), 1.81 (m, 2 H), 2.66 (m, 2 H), 4.16 (q, J = 6 Hz, 1 H), 5.07 (dt, J = 10, 1 Hz, 1 H), 5.18 (dt, J = 17, 1 Hz, 1 H), 5.84 (ddd, J = 17, 10, 6 Hz, 1 H), 7.1-7.3 (m, 5 H). Mass spectrum: (M+H)+ = 277.
- A solution of 0.81 g (2.93 mmol) of the resultant compound of Example 1B in 20 ml of dichloromethane and 10 ml of methanol was cooled to -78°C. A mixture of ozone in air was bubbled through the solution until a blue color persisted. Air was bubbled through the solution to discharge excess ozone, and the solution was treated with dimethylsulfide. After being stirred overnight at ambient temperature, the solution was diluted with dichloromethane, washed with water, dried over MgSO4, and concentrated in vacuo to give 0.81 g (100%) of the crude desired product.
- A suspension of 120 mg (3.0 mmol) of sodium hydride (60% suspension in oil) in 20 ml of tetrahydrofuran was cooled to 0°C and treated with a solution of 937 mg (2.95 mmol) of bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate in 5 ml of tetrahydrofuran. The resulting solution was stirred for 10 min at 0°C, treated with a solution of 2.93 mmol of the resultant compound of Example 1C in 5 ml of tetrahydrofuran, and stirred at ambient temperature for 1 h. The solution was subsequently quenched with aqueous ammonium chloride, extracted with ether, washed with saturated brine, dried over MgSO4, and concentrated in vacuo. Flash chromatography using 3% ethyl acetate in hexane gave 578 mg (59%) of the desired compound. 1H NMR (CDCl3) δ 0.02 (s, 3 H), 0.08 (s, 3 H), 0.90 (s, 9 H), 1.83 (m, 2 H), 2.64, (ddd, J = 13, 11, 6 Hz, 1 H), 2.77 (ddd, J = 13, 11, 6 Hz, 1 H), 3.70 (s, 3 H), 5.38 (br q, J = 7 Hz, 1 H), 5.72 (dd, J = 11, 1 Hz, 1 H), 6.21 (dd, J = 11, 8 Hz, 1 H), 7.15-7.3 (m, 5 H). Mass spectrum (M+H)+ = 335.
- A solution of 567 mg (1.69 mmol) of the resultant compound of Example 1D in 13 ml of dioxane was cooled to 0°C, treated with 6.5 ml (3.2 mmol) of 0.5 M aqueous lithium hydroxide, and stirred at ambient temperature for 24 h. The resulting solution was poured into chloroform/1 N HCl, separated, dried over MgSO4, and concentrated to give the desired product. 1H NMR (CDCl3) δ 0.04 (s, 3 H), 0.09 (s, 3 H), 0.91 (s, 9 H), 1.88 (m, 2 H), 2.66, (m, 1 H), 2.78 (m, 1 H), 5.31 (br q, J = 7 Hz, 1 H), 5.78 (dd, J = 12, 1 Hz, 1 H), 6.34 (dd, J = 12, 8 Hz, 1 H), 7.15-7.3 (m, 5 H). Mass spectrum (M+H)+ = 321.
- A solution of the resultant compound of Example 1E (225 mg, 0.70 mmol) and 0.85 ml of 4-methylmorpholine in 15 ml of dichloromethane was cooled to 0°C and treated with 0.10 ml (0.77 mmol) of isobutyl chloroformate. The resulting solution was stirred for 10 min, treated with 0.089 ml (0.77 mmol) of isoamylamine, and stirred at ambient temperature for 2 h. The solution was subsequently diluted with dichloromethane, washed sequentially with 10% aqueous citric acid and aqueous NaHCO3, dried over Na2SO4, and concentrated. Flash chromatography using 15% ethyl acetate in hexane gave 245 mg (90%) of the desired compound as an oil. 1H NMR (CDCl3) δ 0.04 (s, 3 H), 0.09 (s, 3 H), 0.90 (s, 9 H), 0.92 (d, J = 7 Hz, 6 H), 1.41 (br q, J = 7 Hz, 2 H), 1.63 (heptet, J = 7 Hz, 1 H), 1.86 (m, 2 H), 2.63 (m, 1 H), 2.78 (m, 1 H), 3.30 (m, 2 H), 5.50 (br q, 1 H), 5.59 (dd, J = 11, 1 Hz, 1 H), 5.98 (dd, J = 11, 8 Hz, 1 H), 7.15-7.3 (m, 5 H). Mass spectrum (M+H)+ = 391.
- A solution of 15.1 g (54.5 mmol) of the resultant compound of Example 1A and 38 ml (220 mmol) of diisopropylethylamine in 450 ml of dry dichloromethane was cooled under N2 atmosphere in an acetone/ice bath and treated dropwise with 8.5 ml (110 mmol) of methanesulfonyl chloride. The solution was stirred for 7 min after addition was complete, then was quenched with 400 ml of 10% citric acid. The bath was removed, and the mixture was extracted with 800 ml of ether. The organic layer was washed sequentially with 500 ml of water and 300 ml of saturated brine, dried over MgSO4, and concentrated in vacuo to give the crude mesylate as an off-white solid. To a flame-dried 3-neck 1000 mL. flask equipped with an internal low-temperature thermometer was added 1.45 g (16 mmol) of anhydrous cuprous cyanide. The flask was then charged with 500 ml of anhydrous tetrahydrofuran. The suspension was cooled under N2 altmosphere in a dry ice/acetone bath. A solution of phenylmagnesium bromide (55 ml, 165 mmol) in ether (3M) was added via syringe. The bath was removed, and the resulting beige suspension was warmed with stirring by use of a water bath. As the internal temperature reached -5°C, the solid began to dissolve, and the solution began to turn darker. By the time the internal temperature reached -1°C, the solution was homogenous, and was immediately recooled by placement of the flask in a dry ice/acetone bath. As the internal temperature reached -65°C, addition of a solution of the above crude mesylate in 75 ml of tetrahydrofuran was added via cannula. The resulting solution was stirred at ca. -70°C for 15 min. The bath was then removed, and the solution was immediately treated with 100 ml of saturated aqueous ammonium chloride followed by 300 ml of ether. As the mixture warmed, 100 ml of 1 N NH4OH was added, and the mixture was stirred under air atmosphere for several hours while the aqueous layer turned dark blue. The mixture was then extracted with 500 ml of ether. The organic layer was washed with saturated brine and concentrated in vacuo without drying to give a yellow oil. The combined aqueous layers were extracted with 500 ml of additional ether, which was added to the above oil. The resulting solution was washed with saturated brine, dried over MgSO4, and concentrated to a yellow oil. The oil was taken up in 100 ml of dichloromethane, treated with 50 g of silica gel, and concentrated in vacuo until the residue was a freely flowing solid. The solid was placed on top of a 60 mm column containing 300 g of silica gel and eluted sequentially with 1200 ml of hexane (to bring out biphenyl formed as a side product) followed by 5000 ml of 5% ethyl acetate in hexane. Combination of the pure fractions gave 11.95 g (65%) of the desired compound. 1H NMR (CDCl3, major isomer) δ 1.40 (s, 9 H), 2.7-2.9 (m, 2 H), 3.32 (d, J = 7 Hz, 2 H), 4.4 (br, 2 H), 5.43 (dd, J = 15, 6 Hz, 1 H), 5.64 (dt, J = 15, 7 Hz, 1 H), 7.0-7.3 (m, 10 H).
- A solution of 11.71 g (34.75 mmol) of the resultant compound of Example 2A in 200 ml of dichloromethane was treated with 15 g (174 mmol) of solid sodium bicarbonate, cooled to 0°C, and treated with 24 g (69 mmol) of m-chloroperbenzoic acid (50%). The resulting suspension was sealed with a septum and stirred in a cold room (5°C) for three days. The resulting mixture, which contained much precipitate, was decanted into a 1000 ml flask. The white residue was broken up and washed out with 400 ml of 10% sodium thiosulfate solution and 300 ml of ether. The two-phase mixture was stirred for 2 hours, and the layers were separated. The organic layer was washed sequentially with 200 ml portions of 2 M NaOH, water, and saturated brine. The combined aqueous layers were extracted with 200 ml of ether, which was washed sequentially with 50 ml of water and 50 mL of aqueous brine, combined with the original organic phase, dried over MgSO4, and concentrated in vacuo. The resulting oil was taken up in 100 ml of dichloromethane, treated with 50 g of silica gel, and concentrated in vacuo until the residue was a freely flowing solid. The solid was placed on top of a 60 mm column containing 300 g of silica gel and eluted sequentially with 1000 ml of 5% ethyl acetate in hexane followed by 3500 ml of 12% ethyl acetate in hexane. Concentration of the combined fractions gave 9.36 g (76%) of the desired compound (ca. 4:1 mixture of diastereomers) as an oil which solidified upon standing.
- A solution of 9.12g (25.84 mmol) of the resultant compound of Example 2B 7.0 g (140 mmol) of lithium azide, and 1.73 g (32 mmol) of ammonium chloride in 75 ml of dimethylformamide and 7.5 ml of water was heated in an oil bath at 70°C for 32 hours. After being allowed to cool, the resulting solution was treated with 1000 ml of 1:1 ether/hexane and 800 ml of water. The layers were separated, and the aqueous layer was extracted with 500 ml of additional 1:1 ether/hexane. The combined organic layers were washed sequentially with 400 ml of water and 200 ml of saturated brine, dried over MgSO4, and concentrated in vacuo to a solid. The solid was taken up in 100 ml of dichloromethane, treated with 50 g of silica gel, and concentrated in vacuo until the residue was a freely flowing solid. The solid was placed on top of a 60 mm column containing 300 g of silica gel and eluted sequentially with 1000 ml of 10% ethyl acetate in hexane, 1000 ml of 15% ethyl acetate in hexane, and 2000 ml of 25% ethyl acetate in hexane. Concentration of the fractions gave 9.26 g (91%) of the desired compound as a ca. 4:1 mixture of diastereomers. 1H NMR (CDCl3) δ 1.42 (s, 9 H), 2.78 (m, 1 H), 2.89 (m, 1 H), 3.13 (m, 1 H), 3.29 (m, 1 H), 3.41 (m, 1 H), 3.53 (m, 1 H), 3.80 (m, 1 H), 4.06 (m, 1 H), 4.83 (m, 1 H), 7.2-7.35 (m, 10 H). Mass spectrum (M+H)+ = 338.
- A rapidly stirring suspension of 10 mg of 10% palladium on carbon in 0.3 ml of methanol was treated under inert atmosphere with 60 mg (0.95 mmol) of solid ammonium formate. After 3 min, a solution of 52 mg (0.13 mmol) of the resultant compound of Example 2C in 0.4 ml of methanol was added. The resulting mixture was stirred for 2 h, diluted with methanol and 1 N ammonium hydroxide, filtered through Celite, and concentrated in vacuo. The residue was treated with 1 N NaOH, extracted with two portions of chloroform, dried over sodium sulfate, and concentrated. Flash chromatography using 7.5% methanol in chloroform gave 37 mg (76%) of the desired compound (Rf 0.38, 2.5% methanol/2% isopropylamine in chloroform) as a white solid, m.p. 134-135°C. 1H NMR (CDCl3) δ 1.48 (s, 9 H), 2.50 (dd, J = 13, 10 Hz, 1 H), 2.8-3.1 (m, 4 H), 3.41 (br d, J = 7 Hz, 1 H), 4.11 (br q, J = 8 Hz, 1 H), 4.83 (br d, J = 9 Hz, 1 H), 7.15-7.35 (m, 10 H). Mass spectrum (M+H)+ = 370.
- Anal. Calcd. for C22H30N2O3·0.15H2O: C, 70.81; H, 8.18; N, 7.51. Found: C, 70.89; H, 8.15; N, 7.43.
- Using the procedure of Example 2A but replacing phenylacetaldehyde with N-benzyl-N-(benzyloxycarbonyl)-phenylalaninal gave, after flash chromatography using 20% ethyl acetate in hexane, 45 mg (30%) of the desired compound. 1H NMR (d6-DMSO, 100°C) δ 1.32 (s, 9 H), 2.54 (dd, J = 14, 7 Hz, 1 H), 2.62 (dd, J = 14, 7 Hz, 1 H), 2.77 (dd, J = 14, 7 Hz, 1 H), 2.83 (dd, J = 14, 7 Hz, 1 H), 4.04 (br pentet, J = 7 Hz, 1 H), 4.20 (d, J = 16 Hz, 1 H), 4.33 (d, J = 16 Hz, 1 H), 4.48 (br q, J = 7 Hz, 1 H), 5.03 (AA', 2 H), 5.44 (dd, J = 16, 6 Hz, 1 H), 5.61 (dd, J = 16, 7 Hz, 1 H), 7.0-7.4 (m, 20 H). Mass spectrum (M+H)+ = 591.
- A solution of 40 mg (0.068 mmol) of the resultant compound of Example 4A in 1 ml of tetrahydrofuran was treated sequentially with 0.034 ml (0.0034 mmol) of osmium tetroxide (2.5% in t-butanol) and 20 mg (0.14 mmol) of 4-methylmorpholine-N-oxide. After 20 h, the solution was treated with 10% Na2S2O3, stirred for 15 min, diluted with ether, washed with two portions of 10% Na2S2O3, one portion of water, and one portion of saturated aqueous NaHCO3, dried over Na2SO4, and concentrated in vacuo. Flash chromatography using 30% ethyl acetate in hexane gave the desired compound (Rf 0.43, 30% ethyl acetate in hexane) as a 2:1 mixture of diastereomers. Mass spectrum (M+H)+ = 625.
- Ammonia (ca. 3 ml) was condensed into a precooled (-78°C) mixture of excess sodium metal in 2 ml of tetrahydrofuran. A solution of 25 mg (0.040 mmol) of the resultant compound of Example 4B in 1 ml of tetrahydrofuran was added, and the resulting solution was stirred for 10 min, quenched with saturated aqueous ammonium chloride, allowed to warm to ambient temperature, extracted with ether, dried over Na2SO4, and concentrated to give the crude desired product. Mass spectrum: (M+H)+ = 491.
- The resultant compound of Example 5 (18.5 mg, 0.038 mmol) was treated with 1 ml of 4 M HCl in dioxane. After 1 h, the solution was concentrated in vacuo to give the desired compound.
- A solution of the resultant compound of Example 1E (57 mg, 0.18 mmol) and 0.022 ml of 4-methylmorpholine in 3 ml of dichloromethane was cooled to 0°C and treated with 0.026 ml (0.19 mmol) of isobutyl chloroformate. The resulting solution was stirred for 10 min, treated with a solution of 41 mg (0.19 mmol) of H-Val-Val-NH2 in 1.5 ml of dimethylformamide, and stirred at ambient temperature for 2 h. The solution was subsequently diluted with ethyl acetate, washed sequentially with 10 % aqueous citric acid and aqueous NaHCO3, dried over MgSO4, and concentrated. Flash chromatography using 60% ethyl acetate in chloroform gave 53 mg (57%) of the desired compound as a 1:1 mixture of diastereomers.
- A solution of 13 mg (0.025 mmol) of the resultant compound of Example 7A in 0.5 ml of tetrahydrofuran was treated with 0.065 ml (0.065 mmol) of tetra-n-butylammonium fluoride (1 M in tetrahydrofuran). After being stirred for 16 h, the solution was concentrated in vacuo. Flash chromatography using 7.5% methanol in chloroform gave the desired compound, m.p. 147-149°C, as a 1:1 mixture of diastereomers (Rf 0.15, 7.5% methanol in chloroform). Mass spectrum: (M+H)+ = 403.
- Anal. Calcd. for C22H33N3O4·0.5H2O: C, 64.05; H, 8.31; N, 10.19. Found: C, 63,84; H, 7.65; N, 10.06.
- A solution of 39 mg (0.16 mmol) of Cbz-Val-OH, 52 mg (0.14 mmol) of the resultant compound of Example 3 and 23 mg (0.17 mmol) of 1-hydroxybenzotriazole in 2 ml of dimethylformamide was treated with 0.019 ml (0.17 mmol) of 4-methylmorpholine, cooled to 0°C, and treated with 33 mg (0.17 mmol) of N-ethyl-N'-(dimethylaminopropyl)-carbodiimide hydrochloride. After being stirred at ambient temperature overnight, the solution was diluted with ethyl acetate, washed sequentially with 10% citric acid, water, and aqueous NaHCO3, dried over Na2SO4, and concentrated in vacuo. Separation of the desired compounds by flash chromatography using methanol in chloroform gave 80 mg (95%) of the desired compound (Rf 0.40, 10% methanol in chloroform) as a white solid, m.p. 187-187.5°C. Mass spectrum (M+H)+ = 604.
- The resultant compound of Example 2C (25 mg, 0.063 mmol) was treated with 1 ml of 4 M HCl in dioxane, stirred for 0.5 h at ambient temperature, and concentrated in vacuo to give the desired compound.
- A solution of 10 mg (0.04 mmol) of Ac-Val-Val-OH, 0.039 mmol of the resultant compound of Example 6, and 6 mg (0.044 mmol) of 1-hydroxybenzotriazole in 1 ml of dichloromethane and 0.4 ml of dimethylformamide was treated with 0.009 ml (0.08 mmol) of 4-methylmorpholine, cooled to 0°C, and treated with 9 mg (0.047 mmol) of N-ethyl-N'-(dimethylaminoethyl)carbodiimide. After being stirred at ambient temperature overnight, the solution was diluted with ethyl acetate, washed sequentially with aqueous NaHCO3 and water, dried over Na2SO4, and concentrated in vacuo. Separation of the desired compounds by flash chromatography using 6% methanol in chloroform gave 3.0 mg (13%) of the less.polar diastereomer (Rf 0.33, 10% methanol in chloroform), m.p. 154-156°C, and 4.1 mg (17%) of the more polar diastereomer (Rf 0.28), m.p. 121-124°C. Mass spectrum (for each diastereomer): (M+H)+ = 631.
- Using the procedure of Example 9 with the resultant compound of Example 8 gave, after silica gel chromatography using methanol/ isopropylamine/ chloroform, the desired compound (RF 0.3; 2.5% methanol/ 2% isopropylamine/ chloroform) in 100% yield, m.p. 158-160°C. Mass spectrum (M+H)+ = 504.
- Using the procedure of Example 8 but replacing the resultant compound of Example 3 with the resultant compound of Example 11 gave, after silica gel chromatography using methanol/ chloroform, the desired compound (RF 0.4; 2.5% methanol/ 2% isopropylamine/ chloroform) in 98% yield, m.p. 198-200°C. Mass spectrum (M+H)+ = 737.
- Anal. Calcd. for C43H52N4O7·0.5H2O: C, 69.24; H, 7.16; N, 7.51. Found: C, 69.40; H, 7.29; N, 7.47.
- Boc-Val-OH (2.86 g, 13.2 mmol) was coupled to valine benzyl ester p-toluenesulfonate (5.0 g, 13.2 mmol) using the procedure of Example 8 to give 5.41g, (100%) of the desired product (RF 0.15; 20% ethyl acetate in hexane) as a colorless gum. Mass spectrum (M+H)+ = 407.
- The resultant compound of Example 13A (0.50 g, 1.23 mmol) was deprotected according to the procedure of Example 9 and coupled to adipic acid monomethyl ester (0.21 g, 1.28 mmol) using the mixed anhydride procedure of Example 7A to give, after flash chromatography using 40% ethyl acetate in chloroform, 0.53 g (96%) of the desired compound.
- A mixture of the resultant compound of Example 13B (0.53 g, 1.18 mmol) and 100 mg of 10% palladium on carbon in 30 ml of methanol was stirred under one atmosphere of hydrogen. After 5 h, the mixture was filtered through Celite and concentrated to give 0.40 g (93%) of the desired compound as a solid.
- To a stirred solution of 4-(2-propyl)-oxazolidine-2-one in anhydrous tetrahydrofuran (250 ml) under a nitrogen atmosphere at -78°C was added in a dropwise fashion a solution of n-butyllithium in hexane (50 ml, 77.4 mmol) over 5 to 10 min. After stirring an additional 20 min at -78°C, 4-methylpentanoyl chloride (85.2 mmol) was added neat. The reaction was warmed to room temperature and stirred 1 to 2 h at the temperature. The reaction was quenched by adding 100 ml of saturated aqueous ammonium chloride and the volatiles were removed by rotary evaporation. The resulting aqueous residue was extracted three times with ether and the combined organic phases were washed with brine, dried (Na2SO4), filtered and concentrated in vacuo. Recrystallization from hexanes/ethyl acetate provided the desired compound.
- To a stirred solution of the resultant compound of Example 14A (8.72 mmol) in anhydrous tetrahydrofuran (30 ml) under a nitrogen atmosphere at -78°C was added a solution of sodium hexamethyldisilylamide (9.6 ml, 9.59 mmol) in tetrahydrofuran. After stirring for 30 min at -78°C, t-butyl bromoacetate (2.21 g, 11.34 mmol) was added in anhydrous tetrahydrofuran and the resulting solution stirred 1 h at -78°C. The reaction was quenched by adding 20 ml of saturated aqueous ammonium chloride and partitioned between water and ether. The aqueous layer was drawn off and extracted with ether. The combined organic phases were washed with 10% aqueous HCl, saturated aqueous NaHCO3, and brine, dried (Na2SO4), filtered, and concentrated in vacuo. Recrystallization from acetone/hexanes provided the desired compound.
- To a stirred solution of dry benzyl alcohol (0.55 ml, 5.33 mmol) in anhydrous tetrahydrofuran (18 ml) under a nitrogen atmosphere at 0°C was added a hexane solution of n-butyllithium (2.58 ml; 4.00 mmol). To this solution was added the resultant compound of Example 14B in anhydrous tetrahydrofuran (10 ml). After stirring 1 h at 0°C the reaction was quenched by adding excess saturated aqueous ammonium chloride. The volatiles were removed by rotary evaporation and the resulting aqueous residue was extracted two times with ether. The combined organic layers were washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide an oil which was purified by chromatography on SiO2 to give the desired compound.
- The resultant compound of Example 14C (1.47 mmol) was dissolved in a 1:1 (v:v) solution (6 ml) of trifluoroacetic acid and dichloromethane and stirred at room temperature for 1 h. The volatiles were removed in vacuo to provide the desired compound. The unpurified material was of sufficient purity to employ in subsequent steps.
- a-Benzylacrylic acid (1.00 g, 6.17 mmol) in methanol (20 ml) was treated with BF3·Et2O (2 ml). The mixture was heated to reflux for 14 h, cooled, and poured into saturated NaHCO3 solution. Extraction with ether followed by drying over Na2SO4 and evaporation afforded 1.03 g (95%) of a mobile oil. 1H NMR (CDCl3) δ 7.17-7.35 (m,5H), 6.23 (m,1H), 5.47 (m,1H), 3.74 (s,3H), 3.63 (s,2H).
- The resultant compound from Example 15A (800 mg, 4.54 mmol), N-methyl,O-methylhydroxylamine hydrochloride (0.57 g, 5.4 mmol), and NaHCO3 (0.46 g, 5.48 mmol) in dimethylsulfoxide (5 ml) were heated at 130°C for 20 h. The mixture was diluted with ethyl acetate, washed with water, saturated NaHCO3 solution and brine, and then was dried over Na2SO3 and evaporated. Chromatography of the residue on silica gel with 10% ethyl acetate in hexane afforded 226 mg (21%) of a mobile oil. 1H NMR (CDCl3) δ 7.10-7.30 (m,5H), 3.60 (s,3H), 3.47 (s,3H), 2.80-3.10 (m,4H), 2.60 (dd,1H), 2.55 (s,3H).
- Using the procedure of Example 15B but replacing N-methyl,O-methylhydroxylamine hydrochloride and NaHCO3 with pyrazole provided the desired product as an oil. 1H NMR (CDCl3) δ 7.52 (d, 1H), 7.10-7.35 (m,6H), 6.10 (dd,1H), 4.38 (dd,1H), 4.24 (dd,1H), 3.57 (s,3H), 3.37 (m,1H), 2.98 (dd,1H), 2.82 (dd,1H).
coupled to the resultant compound of Example 138 to give the desired compound. - The resultant compound of Example 12 was hydrogenolyzed according to the procedure of Example 13C to provide the desired compound (Rf 0.1, 10% methanol in chloroform) as a white solid, m.p. 131-132°C.
- A mixture of 0.13 g of the resultant compound of Example 4B and 0.13 g of 10% palladium on carbon in 50 ml of ethyl acetate was shaken under 4 atmospheres of H2 for 4 h. The resulting mixture was filtered through Celite and concentrated in vacuo to provide 72 mg (86%) of the desired compound as a 1:1 mixture of diastereomers. Mass spectrum: (M + H)+ = 401.
- The resultant compound from Example 15A (4 mmol), O-benzylhydroxylamine hydrochloride (2 mmol), and NaHCO3 (2.2 mmol) in dimethylsulfoxide (5 ml) were heated at 130°C for 20 h. The mixture was diluted with ethyl acetate, washed with water, saturated NaHCO3 solution and brine, and then was dried over Na2SO3 and evaporated. Silica gel chromatography provided the desired compound.
- A suspension of L-valine methyl ester hydrochloride (10 g) in toluene (400 ml) was heated to 100°C and phosgene gas was bubbled into the reaction mixture. After approximately 6 h, the mixture became homogeneous. The bubbling of phosgene was continued for 10 more min, then the solution was cooled with the bubbling of N2 gas. The solvent was then evaporated and the residue chased with toluene two times. Evaporation of solvent gave 14.2 g of the crude desired compound.
- A solution of 0.73 g (4.65 mmol) of the resultant compound of Example 20A and 0.51 g (4.65 mmol) of pyridine-4-methanol in 30 mL of toluene was heated at reflux under N2 atmosphere for 4 h. The solvent was removed in vacuo, and the residue was purified by silica gel chromatography using 2% methanol in chloroform to give 1.01 g (82%) of the desired compound as an oil. 1H NMR (CDCl3) δ 0.91 (d, J = 7 Hz, 3 H), 0.99 (d, J = 7 Hz, 3 H), 2.19 (m, 1 H), 3.76 (s, 3 H), 4.31 (dd, J = 9, 5 Hz, 1 H), 5.12 (s, 2 H), 5.37 (br d, 1 H), 7.25 (d, J = 6 Hz, 2 H), 8.60 (d, J = 6 Hz, 2 H).
- A solution of 50.8 mg (0.191 mmol) of the resultant compound of Example 20B in 0.75 ml of dioxane was treated with 0.46 ml (0.23 mmol) of 0.5 M aqueous lithium hydroxide. The resulting solution was stirred overnight at ambient temperature and concentrated in vacuo to provide the desired compound.
- A solution of the resultant compound of Example 20C (0.191 mmol), 94 mg (0.97 mmol) of the resultant compound of Example 11, and 31 mg (0.23 mmol) of 1-hydroxybenzotriazole in 2 ml of dimethylformamide was treated under N2 atmosphere with 44 mg (0.23 mmol) of N-ethyl-N'-(dimethylaminopropyl) carbodiimide hydrochloride and stirred overnight at ambient temperature. The resulting solution was taken up in ethyl acetate, washed sequentially with aqueous NaHCO3, H2O, and saturated brine, dried over Na2SO4, and concentrated in vacuo. Chromatography on silica gel using 3% methanol in chloroform provided 119 mg (87%) of the desired compound (Rf 0.19, 5% methanol in chloroform) as a white solid, m.p. 170-172°C (dec). Mass spectrum: (M + 1)+ = 738.
- Anal. Calcd for C42H51N5O7·0.5H2O: C, 67.54; H, 7.02; N, 9.38. Found: C, 67.53; H, 7.00; N, 9.39.
- Using the procedure of Example 20B but replacing pyridine-4-methanol with pyridine-3-methanol provided the desired compound as an oil after silica gel chromatography using 2% methanol in chloroform. 1H NMR (CDCl3) δ 0.90 (d, J = 7 Hz, 3 H), 0.98 (d, J = 7 Hz, 3 H), 2.16 (m, 1 H), 3.65 (s, 3 H), 4.30 (dd, J = 9, 5 Hz, 1 H), 5.14 (s, 2 H), 5.30 (br d, 1 H), 7.30 (dd, J = 8, 5 Hz, 1 H), 7.70 (br d, J = 8 Hz, 1 H), 8.58 (dd, J = 4, 1 Hz, 1 H), 8.63 (br s, 1 H).
- Using the procedure of Example 20C with the resultant compound of Example 21A provided the desired compound.
- Using the procedure of Example 20B but replacing pyridine-4-methanol with pyridine-2-methanol provided 0.72 g (54%) of the desired compound as an oil after silica gel chromatography using 2% methanol in chloroform. 1H NMR (CDCl3) δ 0.91 (d, J = 7 Hz, 3 H), 0.98 (d, J = 7 Hz, 3 H), 2.19 (m, 1 H), 3.75 (s, 3 H), 4.32 (dd, J = 9, 5 Hz, 1 H), 5.24 (s, 2 H), 5.39 (br d, 1 H), 7.23 (ddd, J = 8, 4, 1 Hz, 1 H), 7.37 (d, J = 8 Hz, 1 H), 7.70 (td, J = 8, 2 Hz, 1 H), 8.60 (br d, 1 H).
- Using the procedure of Example 20C with the resultant compound of Example 22A provided the desired compound.
- A solution of 2.44 g (6.44 mmol) of L-valine benzyl ester p-toluenesulfonate in 100 ml of dichloromethane was cooled under N2 atmosphere to 0°C and treated sequentially with 1.15 g (6.44 mmol) of nicotinyl chloride hydrochloride and 2.8 ml (26 mmol) of 4-methylmorpholine. After being stirred at ambient temperature overnight, the resulting solution was diluted with 200 ml of diethyl ether, washed sequentially with water, aqueous NaHCO3, and saturated brine, dried over Na2SO4, and concentrated in vacuo to give 2.09 g (95%) of the desired compound. 1H NMR (CDCl3) δ 0.96 (d, J = 7 Hz, 3 H), 1.01 (d, J = 7 Hz, 3 H), 2.30 (m, 1 H), 4.83 (dd, J = 9, 5 Hz, 1 H), 5.20 (AA', 2 H), 6.67 (br d, 1 H), 7.37 (br s, 6 H), 8.11 (dd, J = 8, 2 Hz, 1 H), 8.74 (br, 1 H), 9.01 (s, 1 H).
- A suspension of 0.16 g of 10% palladium on carbon in 20 ml of methanol was treated with a solution of 1.08 g (3.16 mmol) of the resultant compound of Example 23A in 10 ml of methanol. The resulting mixture was stirred vigorously under H2 atmosphere for 4 h, filtered through Celite, and concentrated in vacuo to provide the desired compound as an off-white solid.
- A solution of 1.04 g (6.60 mmol) of the resultant compound of Example 20A and 0.88 ml (7.25 mmol) of 4-(2-hydroxyethyl)morpholine in 30 mL of toluene was heated at reflux under N2 atmosphere for 12 h. The solvent was removed in vacuo, and the residue was purified by silica gel chromatography using 5% methanol in chloroform to give 1.41 g (71%) of the desired compound as an oil. 1H NMR (CDCl3) δ 0.89 (d, J = 7 Hz, 3 H), 0.96 (d, J = 7 Hz, 3 H), 2.16 (m, 1 H), 2.50 (br t, 4 H), 2.62 (t, J = 6 Hz, 2 H), 3.72 (t, J = 6 Hz, 4 H), 3.75 (s, 3 H), 4.20 (br t, 2 H), 4.37 (dd, J = 9, 5 Hz, 1 H), 5.25 (br d, 1 H).
- A solution of 77.7 mg (0.27 mmol) of the resultant compound of Example 24A in 1 ml of dioxane was treated with 1.04 ml (0.52 mmol) of 0.5 M aqueous lithium hydroxide. After being stirred for 2.5 h at ambient temperature, the resulting solution was treated with 0.26 ml (0.26 mmol) of 1 N aqueous HCl and concentrated in vacuo to provide the desired compound as a white solid.
- A solution of 2.8 ml (40 mmol) of dry dimethylsulfoxide in 150 ml of dry dichloromethane was cooled under nitrogen atmosphere in a dry ice/chloroform bath (ca. -60°C). In a separate flask, a 2 M solution of oxalyl chloride in dichloromethane (15 ml, 30 mmol) was precooled to -60°C and then added via cannula. After 10 min, a solution of 5 g (20 mmol) of N-((t-butyloxy)carbonyl)-phenylalaninol in 30 ml of dry dichloromethane was added via cannula. The resulting solution was stirred at -60°C for 45 min, and was subsequently treated via syringe with 11 ml (80 mmol) of dry triethylamine. After being stirred for an additional 15 min at -60°C, the solution was quenched by addition of 10% aqueous citric acid, then immediately poured into a rapidly stirred mixture of 200 ml of 1:1 hexane:ether and 100 ml of 10% aqueous citric acid. The reaction flask was rinsed with ether which was added to the above mixture. The mixture was poured into a separatory funnel and the layers were separated. The aqueous layer was washed sequentially with dilute aqueous sodium bicarbonate and saturated brine, dried over MgSO4, and concentrated in vacuo to provide the crude desired compound.
- In a glove bag purged with argon, a 500 ml three-neck flask was charged with 27 g of TiCl3(DME)2 followed by 200 ml of anhydrous dimethoxyethane (DME). A separate flask was charged with 20 g of Zn-Cu couple and connected to one of the side necks of the three-neck flask with Gooch tubing. The flask was sealed with septa, removed from the glove bag, and outfitted under positive argon flow with an overhead mechanical stirrer. Under positive argon pressure, Zn-Cu was added in portions with vigorous stirring. After addition, the Gooch tubing was removed and replaced with a rubber septum. Stirring was continued while the flask was placed in an oil bath and heated to 85°C for 2.5 h. After being allowed to cool, the flask was placed in an ice bath while stirring was continued, and the mixture was treated via cannula with a solution of the resultant compound of Example 25A (20 mmol) in 20 ml of anhydrous dimethoxyethane. The progress of the reaction was monitered by tlc. After 1 h, the reaction mixture was filtered through Celite, and the residue was washed with ethyl acetate. The filtrate was treated with saturated aqueous sodium bicarbonate, and air was bubbled through the suspension until it became white. The layers were separated, and the organic layer was washed with saturated brine, dried over MgSO4, and concentrated to give 3.7 g of a light yellow solid. The solid was taken up in dichloromethane, treated with silica gel, and concentrated to a freely flowing powder. The powder was placed on the top of a silica gel column and eluted first with 70:30 hexane:ethyl acetate to bring off the more mobile product (Rf 0.26, 70:30 hexane:ethyl acetate) which contained two diastereomers (2S,3S,4S,5S and 2S,3R,4S,5S) followed by 60:40 hexane:ethyl acetate to bring off the less mobile product (Rf 0.10) which contained one major diastereomer (2S,3R,4R,5S).
- (2S,3R,4R,5S)-2,5-Di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane: m.p. 200-202°C. 1H NMR δ 1.35 (s, 18 H), 2.87 (dd, J = 13, 7 Hz, 2 H), 2.98 (dd, J = 13, 7 Hz, 2 H), 3.41 (m, 2 H), 3.76 (br q, J = 8 Hz, 2 H), 3.96 (m, 2 H), 4.77 (br d, J = 8 Hz, 2 H), 7.15-7.3 (m, 10 H). Mass spectrum: (M + H)+ = 501.
- Anal. Calcd for C28H40N2O6·0.5H2O: C, 65.99; H, 8.11; N, 5.50. Found: 65.96; H, 7.96; N, 5.49.
- (2S,3R,4R,5S)-2,5-Di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane (2.7 g, 5.4 mmol) was treated with 200 ml of 6N aqueous hydrochloric acid and heated to 90°C until the solid had completely dissolved (30 min). The resulting solution was cooled, concentrated in vacuo, treated with saturated brine and 3N aqueous NaOH, extracted with chloroform, dried over Na2SO4, and concentrated in vacuo. Silica gel chromatography using 3% methanol/2% isopropylamine in chloroform provided the pure desired compound (Rf 0.40, 5% methanol/2% isopropylamine in chloroform) as a white solid, m.p. 86-89°C. 1H NMR (CDCl3) δ 2.72 (dd, J = 14, 9 Hz, 2 H), 2.92 (dd, J = 14, 6 Hz, 2 H), 3.03 (dd, J = 9, 5 Hz, 2 H), 3.69 (s, 2 H), 7.15-7.35 (m, 10 H). Mass spectrum: (M + H)+ = 301.
- Anal. Calcd for C18H24N2O2·0.25H2O: C, 70.91; H, 8.10; N, 9.19. Found: C, 70.52; H, 7.92; N, 8.93.
- A suspension of 3.40 g (13.5 mmol) of Cbz-valine and 1.56 g (13.5 mmol) of N-hydroxysuccinimide in 200 ml of dichloromethane was treated with 2.86 g (14.9 mmol) of N-ethyl-N'-(dimethylaminopropyl) carbodiimide hydrochloride and stirred at ambient temperature for 4 h. The resulting solution was washed sequentially with 10% citric acid, aqueous NaHCO3, and water; dried over Na2SO4, and concentrated in vacuo to provide 4.00 g (85%) of the desired compound.
- A solution of 28.7 mg (0.096 mmol) of the resultant compound of Example 26 in 1 ml of dioxane was treated with 139 mg (0.40 mmol) of the resultant compound of Example 27A and stirred at ambient temperature for 24 h. The resulting solution was treated with 0.5 ml of 3N NaOH, stirred for 15 min, extracted with two portions of 10% methanol in chloroform, dried over Na2SO4, and concentrated in vacuo. The residue was chromatographed on silica gel using 3% methanol in chloroform to provide 42.4 mg (58%) of the desired compound (Rf 0.35, 5% methanol in chloroform) as a white solid, m.p. 231-232°C. Mass spectrum: (M + H)+ = 767.
- Anal. Calcd for C44H54N4O8·0.25H2O: C, 68.51; H, 7.12; N, 7.26. Found: C, 68.48; H, 7.11; N, 7.12.
- Using the procedure of Example 13C with the resultant compound of Example 27B provided the desired compound (Rf 0.07, 10% methanol in chloroform) as a white solid, m.p. 205-207°C. Mass spectrum: (M + H)+ = 499.
- Anal. Calcd for C28H42N4O4·0.75H2O: C, 65.66; H, 8.56; N, 10.94. Found: C, 65.47; H, 7.93; N, 10.59.
- Using the procedure of Example 22B but adding twice the amount of 1M HCl provided the desired compound.
- A solution of 15 mg (0.032 mmol) of the resultant compound of Example 17 and 0.01 ml (0.09 mmol) of 4-methylmorpholine in 2 ml of dichloromethane was cooled to 0°C and treated with 12 mg (0.067 mmol) of nicotinyl chloride hydrochloride. The resulting solution was stirred at 0°C for 1 h, washed with aqueous NaHCO3, dried over Na2SO4, and concentrated in vacuo. The residue was recrystallized from chloroform/ethyl acetate/hexane to afford the desired compound (Rf 0.40, 10% methanol in chloroform) as a white solid, m.p. 228-230. Mass spectrum: (M + H)+ = 679.
- Using the procedure of Example 30 with the resultant compound of Example 28 provided the desired compound.
- Using the procedure of Example 30 but replacing the resultant compound of Example 17 with the resultant compound of Example 26 provided the desired compound.
- Using the procedure of Example 30 but replacing the resultant compound of Example 17 with the resultant compound of Example 26 and replacing nicotinyl chloride hydrochloride with isonicotinyl chloride hydrochloride provided the desired compound.
- A solution of 1.5 ml (17 mmol) of morpholine in 40 ml of dichloromethane was treated with 1 ml (6.3 mmol) of benzyl 2-bromoacetate. The resulting solution was stirred at ambient temperature for 16 h. The resulting solution was filtered and concentrated in vacuo. The residue was purified by silica gel chromatography using 3:1 chloroform:ethyl acetate to provide 1.35 g (91%) of the desired compound. 1H NMR (CDCl3) δ 2.59 (m, 4 H), 3.27 (s, 2 H), 3.77 (m, 4 H), 5.17 (s, 2 H), 7.3-7.4 (m, 5 H).
- Using the procedure of Example 23B with the resultant compound of Example 34A provided the desired compound.
- The resultant compound of Example 34B was coupled to the resultant compound of Example 28 using the coupling procedure of Example 8 provided, after silica gel chromatography using a gradient of 3-5% methanol in chloroform, the desired compound (Rf 0.31, 10% methanol in chloroform).
- A solution of 1.4 g (21 mmol) of imidazole and 1.0 ml (6.3 mmol) of benzyl 2-bromoacetate in 40 ml of dichloromethane was stirred at ambient temperature for 16 h. The resulting solution was washed with water, dried over Na2SO4, and concentrated in vacuo. Silica gel chromotography of the residue using 5% methanol in chloroform provided 1.22 g (89%) of the desired compound as an oil. 1H NMR (CDCl3) δ 4.73 (s, 2 H), 5.21 (s, 2 H), 6.96 (t, J = 1 Hz, 1 H), 7.11 (t, J = 1 Hz, 1 H), 7.36 (m, 5 H), 7.51 (br s, 1 H).
- The resultant compound of Example 35A was hydrogenolyzed according to the procedure of Example 23B except that water was added prior to filtration to solubilize the product. Removal of the solvent after filtration provided the desired compound.
- The resultant compound of Example 35B was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure described in Example 8 to give a crude mixture in which the product was soluble. The mixture was diluted with ethyl acetate, filtered, and the solid was washed sequentially with water and ethyl acetate. The residue was air-dried to provide the desired compound in 40% yield.
- Using the mixed anhydride procedure of Example 1F, 2-bromohexanoic acid was coupled to 1-methylpiperazine to provide the desired compound.
- Using the procedure of Example 19A but replacing the resultant compound of Example 15A with the resultant compound of Example 36A and replacing O-benzylhydroxylamine hydrochloride with the resultant compound of Example 26 provided the desired compound.
- Using the procedure of Example 19A but replacing O-benzylhydroxylamine hydrochloride with the resultant compound of Example 26 provided the desired compound.
- According to the method of Kawaguchi, et. al. (Agric. Biol. Chem. 1987, 51, 435), 3-sulfolene was ozonolyzed and aminated with L-valine benzyl ester p-toluenesulfonate to provide the desired compound.
- The resultant compound of Example 38A was hydrogenolyzed according to the procedure of Example 23B to provide the desired compound.
- The resultant compound of Example 38B was coupled to the resultant compound of Example 26 using the coupling procedure described in Example 20D to provide the desired compound.
- According to the method of Kawaguchi, et al. (Agric. Biol. Chem. 1987, 51, 435), 2,5-dihydrofuran was ozonolyzed and aminated with L-valine benzyl ester p-toluenesulfonate to provide the desired compound.
- The resultant compound of Example 39A was hydrogenolyzed according to the procedure of Example 23B to provide the desired compound.
- The resultant compound of Example 39B was coupled to the resultant compound of Example 26 using the coupling procedure described in Example 20D to provide the desired compound.
- A mixture of 10 mg (0.033. mmol) of the resultant compound of Example 26 and 38.6 mg (0.10 mmol) of Cbz-isoleucine p-nitrophenyl ester in 0.2 ml of tetrahydrofuran was stirred at ambient temperature for 21 h.. The resulting misture was diluted with 1 ml of tetrahydrofuran, treated with 0.5 ml of 3N NaOH, stirred for 45 min, extracted with chloroform, washed sequentially with 3N NaOH and saturated brine, dried over MgSO4, and concentrated. The residue was purified on silica gel by eluting with 2% methanol in chloroform to provide 23 mg (86%) of the desired compound. Mass spectrum: (M + H)+ = 795.
- Using the procedure of Example 40 but replacing Cbz-isoleucine p-nitrophenyl ester with Cbz-alaninyloxy-succinimide provided the desired compound. Mass spectrum: (M + H)+ = 711.
- Using the procedure of Example 40 but replacing Cbz-isoleucine p-nitrophenyl ester with Cbz-phenylalanine p-nitrophenyl ester provided the desired compound. Mass spectrum: (M + H)+ = 863.
- Using the procedure of Example 40 but replacing Cbz-isoleucine p-nitrophenyl ester with Cbz-leucine p-nitrophenyl ester provided the desired compound. Mass spectrum: (M + H)+ = 795.
- A solution of 2.12 g (12.6 mmol) of L-valine methyl ester hydrochloride, 2.0 ml (12.6 mmol) of benzyl bromoacetate, and 3.5 ml (31 mmol) of 4-methylmorpholine in 100 ml of dioxane was heated at reflux for 4 h. After being allowed to cool, the solution was concentrated in vacuo and partitioned between ether and water. The organic layer was dried over MgSO4 and concentrated in vacuo. Chromatography on silica gel using 20% ethyl acetate in hexane provided 0.77 g (22%) of the desired compound as a colorless oil (Rf 0.24, 20% ethyl acetate in hexane). 1H NMR δ 0.95 (d, J = 7 Hz, 6 H), 1.96 (br, 1 H), 1.98 (octet, J = 7 Hz, 1 H), 3.08 (d, J = 6 Hz, 1 H), 3.43 (AA', 2 H), 3.71 (s, 3 H), 5.16 (s, 2 H), 7.36 (m, 5 H).
- Using the procedure of Example 26 with the more mobile mixture of compounds of Example 25B provided a mixture of diamines which were separated by silica gel chromatography using 2% isopropylamine in chloroform containing sequential amounts of 1%, 2% and 5% methanol.
- (2S,3S,4S,5S)-2,5-Diamino-3,4-dihydroxy-1,6-diphenylhexane: Rf 0.40 (5% methanol/2% isopropylamine in chloroform), 1H NMR (CDCl3) δ 2.63 (dd, J = 14, 11 Hz, 2 H), 2.85 (dd, J = 14, 4 Hz, 2 H), 3.60 (dt, J = 11, 4 Hz, 2 H), 3.92 (d, J = 3 Hz, 2 H), 7.2-7.4 (m, 10 H).
- (2S,3R,4S,5S)-2,5-Diamino-3,4-dihydroxy-1,6-diphenylhexane: Rf 0.23 (5% methanol/2% isopropylamine in chloroform), m.p. 115-119°C, 1H NMR (CDCl3) δ 2.46 (dd, J = 14, 9 Hz, 1 H), 2.61 (dd, J = 14, 11 Hz, 1 H), 3.02 (td, J = 9, 3 Hz, 1 H), 3.19 (dd, J = 14, 4 Hz, 1 H), 3.35-3.4 (m, 2 H), 3.51 (t, J = 9 Hz, 1 H), 3.76 (dd, J = 9, 3 Hz, 1 H), 7.2-7.4 (m, 10 H).
- A solution of 15 mg (0.05 mmol) of (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane in 0.5 ml of dichloromethane was treated with 24 mg (0.11 mmol) of di-t-butyldicarbonate and stirred at ambient temperature. After 16 h, the solution was concentrated in vacuo, and the residue was purified by silica gel chromatography using 30% ethyl acetate in hexane to provide 17 mg (68%) of the desired compound, m.p. 216-218°C. 1H NMR δ 1.40 (s, 18 H), 2.97 (dd, J = 14, 5 Hz, 2 H), 3.20 (dd, J = 14, 5 Hz, 2 H), 3.22 (m, 2 H), 4.03 (m, 2 H), 4.35 (d, J = 5 Hz, 2 H), 4.41 (d, J = 9 Hz, 2 H), 7.2-7.3 (m, 10 H). Mass spectrum: (M + H)+ = 501.
- Using the procedure of Example 46 with (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided the desired compound (Rf 0.32, 30% ethyl acetate in hexane), as a white solid, m.p. 208-212°C. 1H NMR δ 1.33 (s, 9 H), 1.40 (s, 9 H), 2.67 (m, 1 H), 2.75-2.95 (m, 6 H), 3.47 (m, 2 H), 4.14 (m, 2 H), 4.58 (m, 1 H), 4.83 (br d, 1 H), 4.93 (br d, 1 H), 7.15-7.3 (m, 10 H).
- Using the procedure of Example 27B with 25 mg (0.083 mmol) of (2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided the desired compound (31%, Rf 0.3, 5% methanol in chloroform) as a white solid, m.p. 230-234°C. Mass spectrum: (M + H)+ = 767.
- Cbz-valine p-nitrophenyl ester was coupled to (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane using the procedure of Example 27B to provide the desired compound (Rf 0.42, 5% methanol in chloroform) as a white solid, m.p. 239-242°C in 86 % yield.
- A mixture of 180 mg (0.36 mmol) of (2S,3R,4R,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane and 180 mg of 5% rhodium on carbon in 50 ml of methanol was shaken under 4 atmospheres of hydrogen for 24 h. The resulting mixture was filtered and'concentrated in vacuo. The residue was purified by silica gel chromatography using 5% ethyl acetate in hexane to provide 120 mg (65%) of the desired compound (Rf 0.35, 30% ethyl acetate in hexane) as a white solid, m.p. 224-226°C. Mass spectrum: (M + H)+ = 513.
- Anal. Calcd for C28H52N2O6: C, 65.69; H, 10.22; N, 5.46. Found: C, 65.27; H, 10.16; N, 5.40.
- A solution of 200 mg (0.67 mmol) of (2S,3S,4R,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane in 10 ml of dichloromethane was treated with 174 mg (0.8 mmol) of di-t-butyldicarbonate. After being allowed to stir overnight at ambient temperature, the solution was concentrated, and the residue was purified by silica gel chromatography using 10% methanol in chloroform to provide 180 mg (56%) of the desired compound along with 80 mg (20%) of the resultant compound of Example 47
- The resultant compound of Example 51 was coupled to Cbz-valine using the carbodiimide coupling procedure of Example 8 to provide the desired compound (Rf 0.48, 5% methanol in chloroform) as a white solid, m.p. 178-182°C, in 88% yield. Mass spectrum: (M + H)+ = 634.
- Anal. Calcd for C36H47N3O7·0.5H2O: C, 67.27; H, 7.53; N, 6.54. Found: C, 67.18; H, 7.45; N, 6.71.
- A mixture of 2.5 g of L-valine, 0.5 g of 10% palladium on carbon, in 93 ml of methanol and 7 ml of formalin was shaken under 4 atmospheres of hydrogen. After 24 h, the solution was filtered and concentrated in vacuo to provide the crude desired compound.
- The resultant compound of Example 53A was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 8 to provide the desired compound (20%, Rf 0.3, 10% methanol in chloroform) as a white solid, m.p. 200-204°C. Mass spectrum: (M + H)+ = 555.
- A solution of 0.87 mmol of the resultant compound of Example 29A and 133. mg (0.96 mmol) of p-nitrophenol in 4 ml of tetrahydrofuran and 2 ml of dimethylformamide was treated with 183 mg (0.96 mmol) of N-ethyl-N'-(dimethylaminopropyl) carbodiimide hydrochloride and stirred at ambient temperature. After 4 h, the solvent was removed in vacuo, and the residue was partially purified by silica gel chromatography using 20% ethyl acetate in chloroform to give 0.34 mg of the desired compound contaminated with excess p-nitrophenol.
- A solution of 230 mg of the crude resultant compound of Example 54A and 70 mg (0.23 mmol) of the resultant compound of Example 26 in 1 ml of 1:1 tetrahydrofuran/ dimethylformamide was stirred at ambient temperature for 16 h. The resulting solution was treated with aqueous NaHCO3, stirred for 1 h, diluted with 5% methanol in chloroform, washed with aqueous NaHCO3 until the washes were colorless, dried over Na2SO4, and concentrated. Chromatography on silica gel using 2% methanol in chloroform followed by 5% methanol in chloroform provided 140.6 mg (80%) of the desired compound (Rf 0.32, 10% methanol in chloroform) as a white solid, m.p. 196-200°C. Mass spectrum: (M + H)+ = 769.
- Anal. Calcd for C42H52N6O8: C, 65.61; H, 6.82; N, 10.93. Found: C, 65.68; H, 6.93; N, 10.95.
- Using the procedure of Example 54B but replacing the resultant compound of Example 26 with (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided, after silica gel chromatography using a gradient of 2-5% methanol in chloroform, the desired compound (Rf 0.32, 5% methanol in chloroform) as a white solid, m.p. 220-223°C, in 79% yield. Mass spectrum: (M + H)+ = 769.
- Anal. Calcd for C42H52N6O8·0.5H2O: C, 64.85; H, 6.87; N, 10.80. Found: C, 64.69; H, 6.84; N, 10.63.
- Using the procedure of Example 54B but replacing the resultant compound of Example 26 with (2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided, after silica gel chromatography using a gradient of 2-5% methanol in chloroform, the desired compound (Rf 0.23, 5% methanol in chloroform) as a white solid, m.p. 238-240°C, in 82% yield. Mass spectrum: (M + H)+ = 769.
- Anal. Calcd for C42H52N6O8·0.25H2O: C, 65.23; H, 6.84; N, 10.87. Found: C, 65.01; H, 6.89; N, 10.92.
- A solution of 21.2 g (97 mmol) of di-t-butyldicarbonate in 200 ml of dichloromethane was cooled to 0°C and treated in portions with 10 ml (97 mmol) of 2-(aminomethyl)pyridine. After being allowed to warm to ambient temperature and stirred overnight, the resulting solution was diluted with 100 ml of dichloromethane, washed with three 100 ml portions of water, dried over Na2SO4, and concentrated in vacuo to provide 19.8 g (98%) of the desired compound (Rf 0.28, 5% methanol in chloroform). 1H NMR (CCDl3) δ 1.47 (s, 9 H), 4.45 (d, J = 6 Hz, 2 H), 5.56 (br, 1 H), 7.18 (m, 1 H), 7.28 (d, J = 8 Hz, 1 H), 7.66 (td, J = 7, 2 Hz, 1 H), 8.53 (m, 1 H).
- A solution of 19.8 g (95 mmol) of the resultant compound of Example 57A in anhydrous tetrahydrofuran was cooled under N2 atmosphere to 0°C and treated with 4.95 g (124 mmol) of sodium hydride (60% dispersion in oil). The solution was stirred for 15 min, treated dropwise with 7.1 ml (114 mmol) of methyl iodide, stirred at ambient temperature for 2 h, and quenched cautiously with water. The resulting mixture was partitioned between ether and water, dried over Na2SO4, and concentrated.
Chromatography on silica gel provided 14.9 g (70%) of the desired compound as a colorless oil. - The resultant compound of Example 57B (3.05 g, 13.7 mmol) was treated with 30 ml of 4N HCl in dioxane and heated at 40°C for 0.5 h. The solvent was removed in vacuo to provide the crude desired compound as a light brown solid.
- A mixture of 1.61 g (7.2 mmol) of the resultant compound of Example 57C and 1.14 g (7.2 mmol) of the resultant compound of Example 20A in 40 ml of dichloromethane was treated with 2 ml (18 mmol) of 4-methylmorpholine. After being stirred for 2 h, the solution was partitioned between dichloromethane and water, dried over Na2SO4, and concentrated.
Chromatography on silica gel using 2% methanol in chloroform provided 1.94 g (96%) of the desired compound (Rf 0.32, 5% methanol in chloroform) as a colorless oil. 1H NMR (CCDl3) δ 0.93 (d, J = 7 Hz, 3 H), 0.97 (d, J = 7 Hz, 3 H), 2.16 (m, 1 H), 3.03 (s, 3 H), 3.72 (s, 3 H), 4.43 (dd, J = 8, 5 Hz, 1 H), 4.55 (s, 2 H), 6.15 (br, 1 H), 7.22 (dd, J = 8, 6 Hz, 1 H), 7.28 (d, J = 6 Hz, 1 H), 7.69 (br t, 1 H), 8.55 (d, J = 5 Hz, 1 H). - Using the procedures of Example 29A and Example 54A but replacing the resultant compound of Example 22A with the resultant compound of Example 57D provided the desired compound.
- Using the procedure of Example 54B but replacing the resultant compound of Example 54A with the resultant compound of Example 57E provided, after silica gel chromatography using a gradient of 2-5% methanol in chloroform, the desired compound (Rf 0.28, 5% methanol in chloroform) as a white solid, m.p. 108-111°C, in 85% yield. Mass spectrum: (M + H)+ = 795.
- Anal. Calcd for C44H58N8O6·1.25H2O: C, 64.65; H, 7.46; N, 13.71. Found: C, 64.35; H, 7.06; N, 13.58.
- Using the procedure of Example 54B but replacing the resultant compound of Example 54A with the resultant compound of Example 57E and replacing the resultant compound of Example 26 with (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided, after silica gel chromatography using a gradient of 1-5% methanol in chloroform, the desired compound (Rf 0.38, 5% methanol in chloroform) as a white solid, m.p. 110-112°C, in 75% yield. Mass spectrum: (M + H)+ = 795.
- Anal. Calcd for C44H58N8O6·H2O: C, 65.00; H, 7.44; N, 13.78. Found: C, 64.61; H, 7.21; N, 13.60.
- Using the procedure of Example 54B but replacing the resultant compound of Example 54A with the resultant compound of Example 57E and replacing the resultant compound of Example 26 with (2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided, after silica gel chromatography using a gradient of 1-2% methanol in chloroform, the desired compound (Rf 0.36, 5% methanol in chloroform) as a white solid, m.p. 159-162°C, in 79% yield. Mass spectrum: (M + H)+ =795.
- Anal. Calcd for C44H58N6O8: C, 66.48; H, 7.35; N, 14.09. Found: C, 66.31; H, 7.43; N, 13.95.
- Picolinic acid was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure described in Example 8 to provide after silica gel chromatography using a gradient of 5-10% methanol in chloroform, the desired compound (Rf 0.16, 10% methanol in chloroform) as a white solid, m.p. 167-171°C, in 61% yield. Mass spectrum: (M + H)+ = 709.
- Anal. Calcd for C40H48N6O6: C, 67.78; H, 6.83; N, 11.86. Found: C, 67.81; H, 6.59; N, 11.78.
- A mixture of 3 g (20 mmol) of 3-(3-pyridinyl)acrylic acid and 0.3 g of 10% palladium on carbon in 150 ml of ethyl acetate was shaken under 4 atmospheres of hydrogen for 24 h. After filtration, the resulting solution was concentrated in vacuo to provide the desired compound.
- The resultant compound of Example 61A was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure described in Example 8 to provide after silica gel chromatography using a gradient of 5-10% methanol in chloroform, the desired compound (Rf 0.1, 10% methanol in chloroform) as a white solid, m.p. 260-263°C, in 37% yield. Mass spectrum: (M + H)+ = 765.
- (2-Pyridyl)acetic acid was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure described in Example 8 to provide after silica gel chromatography using a gradient of 2-5% methanol in chloroform, the desired compound (41%, Rf 0.21, 5% methanol in chloroform) as a white solid, m.p. 208-213°C. Mass spectrum: (M + H)+ = 737.
- Using the procedures of Example 29A and Example 54A but replacing the resultant compound of Example 22A with the resultant compound of Example 20B provided the desired compound.
- Using the procedure of Example 54B but replacing the resultant compound of Example 54A with the resultant compound of Example 63A provided, after silica gel chromatography using a gradient of 2-5% methanol in chloroform, the desired compound (Rf 0.11, 10% methanol in chloroform) as a white solid, m.p. 221-224°C in 48% yield. Mass spectrum: (M + H)+ = 769.
- Anal. Calcd for C42H52N6O8·0.5H2O: C, 64.85; H, 6.87; N, 10.80. Found: C, 64.91; H, 6.81; N, 10.80.
- A solution of 30 mg (0.1 mmol) of (2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane in 1 ml of dichloromethane was treated with 25 µl (0.22 mmol) of t-butylisocyanate. The resulting solution was stirred at ambient temperature, diluted with dichloromethane, washed with brine, dried over Na2SO4, and concentrated in vacuo. Silica gel chromatography using a gradient of 1-3% methanol in chloroform provided 49 mg (98%) of the desired compound (Rf 0.4, 10% methanol in chloroform) as a white solid, m.p. 193-196°C. Mass spectrum: (M + H)+ = 499.
- Anal. Calcd for C28H42N4O4·H2O: C, 65.09; H, 8.58; N, 10.84. Found: C, 65.17; H, 8.21; N, 10.77.
- Using the procedure of Example 64 but replacing t-butylisocyanate with isopropylisocyanate provided the desired compound (Rf 0.24, 10% methanol in chloroform) as a white solid, m.p. 220-222°C, in 81% yield. Mass spectrum: (M + H)+ = 471.
- Anal. Calcd for C26H38N4O4·0.25H2O: C, 65.73; H, 8.17; N, 11.79.
- Using the procedure of Example 54B but replacing the resultant compound of Example 54A with the resultant compound of Example 63A and replacing the resultant compound of Example 26 with (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided, after silica gel chromatography using a gradient of 2-5% methanol in chloroform, the desired compound (35%, Rf 0.25, 10% methanol in chloroform) as a white solid, m.p. 190-193°C. Mass spectrum: (M + H)+ = 769.
- Using the procedures of Example 29A and Example 54A but replacing the resultant compound of Example 22A with the resultant compound of Example 21A provided the desired compound.
- Using the procedure of Example 54B but replacing the resultant compound of Example 54A with the resultant compound of Example 67A and replacing the resultant compound of Example 26 with (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided, after silica gel chromatography using a gradient of 5-10% methanol in chloroform, the desired compound (Rf 0.31, 10% methanol in chloroform) as a white solid, m.p. 202-207°C. Mass spectrum: (M + H)+ = 769.
- Using the procedure of Example 54B but replacing the resultant compound of Example 54A with the resultant compound of Example 67A and replacing the resultant compound of Example 26 with (2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane provided, after silica gel chromatography using a gradient of 2-5% methanol in chloroform, the desired compound (31%, Rf 0.28, 10% methanol in chloroform) as a white solid, m.p. 212-216°C. Mass spectrum: (M + H)+ = 769.
- Using the procedure of Example 54B but replacing the resultant compound of Example 26 with the resultant compound of Example 51 provided, after silica gel chromatography using a gradient of 0-2% methanol in chloroform, the desired compound (Rf 0.57, 5% methanol in chloroform) as a white solid, m.p. 202-204°C, in 61% yield. Mass spectrum: (M + H)+ = 635.
- The resultant compound of Example 69 (200 mg, 0.31 mmol) was treated with 20 ml of 4N HCl in dioxane. After being stirred at ambient temperature for 2 h, the solvent was removed in vacuo. The residue was partitioned between chloroform and aqueous NaHCO3, dried over Na2SO4, and concentrated. Silica gel chromatography using a gradient of 2% methanol/2% isopropylamine in chloroform provided 140 mg (84%) of the desired compound.
- A solution of 50 mg (0.93 mmol) of the resultant compound of Example 70 in 0.5 ml of dichloromethane was treated with 9.3 mg (0.93 mmol) of succinic anhydride. The resulting mixture was stirred overnight at ambient temperature and concentrated in vacuo to a solid which was washed with chloroform. The solvent was decanted to provide the desired compound (Rf 0.91, 1:1:1:1 ethyl acetate/n-butanol/water/acetic acid) as a white solid. Mass spectrum: (M + H)+ = 635.
- A suspension of 15.3 g (90 mmol) of L-valine methyl ester hydrochloride in 45 ml of acetonitrile was treated with 22 ml (270 mmol) of sulfuryl chloride and heated at reflux for 16 h. The resulting light yellow solution was allowed to cool and concentrated in vacuo to a viscous oil. The oil was treated two times with acetonitrile followed each time by concentration in vacuo. The crude desired product was thus obtained as a viscous oil.
- A mixture of 13.7 mmol of the resultant compound of Example 57C and 3.17 g (13.7 mmol) of the resultant compound of Example 72A in 100 ml of dichloromethane was cooled to 0°C and treated with 6 ml of 4-methylmorpholine. The resulting solution stirred for 2 h, diluted with dichloromethane, washed with aqueous NaHCO3, dried over Na2SO4, and concentrated in vacuo. Chromatography on silica gel using 30% ethyl acetate in chloroform provided 1.72 g (40%) of the desired compound as a colorless oil. 1H NMR (CCDl3, major rotamer) δ 0.95 (d, J = 7 Hz, 3 H), 1.03 (d, J = 7 Hz, 3 H), 2.12 (m, 1 H), 2.79 (s, 3 H), 3.76 (s, 3 H), 3.95 (dd, J = 8, 4 Hz, 1 H), 4.54 (AA', 2 H), 6.40 (d, J = 8 Hz, 1 H), 7.26 (m, 1 H), 7.35 (d, 6 Hz, 1 H), 7.71 (br t, 1 H), 8.59 (d, J = 4 Hz, 1 H). Mass spectrum: (M + H)+ = 316.
- A solution of 200 mg (0.63 mmol) of the resultant compound of Example 72B in 2.5 ml of dioxane was treated with 2.5 ml of 0.5M LiOH. After being stirred overnight at ambient temperature, the solution was concentrated in vacuo at 30°C, diluted with dioxane and water, neutralized with 1M HCl, and concentrated in vacuo to provide the crude desired compound.
- The resultant compound of Example 72C was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 8 to provide, after silica gel chromatography using 2% methanol in chloroform, the desired compound (45%, Rf 0.5, 10% methanol in chloroform) as a white solid, m.p. 85-89°C. Mass spectrum: (M + H)+ = 867.
- Anal. Calcd for C42H58N8O8S2·H2O: C, 57.00; H, 6.83; N, 12.66. Found: C, 56.78; H, 6.56; N, 12.45.
- Using the procedure of Example 14A but replacing 4-(2-propyl)-oxazolidine-2-one with 4-benzyloxazolidine-2-one and replacing 4-methylpentanoyl chloride with isovaleryl chloride provided the desired compound.
- Using the procedure of Example 14B with the resultant compound of Example 73A provided, after silica gel chromatography using 15% ethyl acetate in hexane followed by dichloromethane, the desired compound (Rf 0.35, 20% ethyl acetate in hexane) in 88% yield.
- Using the procedure of Example 14C with the resultant compound of Example 73B provided, after silica gel chromatography using 6% ethyl acetate in hexane, the desired compound (Rf 0.43, 10% ethyl acetate in hexane) in 60% yield.
- Using the procedure of Example 14D with the resultant compound of Example 73C provided the desired compound as a crude colorless oil.
- The resultant compound of Example 73D was coupled to the resultant compound of Example 57C using the mixed anhydride coupling method described in Example 1F to provide, after silica gel chromatography using 60% ethyl acetate in chloroform, the desired compound (Rf 0.19, 60% ethyl acetate in chloroform) in 73% yield.
- The resultant compound of Example 73E was hydrogenolyzed according to the procedure described in Example 13C to provide the desired compound.
- The resultant compound of Example 73F was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 8 to provide, after silica gel chromatography using 5% methanol in chloroform, the desired compound in 42% yield, m.p. 169-170°C. Mass spectrum: (M + H)+ = 793.
- Anal. Calcd for C46H60N6O6·0.5H2O: C, 68.89; H, 7.67; N, 10.48. Found: C, 68.85; H, 7.80; N, 10.16.
- A suspension of 0.43 g (10.7 mmol) of sodium hydride (60% dispersion in oil) in 60 ml of anhydrous tetrahydrofuran was cooled to 0°C and treated with 2.1 ml (10.5 mmol) of triethylphosphonoacetate. The resulting solution was stirred for 10 min, treated with 1.0 ml (10.5 mmol) of pyridine-2-carboxaldehyde, heated at reflux for 2 h, and stirred overnight at ambient temperature. The resulting mixture was partitioned between ether and aqueous ammonium chloride, washed sequentially with water and saturated brine, dried over MgSO4, and concentrated in vacuo. Chromatography on silica gel using 25% ethyl acetate in hexane provided 1.54 g (83%) of the desired compound as a colorless liquid. 1H NMR (CDCl3) δ 1.34 (t, J = 7 Hz, 3 H), 4.28 (q, J = 7 Hz, 2 H), 6.92 (d, J = 16 Hz, 1 H), 7.27 (ddd, J = 8, 5, 1 Hz, 1 H), 7.43 (d, J = 8 Hz, 1 H), 7.72 (m, 1 H), 8.65 (m, 1 H).
- The resultant compound of Example 74A was hydrolyzed according to the procedure of Example 29A to provide the desired compound.
- Using the procedures of Example 61A and Example 61B but replacing 3-(3-pyridinyl)acrylic acid with the resultant compound of Example 74B provided the desired compound.
- Using the procedures of Example 61A and Example 61B but replacing 3-(3-pyridinyl)acrylic acid with 3-(2-pyridinyl)acrylic acid provided the desired compound (Rf 0.21, 10% methanol in chloroform). Mass spectrum: (M + H)+ = 765.
- Using the procedure of Example 20D, the resultant compound of Example 21B was coupled to the resultant compound of Example 26 to provide, after silica gel chromatography using 5% methanol in chloroform, the desired compound (Rf 0.25, 10% methanol in chloroform) as a white solid, m.p. 207-208°C, in 32% yield. Mass spectrum: (M + H)+ = 769.
- Anal. Calcd for C42H52N6O8·1.25H2O: C, 63.74; H, 6.94; N, 10.62. Found: C, 63.70; H, 6.70; N, 10.54.
- The resultant compound of Example 24B was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 20D to provide, after silica gel chromatography using 5% methanol in chloroform, the desired compound (Rf 0.21, 10% methanol in chloroform) as a white solid, m.p. 227-230°C (dec) in 47% yield. Mass spectrum: (M + H)+ = 813.
- Anal. Calcd for C42H64N6O10·1.25H2O: C, 60.38; H, 8.02; N, 10.06. Found: C, 60.21; H, 7.78; N, 10.43.
- Using the procedure of Example 20D the resultant compound of Example 21B was coupled to the resultant compound of Example 51 to provide, after silica gel chromatography using 3% methanol in chloroform, the desired compound (Rf 0.21, 5% methanol in chloroform) as a white solid, m.p. 175-178°C, in 66% yield. Mass spectrum: (M + H)+ = 635.
- Anal. Calcd for C35H46N4O2·0.75H2O: C, 64.65; H, 7.38; N, 8.64. Found: C, 64.61; H, 7.16; N, 8.80.
- The resultant compound of Example 72C was coupled to (2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane using the carbodiimide coupling procedure of Example 8 to provide, after silica gel chromatography, the desired compound (Rf 0.65, 10% methanol in chloroform) as a white solid, m.p. 91-93°C. Mass spectrum: (M + H)+ = 867.
- Anal. Calcd for C42H58N8O8S2·H2O: C, 57.00; H, 6.83; N, 12.66. Found: C, 67.26; H, 8.30; N, 4.98.
- The resultant compound of Example 72C was coupled to (2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane using the carbodiimide coupling procedure of Example 8 to provide, after silica gel chromatography, the desired compound (Rf 0.54, 10% methanol in chloroform) as a white solid, m.p. 75-77°C. Mass spectrum: (M + H)+ = 867.
- L-2-Hydroxy-3-methylvaleric acid was coupled to the resultant compound of Example 26 using the diimide coupling procedure described in Example 8 to provide the desired compound (Rf 0.23, 10% methanol in chloroform) as a white solid, m.p.226-230°C.
- Anal. Calcd for C30H44N2O6·0.5H2O: C, 67.01; H, 8.44; N, 5.21. Found: C, 67.26; N, 8.30; N, 4.98.
- The resultant compound of Example 73B was hydroyzed according to the procedure of Example 1D except that excess 30% hydrogen peroxide was included in the reaction mixture to provide the crude desired compound.
- The resultant compound of Example 82A was coupled to the resultant compound of Example 70 using the carbodiimide coupling procedure of Example 8 to provide, after silica gel chromatography using a gradient of 1-5% methanol in chloroform, the desired compound in 22% yield.
- The resultant compound of Example 82B (45 mg) was treated with 1.5 ml of 2:1 dichloromethane/trifluoroacetic acid. After 4 h at ambient temperature, the solution was concentrated in vacuo to provide 28 mg (55%) of the desired compound as an off-white solid, m.p. 208-210°C.
- Using the procedure of Example 81 but replacing L-2-hydroxy-3-methylvaleric acid with L-2-((methoxy)-methoxy)-3-methylvaleric acid provided, after silica gel chromatography using 20% ethyl acetate in hexane, the desired compound (88%, Rf 0.18, 20% ethyl acetate in hexane) as a white solid, m.p. 190-194°C. Mass spectrum: (M + H)+ = 617.
- To a solution of 1.175 g (5.715 mmol) of cuprous bromide-dimethylsufide complex in 8 mL of anhydrous, oxygen-free THF at -40°C was added 4.57 mL (11.43 mmol) of 2.5 M n-butyl lithium. The solution was stirred for 0.5 h at -40°C and then cooled to -60°C. A solution of (2S,3R,4R,5S)-1,2:5,6-diimino-3,4-O-isopropylidenehexanediol (703 mg, 1.43 mmol(Y.L. Merrer, et al, Heterocycles, 1987, 25, 541-548)) in -16 mL of anhydrous, oxygen-free THF was added. The solution was allowed to warm slowly to approximately -25°C and stirred for 4 h at that temperature. The reaction mixture was treated with 10% concentrated ammonium hydroxide in saturated ammonium chloride solution and the aqueous mixture was extracted with diethyl ether. The organic solution was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on a 1.0 X 27 cm silica gel column eluted with 20% ethyl acetate in hexane to give 0.414 g (47.6% yield) of the title compound; DCI/NH3 MS M/Z: 626 (M+NH4)+; The 300 MHz 1H NMR spectrum was consistent with the assigned structure.
- The resultant compound of Example 84A in 3 mL of anhydrous diethyl ether was added to -75 mL of liquid ammonia and small pieces of sodium metal were added until a blue color persisted for 5 minutes. The reaction was quenched with ammonium chloride and the ammonia was evaporated. The residue was dissolved in diethyl ether and the ether solution was washed with dilute aqueous ammonium hydroxide and brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the intermediate 6,9-diamino compound. The diamine (159 mg, 0.53 mmol) was dissolved in 5 mL of THF and the THF solution was cooled in an ice bath. To the cooled solution was added 532 mg (2.12 mmol) of N-carbobenzyloxyvaline, followed by 406 mg (2.12 mmol) of N-ethyl-N'-(dimethylaminopropyl)carbodiimide and 295 µL (2.12 mmol) of triethylamine. The reaction mixture was allowed to gradually warm to ambient temperature and was stirred at ambient temperature overnight. The solvent which had evaporated from the reaction mixture was replaced with 5 mL of THF and the mixture was stirred for 2 h. The reaction mixture was then diluted with ethyl acetate and washed with saturated aqueous sodium bicarbonate solution and brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a 1.5 X 35 cm silica gel column eluted with 30% ethyl acetate to to give 83 mg (20% yield) of the title compound; DCI/NH3 MS M/Z: 784 (M+NH4)+, 767 (M+H)+; The 300 MHz 1H NMR spectrum is consistent with the assigned structure. Analysis calculated for C43H66N4O8: C, 67.36; H, 8.62; N, 7.31. Found: C, 67.68; H, 9.02; N, 7.27.
- A solution of the resultant compound of Example 84B (80 mg, 0.1 mmol) in 3.0 mL of trifluoroacetic acid containing 0.3 mL of water was stirred at 0°C for 9.75 h. The solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on a 1.0 X 22 cm silica gel column eluted with 50% ethyl acetate in hexane to give 51 mg (45% yield) of the title compound; 1H NMR (CDCl3) δ 0.86 (t, 6H), 0.92 (d, 6H), 0.98 (d, 6H), 1.20-1.33 (br m, 12H), 1.51-1.61 (br m, 2H), 2.12-2.22 (m, 2H), 3.39 (br s, 1H), 3.55 (br s, 1H), 3.82-3.92 (m, 2H), 3.95 (dd, 2H), 5.10 (s, 4H), 5.10 (s, 4H), 5.20 (br d, 2H), 6.23 (d, 2H), 7.30-7.40 (m, 10H).Analysis calculated for C40H62N4O8: C, 66.12; H, 8.54; N, 7.71. Found: C, 66.04; H, 8.59; N, 7.70.
- To a stirred suspension of 411 mg (2.0 mmol) of CuBr-Me2S in 2 mL of ether at 0 °C was added 3.08 ml (4.0 mmol) of 1.3 M phenyllithium in ether/cyclohexane. After 30 minutes, a suspension of 246 mg (0.50 mmol) of (2S,3R,4R,5S)-1,2:5,6-diimino-3,4-O-isopropylidene-hexanediol (703 mg, 1.43 mmol (Y.L. Merrer, et al, Heterocycles, 1987, 25, 541-548)) was added in 20 mL. After 80 minutes, the reaction mixture was quenched with 10% NH4OH saturated with NH4Cl. The ether layer was washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. Chromatography of the residue on silica gel with 7:3/hexane:EtOAc afforded 280 mg (86.4%) of the title compound. MS m/z 649 (M+H+)
- The resultant compound of Example 85A was converted to the title compound in a manner analogous to that described in Examples 84B and 84C
- A solution of 100 mg (0.68 mmol) of 2,3:4,5-dianhydro-D-iditol (R.S. Tipson, et al, Carbohydrate Research, 1968, 7, 232-243) in 5 mL of dichloromethane and 1 mL of DMSO was added to a solution of 208 mg (1.64 mmol) of oxalyl chloride in 10 mL of dichloromethane which had been treated with 257 mg (3.28 mmol) of DMSO at -78 °C. After 15 minutes at this temperature 685 mg (6.8 mmol) of triethylamine was added and the resulting solution allowed to warm to room temperature. The resulting dialdehyde is purifed by chromatography on silica gel and then oxidized to dimethyl 2,3:4,5-diepoxyadipate according to the procedure of D.R. Williams, et al (Tetrahederon Letters, 1988, 5087-5090). The diepoxide is then treated with the cuprate reagent prepared from benzyl lithium and CuBr-Me2S or CuCN in an ethereal solvent such as tetrahydrofuran or diethyl ether, to affored dimethyl 3,4-dihydroxy-2,5-bis(phenylmethyl)adipate. The resulting diol is then protected as the bis(t-butyldiphenylsilyl) ether by treatment with t-butyldiphenylsilyl chloride in DMF in the presence of imidazole. Saponification of the diester with LiOH in aqueous THF, followed by acidification and coupling to valine benzyl ester in the manner described in Example 304, followed by deprotection with tetrabutylammmonium fluoride in THF affords the title compound.
- Oxidation of of 2,3:4,5-dianhydro-D-iditol (R.S. Tipson, et al, Carbohydrate Research, 1968, 7, 232-243) as described in Example 86 but substituting THF for the dichloromethane/DMSO mixture as solvent, affords a solution of the corresponding dialdehyde. This solution is then recooled' to -78 °C, and treated with four equivalents (relative to the iditol) of phenylmagnesium bromide. The reaction mixture is then quenched with a pH 7 phosphate buffer and extracted into ethyl acetate, dried over sodium sulfate, and concentrated under reduced pressure. The resulting diol is treated with benzyl isocyanate, in the presence of either DMAP or diisopropylethylamine, in an inert solvent, such as benzene or THF. The resulting bis-carbamate is then treated with 2 equivalents of NaH or potassium t-butoxide in THF. The resulting diol is then treated with hydrogen over a Pd catalyst in a solvent such as MeOH to afford (2S, 3S, 4S, 5S)-3,4-dihydroxy-1,6-diphenyl-hexane-2,5-diamine. This is then converted into the title compound by treatment with Cbz-valine p-nitrophenyl ester in THF in the presence of triethylamine.
- A solution of 160 mg (0.27 mmol) of the resultant compound of Example 16A and 117 mg (0.54 mmol) of 3-chloroperoxybenzoic acid in 1 ml of dichloromethane was stirred at ambient temperature for 2 days. The resulting solution was diluted with dichloromethane, washed sequentially with aqueous sodium bicarbonate and saturated brine, dried over MgSO4, and concentrated Silica gel chromatography of the residue using 10% ethyl acetate in hexane provided 150 mg (92%) of the desired compound (Rf 0.50, 20% ethyl acetate in hexane) as an oil. Mass spectrum: (M + H)+ = 607.
- A mixture of the resultant compound of Example 88 (152 mg) and 50 mg of 10% palladium on carbon in 50 ml of methanol was shaken under 4 atmospheres of hydrogen for 1 day. The mixture was filtered and concentrated in vacuo to provide 92 mg (96%) of the desired compound. Mass spectrum: (M + H)+ = 383.
- Using the procedure of Example 46 with the resultant compound of Example 89 provided the desired compound.
- Quinaldic acid was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Using the procedure of Example 13C with the resultant compound of Example 49 provided the desired compound.
- Quinaldic acid was coupled to the resultant compound of Example 92 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Using the procedure of Example 13C with the resultant compound of Example 48 provided the desired compound.
- Quinaldic acid was coupled to the resultant compound of Example 94 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Indole-2-carboxylic acid was coupled to the resultant compound of Example 28 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Indole-2-carboxylic acid was coupled to the resultant compound of Example 92 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- Indole-2-carboxylic acid was coupled to the resultant compound of Example 94 using the carbodiimide coupling procedure of Example 8 to provide the desired compound.
- (1'S)-2-(1-Carboxy-3-methylbutyl)-1,2,3,4-tetrahydropyrrolo[3,4-b]indol-3-one lithium salt, prepared according to the procedure of Kempf et. al. (J. Org. Chem. 1990, 55, 1390) was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 20D to provide the desired compound.
- (1'S)-2-(1-Carboxy-2-methylpropyl)-1,2,3,4-tetrahydropyrrolo[3,4-b]indol-3-one lithium salt, prepared according to the procedure of Kempf et. al. (J. Org. Chem. 1990, 55, 1390) was coupled to the resultant compound of Example 26 using the carbodiimide coupling procedure of Example 20D to provide the desired compound.
- Using the procedure of Example 44A but replacing L-valine methyl ester hydrochloride with the resultant compound of Example 26 and replacing benzyl bromoacetate with t-butylbromoacetate provided the desired compound.
- The inhibitory potency of the retroviral protease inhibiting Compounds disclosed herein can be determined by the following method.
- Such a compound is dissolved in DMSO and a small aliquot further diluted with DMSO to 100 times the final concentration desired for testing. The reaction is carried out in a 6 X 50 mm tube in a total volume of 300 microliters. The final concentrations of the components in the reaction buffer are: 125 mM sodium acetate, 1 M sodium chloride, 5 mM dithiothreitol, 0:5 mg/ml bovine serum albumin, 1.3 uM fluorogenic substrate, 2% (v/v) dimethylsulfoxide, pH 4.5. After addition of inhibitor, the reaction mixture is placed in the fluorometer cell holder and incubated at 30°C for several minutes. The reaction is initiated by the addition of a small aliquot of cold HIV protease. The fluorescence intensity (excitation 340 nM, emmision 490 nM) is recorded as a function of time. The reaction rate is determined for the first six to eight minutes. The observed rate is directly proportional to the moles of substrate cleaved per unit time. The percent inhibition is 100 X (1 - (rate in presence of inhibitor)/(rate in absence of inhibitor)).
- Fluorogenic substrate: Dabcyl-Ser-Gln-Asp-Tyr-Pro-Ile-Val-Gln-EDANS wherein DABCYL = 4-(4-dimethylaminophenyl)azobenzoic acid and EDANS = 5-((2-aminoethyl)amino)-naphthalene-1-sulfonic acid.
- Retroviral protease inhibiting compounds disclosed herein inhibit HIV-1 protease at concentrations between 0.01 nM and 500,000 nM. Table 3 shows the inhibitory potencies of specific compounds against HIV-1 protease.
Compound of Example Percent Inhibition Inhibitor Concentration (micromolar) 10 100 270 25B 40 0.01 27B 74 0.001 31 58 0.005 47 44 0.01 48 56 0.001 49 65 0.001 50 67 0.1 52 86 0.005 53 73 0.005 54 81 0.001 55 84 0.001 56 76 0.001 57 45 0.001 58 68 0.001 59 62 0.001 60 78 0.1 61 38 0.001 62 62 0.005 63 74 0.005 66 44 0.002 67 78 0.001 68 69 0.001 69 67 0.005 71 68 0.01 73 45 0.01 75 69 0.001 76 74 0.001 77 33 0.01 78 40 0.001 79 60 0.1 80 56 0.05 - The anti-HIV activity of compounds disclosed herein can be determined by the following method.
- A mixture of 0.1 ml (2 X 105 cells/ml) of H9 cells and 0.1 ml (100 infectious units) of HIV-13B was incubated on a shaker for 2 h at 37°C. The resulting culture was washed three times and resuspended into 2 ml of medium containing 10 ul of a compound of the invention in dimethylsulfoxide. The control culture was treated in an identical manner except no compound was added to the medium. Aliquots of culture supernatants were removed at 3 time points, usually 4, 7 and 10 days, and monitored for HIV-1 antigen EIA (HIVAG-1) (Paul, et al., J. Med. Virol., 22 357 (1987)). Cell viability was determined by trypan blue dye exclusion, and cells were refed with media containing compound (except for control wells which were refed with media only) at these time points. Per cent inhibition of HIV by the compound was determined by comparing HIV antigen levels in the supernatants of infected cells incubated with compound to supernatants from the control culture without compound. The IC50 is the concentration of compound that gives 50% inhibition of HIV activity. The LD50 is the concentration of compound at which 50% of the cells remain viable.
- Table 4 shows the inhibitory potencies of compounds disclosed herein against HIV-1 in H9 cells:
Compound of Example IC50 (micromolar) LD50 (micromolar) 27 0.12 11 47 2.3-4.5 25 48 0.015-0.027 60 49 0.05-0.07 >100 52 0.54 30 54 0.10 >100 55 0.04-0.1 >100 57 0.42 >100 58 0.05-0.1 >100 59 0.09-0.18 >100 63 0.27 >100 75 0.4-1.6 >100 76 0.25 180 77 1.2-7.5 >100 78 0.3-0.9 45
Claims (7)
- A compound according to Claim 1 wherein at each occurrence the N-protecting group is independently selected from the group consisting of acyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl, benzyloxycarbonyl, benzoyl, or an L- or D-aminoacyl residue N-protected by acyl, acetyl, pivaloyl, t-butylacetyl, t-butyloxycarbonyl, benzyloxycarbonyl or benzoyl.
- A compound selected from the group consisting of:2-(N-benzylamino)-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane;2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane;5-amino-2-(N-benzylamino)-3,4-dihydroxy-1,6-diphenylhexane dihydrochloride;2-amino-5-(t-butyloxycarbonylamino)-3,4-dihydroxy-1,6-diphenylhexane;2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3R,4R,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3S,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3R,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3R,4R,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane or a hydrochloride salt thereof;(2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane or a hydrochloride salt thereof;(2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane or a hydrochloride salt thereof;(2S,3S,4R,5S)-5-amino-2-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenythexane;
and(2S,3R,4S,5S)-2,5-di-(N-((isopropylaminocarbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane. - A compound selected from the group consisting of:(2S,3R,4R,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3S,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; and(2S,3R,4S,5S)-2,5-di-(N-((t-butyloxy)carbonyl)amino)-3,4-dihydroxy-1,6-diphenylhexane.
- A compound selected from the group consisting of:(2S,3R,4R,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane;(2S,3S,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane;
and(2S,3R,4S,5S)-2,5-diamino-3,4-dihydroxy-1,6-diphenylhexane; - A compound selected from the group consisting of:(2S,3R,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3S,4S,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3R,4R,5S)-2,5-di-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3S,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3R,4S,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane;(2S,3R,4R,5S)-2,5-di-(N-(valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane; and(2S,3S,4R,5S)-2-(N-(t-butyloxy)carbonyl)amino)-5-(N-(Cbz-valinyl)amino)-3,4-dihydroxy-1,6-diphenylhexane.
- A compound selected from the group consisting of:2-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide;2-amino-5-(t-butyloxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide; and2,5-di-(t-buty(oxycarbonylamino)-1,6-diphenyl-3-hexene-3,4-oxide.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35594589A | 1989-05-23 | 1989-05-23 | |
US40560489A | 1989-09-08 | 1989-09-08 | |
US405604 | 1989-09-08 | ||
US45612489A | 1989-12-22 | 1989-12-22 | |
US456124 | 1989-12-22 | ||
US518730 | 1990-05-09 | ||
US07/518,730 US5142056A (en) | 1989-05-23 | 1990-05-09 | Retroviral protease inhibiting compounds |
EP90109319A EP0402646B1 (en) | 1989-05-23 | 1990-05-17 | Retroviral protease inhibiting compounds |
US355945 | 1994-12-14 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90109319.5 Division | 1990-05-17 | ||
EP90109319A Division EP0402646B1 (en) | 1989-05-23 | 1990-05-17 | Retroviral protease inhibiting compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0839798A2 EP0839798A2 (en) | 1998-05-06 |
EP0839798A3 EP0839798A3 (en) | 1998-09-09 |
EP0839798B1 true EP0839798B1 (en) | 2005-08-17 |
Family
ID=27502890
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97119700A Expired - Lifetime EP0839798B1 (en) | 1989-05-23 | 1990-05-17 | Intermediates for preparating non-peptide retroviral protease inhibitors |
EP90109319A Expired - Lifetime EP0402646B1 (en) | 1989-05-23 | 1990-05-17 | Retroviral protease inhibiting compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP90109319A Expired - Lifetime EP0402646B1 (en) | 1989-05-23 | 1990-05-17 | Retroviral protease inhibiting compounds |
Country Status (13)
Country | Link |
---|---|
US (3) | US5142056A (en) |
EP (2) | EP0839798B1 (en) |
JP (1) | JP2963910B2 (en) |
KR (1) | KR0184866B1 (en) |
AT (2) | ATE168677T1 (en) |
AU (1) | AU645493B2 (en) |
CA (1) | CA2017252C (en) |
DE (2) | DE69034202T2 (en) |
DK (2) | DK0402646T3 (en) |
ES (1) | ES2119737T3 (en) |
HK (2) | HK1012337A1 (en) |
IL (1) | IL94444A (en) |
NZ (1) | NZ233717A (en) |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5614533A (en) * | 1987-03-13 | 1997-03-25 | Bio-Mega/Boehringer Ingelheim Research, Inc. | Substituted pipecolinic acid derivatives as HIV protease inhibitors |
USH1649H (en) | 1987-07-31 | 1997-05-06 | Barrish; Joel C. | HIV protease inhibitor combinations |
US5151438A (en) * | 1989-05-23 | 1992-09-29 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5554783A (en) * | 1989-05-23 | 1996-09-10 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
MX22406A (en) * | 1989-09-15 | 1994-01-31 | Pfizer | NEW DERIVATIVES OF N-ARIL AND N-HETEROARILAMIDAS AND UREA AS INHIBITORS OF ACIL COENZYME A: ACIL TRANSFERASA DEL COLESTEROL (ACAT). |
EP0428849A3 (en) * | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
WO1991018866A2 (en) * | 1990-06-01 | 1991-12-12 | The Du Pont Merck Pharmaceutical Company | 1,4-diamino-2,3-dihydroxybutanes |
WO1992000750A1 (en) * | 1990-07-06 | 1992-01-23 | Smithkline Beecham Corporation | Retroviral protease inhibitors |
US5475027A (en) * | 1990-11-19 | 1995-12-12 | G.D. Searle & Co. | Retroviral protease inhibitors |
US5602175A (en) * | 1990-11-19 | 1997-02-11 | G.D. Searle & Co. | Retroviral protease inhibitors |
US5614522A (en) * | 1990-11-19 | 1997-03-25 | G.D. Searle & Co. | Retroviral protease inhibitors |
US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
US5482947A (en) | 1990-11-19 | 1996-01-09 | Talley; John J. | Retroviral protease inhibitors |
US5475013A (en) * | 1990-11-19 | 1995-12-12 | Monsanto Company | Retroviral protease inhibitors |
US5648511A (en) * | 1990-11-19 | 1997-07-15 | G.D. Searle & Co. | Method for making intermediates useful in the synthesis of retroviral protease inhibitors |
EP0492136A3 (en) * | 1990-12-20 | 1993-05-26 | American Cyanamid Company | Retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene |
ZA921279B (en) * | 1991-02-22 | 1993-08-23 | Du Pont Merck Pharma | Substituted alpha-aminoaldehydes and derivatives |
DK0503561T3 (en) * | 1991-03-15 | 1999-07-05 | Hoechst Ag | Process for Preparation of Diastereoselective Reductive Pinacol Coupling of Homochiral Alpha-Amino Aldehydes |
JPH06508146A (en) * | 1991-06-04 | 1994-09-14 | スミスクライン・ビーチャム・コーポレイション | Carbocyclic and heterocyclic HIV protease inhibitors |
US5268361A (en) * | 1991-06-07 | 1993-12-07 | Sri International | Hydroxyazido derivatives and related compounds as renin inhibitors |
DK0521827T3 (en) | 1991-07-03 | 1996-11-11 | Ciba Geigy Ag | Pharmacologically active hydrazine derivatives and processes for their preparation |
US5753652A (en) * | 1991-07-03 | 1998-05-19 | Novartis Corporation | Antiretroviral hydrazine derivatives |
CN1071930A (en) * | 1991-07-10 | 1993-05-12 | 伊莱利利公司 | Inhibitor as the human immunodeficiency virus protease who treats acquired immune deficiency syndrome (AIDS) |
US5508407A (en) * | 1991-07-10 | 1996-04-16 | Eli Lilly And Company | Retroviral protease inhibitors |
DE4126485A1 (en) * | 1991-08-10 | 1993-02-11 | Bayer Ag | TRIFLUOROMETHYL-CONTAINING PSEUDOPEPTIDE |
US5491149A (en) * | 1991-09-16 | 1996-02-13 | The Du Pont Merck Pharmaceutical Company | Dihydroxypropylamine containing retroviral protease inhibitors |
ATE140449T1 (en) * | 1991-10-07 | 1996-08-15 | Hoechst Ag | METHOD FOR THE DIASTEREOSELECTIVE REDUCTIVE PINAKOL COUPLING OF HOMOCHIRAL ALPHA-AMINOALDEHYDES |
EP0607334B1 (en) | 1991-10-11 | 1997-07-30 | The Du Pont Merck Pharmaceutical Company | Cyclic ureas and analogues useful as retroviral protease inhibitiors |
AU668110B2 (en) * | 1991-10-14 | 1996-04-26 | Cash Engineering Research Pty Ltd | Inlet control combination for a compressor system |
US6071895A (en) * | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
AP395A (en) * | 1992-03-11 | 1995-08-08 | Narhex Ltd | Amine derivatives of oxo- and hydroxy-substituted hydrocarbons. |
US5888992A (en) * | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
ATE253050T1 (en) | 1992-03-11 | 2003-11-15 | Narhex Ltd | AMINE DERIVATIVES OF OXO- AND HYDROXY-SUBSTITUTED HYDROCARBONS |
US5679688A (en) * | 1992-03-11 | 1997-10-21 | Narhex Limited | Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons |
DE4215874A1 (en) * | 1992-05-14 | 1993-11-18 | Bayer Ag | Dithiolanylglycine-containing HIV protease inhibitors of the hydroxyethylene isostear type |
CA2136312A1 (en) * | 1992-05-21 | 1993-11-25 | Michael Clare | Retroviral protease inhibitors |
NZ247837A (en) * | 1992-06-19 | 1995-04-27 | Lilly Co Eli | Cyclic oxirane derivatives, medicaments and precursors |
US5559256A (en) * | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
US6046190A (en) * | 1992-08-25 | 2000-04-04 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
DE69311810T2 (en) * | 1992-08-25 | 1997-11-27 | Searle & Co | N- (ALKANOYLAMINO-2-HYDROXYPROPYL) SULFONAMIDES CAN BE USED AS RETROVIRAL PROTEASE INHIBITORS |
US6022994A (en) * | 1992-08-25 | 2000-02-08 | G. D. Searle &. Co. | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US6743929B1 (en) | 1992-08-25 | 2004-06-01 | G. D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US7141609B2 (en) | 1992-08-25 | 2006-11-28 | G.D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
ES2112430T3 (en) * | 1992-08-25 | 1998-04-01 | Searle & Co | SULFONILALCANOYLAMINE HYDROXYETHYLAMINE SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS. |
EP0810209B1 (en) | 1992-08-25 | 2002-06-05 | G.D. Searle & Co. | Alpha - and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5760076A (en) * | 1992-08-25 | 1998-06-02 | G.D Searle & Co. | Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
US5830897A (en) * | 1992-08-27 | 1998-11-03 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
AU677602B2 (en) | 1992-09-25 | 1997-05-01 | Bio-Mega/Boehringer Ingelheim Research Inc. | N-(hydroxyethyl)butanediamide derivatives as renin inhibitors |
KR950703520A (en) | 1992-09-25 | 1995-09-20 | 자크 루 | Renin inhibiting N- (2-amino-2-oxoethyl) butanediamide derivatives |
US5756498A (en) * | 1992-10-30 | 1998-05-26 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
US6337398B1 (en) | 1992-10-30 | 2002-01-08 | G.D. Searle & Co. | Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
EP0666842B1 (en) | 1992-10-30 | 1998-06-24 | G.D. Searle & Co. | Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
US5578606A (en) | 1992-10-30 | 1996-11-26 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors |
US5587388A (en) * | 1992-12-02 | 1996-12-24 | Lucky Limited | Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof |
US5430150A (en) * | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
US5733906A (en) * | 1993-10-12 | 1998-03-31 | Eli Lilly And Company | Inhibitors of HIV Protease useful for the treatment of Aids |
EP0604182B1 (en) * | 1992-12-22 | 2000-10-11 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of Aids |
US5434265A (en) * | 1992-12-22 | 1995-07-18 | Eli Lilly And Company | Inhibitors of HIV protease |
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5846993A (en) * | 1992-12-22 | 1998-12-08 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
MX9308016A (en) * | 1992-12-22 | 1994-08-31 | Lilly Co Eli | HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM. |
US5554653A (en) * | 1992-12-22 | 1996-09-10 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of AIDS |
US5491166A (en) * | 1992-12-22 | 1996-02-13 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of AIDS |
US5475136A (en) * | 1992-12-22 | 1995-12-12 | Eli Lilly And Company | Inhibitors of HIV protease useful for the treatment of AIDS |
ATE143004T1 (en) | 1992-12-23 | 1996-10-15 | Ciba Geigy Ag | ANTIRETROVIRAL HYDRAZINE DERIVATIVES |
US5514801A (en) * | 1992-12-29 | 1996-05-07 | Monsanto Company | Cyclic sulfone containing retroviral protease inhibitors |
ES2189721T3 (en) | 1992-12-29 | 2003-07-16 | Abbott Lab | RETROVIRAL PROTEASA INHIBITORS. |
ES2100109B1 (en) * | 1993-07-14 | 1998-02-16 | Squibb & Sons Inc | AMINODIOL PROTEASE INHIBITORS. |
US5750648A (en) * | 1993-08-20 | 1998-05-12 | G.D. Searle & Co. | Retroviral protease inhibitors and combinations thereof |
IL110752A (en) * | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
PT721449E (en) * | 1993-10-01 | 2002-06-28 | Merrell Pharma Inc | BETA-AMYLOID PROTEIN PRODUCTION INHIBITORS |
US5977074A (en) * | 1993-10-01 | 1999-11-02 | Merrell Pharmaceuticals, Inc. | Inhibitors of β-amyloid protein production |
US5491253A (en) * | 1993-10-22 | 1996-02-13 | Abbott Laboratories | Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane |
US5786500A (en) * | 1993-10-22 | 1998-07-28 | Abbott Laboratories | Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane |
US5602119A (en) * | 1993-10-29 | 1997-02-11 | Vazquez; Michael L. | Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
US5679687A (en) * | 1993-11-30 | 1997-10-21 | Lg Chemical Limited | Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof |
US5670517A (en) * | 1993-11-30 | 1997-09-23 | Lg Chemical Limited | Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof |
KR0125117B1 (en) | 1994-06-15 | 1997-12-05 | 성재갑 | Novel hiv protease inhibitors with anti aids effect and the process for preparation thereof |
KR0159652B1 (en) * | 1995-10-26 | 1998-12-01 | 성재갑 | Irreversible hiv protease inhibitor having an anti-aids activity and the process for the preparation thereof |
US6133444A (en) * | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
US5428167A (en) * | 1994-01-14 | 1995-06-27 | American Cyanamid Company | Asymmetric synthesis of intermediates for retroviral protease inhibitor compounds |
US5733882A (en) * | 1994-01-17 | 1998-03-31 | Smithkline Beecham Corporation | Retroviral protease inhibitors |
US5480887A (en) * | 1994-02-02 | 1996-01-02 | Eli Lilly And Company | Protease inhibitors |
ES2153434T3 (en) * | 1994-02-02 | 2001-03-01 | Lilly Co Eli | INHIBITORS OF HIV PROTEASA AND ITS INTERMEDIATES. |
US5559252A (en) * | 1994-02-16 | 1996-09-24 | The Dupont Merck Pharmaceutical Company | Process for the preparation of diamine intermediates useful in the synthesis of HIV protease inhibitors |
US5527829A (en) * | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
UA49803C2 (en) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Method for treatment of retrovirus infections |
US5530124A (en) * | 1994-06-30 | 1996-06-25 | The Dupont Merck Pharmaceutical Company | Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors |
US5728718A (en) * | 1994-12-20 | 1998-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same |
US5691368A (en) * | 1995-01-11 | 1997-11-25 | Hoechst Marion Roussel, Inc. | Substituted oxazolidine calpain and/or cathepsin B inhibitors |
EP0804428B1 (en) | 1995-01-20 | 2007-12-26 | G.D. Searle LLC. | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
US5831117A (en) | 1995-01-20 | 1998-11-03 | G. D. Searle & Co. | Method of preparing retroviral protease inhibitor intermediates |
US5827827A (en) * | 1995-02-16 | 1998-10-27 | The Scripps Research Institute | HIV-1 protease inhibitors |
US6140505A (en) | 1995-03-10 | 2000-10-31 | G. D. Searle & Co. | Synthesis of benzo fused heterocyclic sulfonyl chlorides |
US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
MX9706946A (en) * | 1995-03-10 | 1997-11-29 | Searle & Co | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors. |
EP1188766A1 (en) | 1995-03-10 | 2002-03-20 | G.D. Searle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6169085B1 (en) | 1995-03-10 | 2001-01-02 | G. D. Searle & Company | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6143788A (en) * | 1995-03-10 | 2000-11-07 | G.D. Searle & Co. | Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors |
US6667307B2 (en) | 1997-12-19 | 2003-12-23 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5985870A (en) * | 1995-03-10 | 1999-11-16 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6861539B1 (en) | 1995-03-10 | 2005-03-01 | G. D. Searle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6407134B1 (en) | 1995-03-10 | 2002-06-18 | G. D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5776971A (en) * | 1995-03-10 | 1998-07-07 | G.D. Searle & Co. | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US7339078B2 (en) | 1995-03-10 | 2008-03-04 | G.D. Searle Llc | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5567823A (en) * | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
WO1997016433A1 (en) | 1995-10-30 | 1997-05-09 | Smithkline Beecham Corporation | Protease inhibitors |
US6586466B2 (en) | 1995-10-30 | 2003-07-01 | Smithkline Beecham Corporation | Carbohydrazide-protease inhibitors |
CA2236236A1 (en) * | 1995-11-15 | 1997-05-22 | G.D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5763464A (en) * | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6160122A (en) * | 1996-06-28 | 2000-12-12 | Abbott Laboratories | Process for the preparation of a disubstituted thiazole |
US5760019A (en) * | 1996-07-12 | 1998-06-02 | The Research Foundation Of State University Of New York | Silanol enzyme inhibitors |
US5962725A (en) | 1996-09-05 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir |
US5705647A (en) * | 1996-09-05 | 1998-01-06 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US5925759A (en) | 1996-09-05 | 1999-07-20 | Agouron Pharmaceuticals, Inc. | Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors |
US6528098B2 (en) * | 1996-10-22 | 2003-03-04 | Advanced Viral Research Corp. | Preparation of a therapeutic composition |
ZA98376B (en) * | 1997-01-23 | 1998-07-23 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitors |
US6376506B1 (en) | 1997-01-23 | 2002-04-23 | Syntex (U.S.A.) Llc | Sulfamide-metalloprotease inhibitors |
US6001851A (en) * | 1997-03-13 | 1999-12-14 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
SE9701245D0 (en) * | 1997-04-04 | 1997-04-04 | Bjoern Classon | antivirals |
US6063790A (en) | 1997-07-29 | 2000-05-16 | University Of The Sciences In Philadelphia | Diarylsulfone non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus |
US6084107A (en) * | 1997-09-05 | 2000-07-04 | Agouron Pharmaceuticals, Inc. | Intermediates for making HIV-protease inhibitors |
US6130220A (en) * | 1997-10-16 | 2000-10-10 | Syntex (Usa) Inc. | Sulfamide-metalloprotease inhibitors |
WO2000002862A1 (en) | 1998-07-08 | 2000-01-20 | G.D. Searle & Co. | Retroviral protease inhibitors |
US20030044399A1 (en) * | 1998-12-23 | 2003-03-06 | Smithkline Beecham Corporation | Method of treatment |
US20030144175A1 (en) * | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
US6436344B1 (en) * | 1999-11-02 | 2002-08-20 | American National Red Cross | Method of inactivating pathogens |
WO2001034600A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
JP2003513971A (en) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
AU1474801A (en) | 1999-11-10 | 2001-06-06 | Smithkline Beecham Corporation | Protease inhibitors |
IL150964A0 (en) * | 2000-03-21 | 2003-02-12 | Smithkline Beecham Corp | Protease inhibitors |
EP1265849B1 (en) | 2000-03-23 | 2006-10-25 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
US6992081B2 (en) | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
US6846813B2 (en) * | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
KR20030058959A (en) * | 2000-06-30 | 2003-07-07 | 엘란 파마슈티칼스, 인크. | Compounds to treat alzheimer's disease |
US20030096864A1 (en) * | 2000-06-30 | 2003-05-22 | Fang Lawrence Y. | Compounds to treat alzheimer's disease |
PE20020276A1 (en) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER |
US20030013656A1 (en) | 2001-05-03 | 2003-01-16 | Bing Wang | Pyruvate derivatives |
US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
BR0210721A (en) * | 2001-06-27 | 2004-07-20 | Elan Pharm Inc | Pharmaceutically acceptable compound, salt or ester, method for making a compound, and method for treating a patient having, or preventing the patient from acquiring a disease or condition. |
US7244755B2 (en) | 2001-10-04 | 2007-07-17 | Pharmacia & Upjohn Company | Hydroxypropylamines |
US20040038965A1 (en) * | 2001-10-09 | 2004-02-26 | Marquis, Jr. Robert W. | Protease inhibitors |
AU2002360403A1 (en) * | 2001-11-19 | 2003-06-10 | Elan Pharmaceuticals, Inc. | (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's disease |
EP1503980A2 (en) * | 2002-02-27 | 2005-02-09 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamines |
AU2003303141A1 (en) * | 2002-04-30 | 2004-07-22 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer's disease |
US20050131017A1 (en) | 2003-12-11 | 2005-06-16 | Degoey David A. | HIV protease inhibiting compounds |
US7834043B2 (en) * | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
MXPA06008598A (en) * | 2004-01-30 | 2006-08-28 | Pfizer | Compositions comprising hiv protease inhibitor and cytochrome p450 enzyme activity inhibitor. |
JP2007536240A (en) * | 2004-05-04 | 2007-12-13 | アカデミア シニカ | Anti-coronavirus compound |
US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
WO2006132623A1 (en) * | 2005-06-03 | 2006-12-14 | Advanced Viral Research Corp. | Methods for providing palliative care with avr118 |
EP3696171A1 (en) * | 2006-07-07 | 2020-08-19 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP2465856A3 (en) * | 2006-08-31 | 2012-12-12 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
DK3150586T3 (en) * | 2007-02-23 | 2020-02-17 | Gilead Sciences Inc | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS |
US8088770B2 (en) * | 2007-07-06 | 2012-01-03 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
BRPI0821116B8 (en) * | 2007-12-20 | 2021-05-25 | Pharma Mar Sa | compound, pharmaceutical composition containing it, use thereof and process for its preparation |
CA2710679A1 (en) * | 2008-01-04 | 2009-07-16 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
SG11201404527QA (en) | 2012-02-03 | 2014-08-28 | Gilead Sciences Inc | Methods and intermediates for preparing pharmaceutical agents |
CN103665043B (en) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | A kind of tenofovir prodrug and its application in medicine |
JP6348904B2 (en) * | 2012-09-20 | 2018-06-27 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションTemple University−Of The Commonwealth System Of Higher Education | Substituted alkyldiaryl derivatives, their production and use |
US9562004B2 (en) * | 2012-11-07 | 2017-02-07 | Council Of Scientific & Industrial Research | 2, 2′-bis (4-hydroxyphenyl) alkyl azides and process for the preparation thereof |
WO2017023912A1 (en) | 2015-08-03 | 2017-02-09 | Temple University - Of The Commonwealth System Of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
CN105198829B (en) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | A kind of Preparation Method And Their Intermediate and purposes than his intermediate of department |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2354866A (en) * | 1941-11-01 | 1944-08-01 | Pure Oil Co | Process for the manufacture of improved motor fuels |
GB1147295A (en) * | 1966-11-03 | 1969-04-02 | Bayer Ag | Process for the production of bis-quaternary ammonium compounds |
US4172094A (en) * | 1976-12-03 | 1979-10-23 | Merck & Co., Inc. | Polyamine compounds |
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
JPS58144918A (en) * | 1982-02-24 | 1983-08-29 | Hitachi Ltd | Pressure and flow rate controlling system of water distributing pipe network |
DE3311702A1 (en) * | 1983-03-30 | 1984-10-04 | Bayer Ag, 5090 Leverkusen | FUNGICIDAL AGENTS, METHOD FOR THE PRODUCTION AND USE THEREOF |
US4652552A (en) * | 1984-09-10 | 1987-03-24 | E. I. Du Pont De Nemours And Company | Tetrapeptide methyl ketone inhibitors of viral proteases |
US4644055A (en) * | 1984-12-17 | 1987-02-17 | E. I. Du Pont De Nemours And Company | Method for preparing specific inhibitors of virus-specified proteases |
NZ223148A (en) * | 1987-01-16 | 1989-10-27 | Merrell Dow Pharma | Peptide derivatives having peptidase inhibition activity |
IL89900A0 (en) * | 1988-04-12 | 1989-12-15 | Merck & Co Inc | Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them |
IL90218A0 (en) * | 1988-05-13 | 1989-12-15 | Abbott Lab | Retroviral protease inhibitors |
CA1340588C (en) * | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
WO1990000399A1 (en) * | 1988-07-08 | 1990-01-25 | Smithkline Beckman Corporation | Retroviral protease binding peptides |
DE3827340A1 (en) * | 1988-08-12 | 1990-02-15 | Hoechst Ag | USE OF (ALPHA) -AMINOBORONIC ACID DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF VIRUS DISEASES |
IL91307A0 (en) * | 1988-08-24 | 1990-03-19 | Merck & Co Inc | Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them |
DK414389A (en) * | 1988-08-24 | 1990-02-26 | Merck & Co Inc | PHARMACEUTICAL PREPARATION CONTAINING AN AMINO ACID DERIVATIVE WITH PURINE-INHIBITORIAL EFFECT |
EP0362002B1 (en) * | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | HIV protease inhibitors |
EP0361341A3 (en) * | 1988-09-28 | 1991-07-03 | Miles Inc. | Therapeutics for aids based on inhibitors of hiv protease |
DE3836955A1 (en) * | 1988-10-29 | 1990-05-03 | Philips Patentverwaltung | COLOR TV PROJECTION ARRANGEMENT |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
-
1990
- 1990-05-09 US US07/518,730 patent/US5142056A/en not_active Expired - Lifetime
- 1990-05-17 DE DE69034202T patent/DE69034202T2/en not_active Expired - Lifetime
- 1990-05-17 EP EP97119700A patent/EP0839798B1/en not_active Expired - Lifetime
- 1990-05-17 DK DK90109319T patent/DK0402646T3/en active
- 1990-05-17 AT AT90109319T patent/ATE168677T1/en not_active IP Right Cessation
- 1990-05-17 EP EP90109319A patent/EP0402646B1/en not_active Expired - Lifetime
- 1990-05-17 DK DK97119700T patent/DK0839798T3/en active
- 1990-05-17 ES ES90109319T patent/ES2119737T3/en not_active Expired - Lifetime
- 1990-05-17 DE DE69032493T patent/DE69032493T2/en not_active Expired - Lifetime
- 1990-05-17 NZ NZ233717A patent/NZ233717A/en unknown
- 1990-05-17 AT AT97119700T patent/ATE302180T1/en not_active IP Right Cessation
- 1990-05-18 AU AU55711/90A patent/AU645493B2/en not_active Expired
- 1990-05-20 IL IL9444490A patent/IL94444A/en not_active IP Right Cessation
- 1990-05-22 CA CA002017252A patent/CA2017252C/en not_active Expired - Lifetime
- 1990-05-23 JP JP2133684A patent/JP2963910B2/en not_active Expired - Fee Related
- 1990-05-23 KR KR1019900007517A patent/KR0184866B1/en not_active IP Right Cessation
-
1995
- 1995-03-23 US US08/409,365 patent/US5670675A/en not_active Expired - Lifetime
- 1995-03-23 US US08/409,391 patent/US5545750A/en not_active Expired - Lifetime
-
1998
- 1998-12-15 HK HK98113371A patent/HK1012337A1/en not_active IP Right Cessation
- 1998-12-15 HK HK00100412A patent/HK1021530A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR0184866B1 (en) | 1999-04-01 |
DE69032493D1 (en) | 1998-08-27 |
US5670675A (en) | 1997-09-23 |
KR900018134A (en) | 1990-12-20 |
AU5571190A (en) | 1990-11-29 |
US5545750A (en) | 1996-08-13 |
ATE302180T1 (en) | 2005-09-15 |
HK1012337A1 (en) | 1999-07-30 |
HK1021530A1 (en) | 2000-06-16 |
IL94444A (en) | 1999-03-12 |
US5142056A (en) | 1992-08-25 |
IL94444A0 (en) | 1991-03-10 |
DE69032493T2 (en) | 1999-02-18 |
ES2119737T3 (en) | 1998-10-16 |
DK0402646T3 (en) | 1999-04-26 |
EP0839798A2 (en) | 1998-05-06 |
JPH03128335A (en) | 1991-05-31 |
AU645493B2 (en) | 1994-01-20 |
DE69034202D1 (en) | 2005-09-22 |
DE69034202T2 (en) | 2006-06-22 |
ATE168677T1 (en) | 1998-08-15 |
EP0839798A3 (en) | 1998-09-09 |
EP0402646A1 (en) | 1990-12-19 |
CA2017252A1 (en) | 1990-11-23 |
EP0402646B1 (en) | 1998-07-22 |
CA2017252C (en) | 2001-08-28 |
DK0839798T3 (en) | 2005-12-19 |
JP2963910B2 (en) | 1999-10-18 |
NZ233717A (en) | 1994-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0839798B1 (en) | Intermediates for preparating non-peptide retroviral protease inhibitors | |
US5151438A (en) | Retroviral protease inhibiting compounds | |
KR100187990B1 (en) | Retroviral protease inhibiting compounds | |
EP0997459B1 (en) | Intermediates for preparing retroviral protease inhibiting compounds | |
KR101217036B1 (en) | Hcv ns-3 serine protease inhibitors | |
US5256677A (en) | Retroviral protease inhibiting compounds | |
US5597926A (en) | Retroviral protease inhibiting compounds | |
US5948790A (en) | Retroviral protease inhibitors | |
EP0415981A1 (en) | Retroviral protease inhibitors | |
CA2022692A1 (en) | Renin inhibitors | |
US5545640A (en) | Protease inhibiting succinic acid derivatives | |
CZ280651B6 (en) | Hydrazine derivatives, pharmaceutical compositions containing thereof, their use, process as well as intermediates for their preparation | |
JPH07607B2 (en) | Renin inhibitor | |
Kempf et al. | Design of orally bioavailable, symmetry-based inhibitors of HIV protease | |
US5646121A (en) | Pseudopeptides with antiviral activity | |
US5455351A (en) | Retroviral protease inhibiting piperazine compounds | |
AU672867B2 (en) | 4-amino-3-hydroxycarboxylic acid and their use as anitvirals | |
WO1995008550A1 (en) | Endothelin antagonists | |
US5969132A (en) | Macrocyclic difluorostatone derivatives useful as antiviral agents | |
US5554783A (en) | Retroviral protease inhibiting compounds | |
MXPA00011244A (en) | Retroviral protease inhibiting compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 402646 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PLATTNER, JACOB J. Inventor name: CODACOVI, LYNN M. Inventor name: SHAM, HING LEUNG Inventor name: ERICKSON, JOHN W. Inventor name: NORBECK, DANIEL W. Inventor name: KEMPF, DALE J. |
|
17P | Request for examination filed |
Effective date: 19990322 |
|
17Q | First examination report despatched |
Effective date: 20021218 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0402646 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69034202 Country of ref document: DE Date of ref document: 20050922 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20050403272 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1021530 Country of ref document: HK |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20060518 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: ABBOTT LABORATORIES Free format text: ABBOTT LABORATORIES#ONE ABBOTT PARK ROAD#ABBOTT PARK, ILLINOIS 60064-3500 (US) -TRANSFER TO- ABBOTT LABORATORIES#ONE ABBOTT PARK ROAD#ABBOTT PARK, ILLINOIS 60064-3500 (US) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060531 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20090527 Year of fee payment: 20 Ref country code: DK Payment date: 20090408 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20090507 Year of fee payment: 20 Ref country code: LU Payment date: 20090420 Year of fee payment: 20 Ref country code: IT Payment date: 20090516 Year of fee payment: 20 Ref country code: FR Payment date: 20090507 Year of fee payment: 20 Ref country code: DE Payment date: 20090529 Year of fee payment: 20 Ref country code: AT Payment date: 20090407 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20090619 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20090430 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20090415 Year of fee payment: 20 Ref country code: GB Payment date: 20090407 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V4 Effective date: 20100517 |
|
BE20 | Be: patent expired |
Owner name: *ABBOTT LABORATORIES Effective date: 20100517 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP |
|
EUG | Se: european patent has lapsed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20100517 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20100516 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20100517 |